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The anatomical barriers and the tear fluid dynamics in the precorneal area have a huge effect on 
the eye-related drug bioavailability. In situ forming gels stand out as the formulation candidates 
for the improvement of bioavailability and efficacy of topical ophthalmic drugs. These are 
prepared as liquid dosage forms that undergo phase transition on eye surface to form viscoelastic 
gel in response to an environmental stimulus following topical administration. During 
formulation development, in situ forming ophthalmic gels need to be fine-tuned considering all 
the biopharmaceutical challenges of the front of the eye. The aim of this thesis was to develop 
temperature-responsive in situ forming poloxamer P407/ poloxamer P188/chitosan gel fine-tuned 
in terms of polymer content, temperature of gelation, viscosity and storage modulus by applying 
Quality by Design principles. Minimizing the total polymer content, while retaining the 
advantageous rheological properties, has been achieved by means of D-optimal statistical design. 
In situ forming gels were prepared by cold method and analyzed by rheological temperature 
sweep test. Statistical software was used to set experimental design, establish the mathematical 
model and analyze the collected data. Validated mathematical models enabled the selection of 4 
candidates of poloxamer 407/poloxamer 188/chitosan systems, which viscoelastic behavior was 
studied in depth by oscillatory rheological tests under biorelevant conditions (after dilution with 
simulated tear fluid in the ratio of 40:7). The optimal in situ forming gel was selected based on 
minimal polymer content (P407, P188 and chitosan concentration of 14.2, 1.7 and 0.25%, w/w, 
respectively), favorable rheological characteristics and in vitro resistance to tear dilution. The 
formulation robustness against entrapment of active pharmaceutical ingredients (API) with 
different physicochemical characteristics was demonstrated using four APIs in the concentrations 
and combinations relevant for topical ophthalmic use. Through discriminative in vitro release 
test, adequate release profile of model drug was proven. Biocompatibility of the optimal in situ 
forming gel was confirmed employing 3D corneal epithelial cell models. In conclusion, a 
systematic approach to in situ forming gel development implemented in this thesis resulted in a 
stable and robust formulation characterized by ease of formulation preparation, ability for sterile 
filtration and autoclaving, ease of administration, accuracy of dosing, avoidance of eye-related 
discomfort, biocompatibility and prolonged residence at the eye surface.  
KEYWORDS: ophthalmic drug delivery, quality by design (QbD), poloxamers, chitosan, 
rheology, temperature-responsive in situ forming gel, temperature of gelation.  
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SAŽETAK 
Uvod: Topikalna je primjena glavni put primjene oftalmičkih lijekova, a kapi za oko najčešće 
korišten farmaceutski oblik. Međutim, pri primjeni kapi za oko, zbog dinamičnih barijera 
prekornealonog područja, dolazi do brze eliminacije lijeka s površine oka. Stoga je lijek dostupan 
za apsorpciju kroz samo nekoliko minuta što rezultira vrlo niskom bioraspoloživošću, uglavnom 
manjom od 5%. Klasični tehnološki pristupi, s ciljem produljenja vremena zadržavanja lijeka na 
površini oka, uključuju pripravu viskoznih otopina, gelova i masti. Međutim, ti su sustavi 
povezani sa zamućenjem vida i otporom gibanju vjeđa pri treptanju te poteškoćama pri doziranju 
što umanjuje suradljivost bolesnika. Iz navedenih je razloga velika potreba za inovativnim 
oftalmičkim pripravcima koji bi omogućili poboljšanje suradljivosti bolesnika i terapijske 
učinkovitosti u odnosu na klasične farmaceutske oblike. In situ gelovi predstavljaju jedno od 
inovativnih rješenja suvremene farmaceutske tehnologije. Izrađuju se od polimera koji pokazuju 
reverzibilne fazne prijelaze, a zbog povoljnih reoloških svojstava nastaloga gela, minimiziraju 
smetnje s treptanjem, osjećaj stranoga tijela u oku, kao i zamućenje vida. Takav je sustav 
oblikovan kao otopina lijeka pogodna za primjenu u oko jer gelira pri fiziološkim uvjetima. In 
situ oftalmički gelovi trebaju biti pomno dizajnirani s ciljem produljenja vremena zadržavanja 
lijeka na mjestu primjene, povećanja bioraspoloživosti i učinkovitosti. Sustavan pristup razvoju 
farmaceutskih proizvoda provodi se po načelima kvalitete ugrađene u dizajn proizvoda (eng. 
Quality by design, QbD). Implementacija QbD principa rezultira uspješnim razvojem 
farmaceutskoga proizvoda, smanjenjem troškova te skraćenjem vremena do pojave lijeka na 
tržištu. Cilj je ovoga doktorskoga rada razviti in situ gel za oftalmičku primjenu korištenjem 
smjese polimera (poloksamera P407, poloksamera P188 i kitozana) specifično dizajnirane u 
smislu ukupnoga sadržaja polimera te reoloških parametara temperature geliranja (Tgel), 
kompleksne viskoznosti (η*) i modula pohrane (G'). 
Metode: In situ oftalmički gelovi poloksamera P407 i P188 i kitozana (CS) pripravljeni su  
''hladnom'' metodom dok je izotoničnost postignuta dodatkom NaCl. Osmolalnost je određena 
metodom snižavanja ledišta, a transparentnost mjerenjem indeksa refrakcije. S obzirom da su 
reološka svojstva formulacije pri sobnoj temperaturi i pri temperaturi površine oka ključna za 
točnost doziranja, vrijeme zadržavanja lijeka na površini oka, kao i njegovo oslobađanje iz in situ 
gela, korištenjem eksperimentalnog dizajna optimirana su reološka svojstava razvijenih sustava. 
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Temeljem eksperimentalne situacije, odabran je D-optimalni dizajn. Koncentracije P407, P188 i 
kitozana odabrane su kao nezavisne varijable, dok su kao odgovori od interesa odabrane Tgel, η* i 
G' pri temperaturi površine oka (γ5°C) mjerene reološkim testom promjene temperature (engl. 
temperature sweep) pri konstantnoj kutnoj frekvenciji i smičnoj deformaciji. Statistički je softver 
korišten za postavljanje eksperimentalnoga dizajna, utvrđivanje modela, generiranje sekvenci i za 
statističku obradu prikupljenih podataka. Kao optimalni raspon za Tgel odabran je 28 – γβ°C; za 
G' vrijednost minimuma je postavljena na 5 Pa, dok se optimalni raspon za vrijednosti 
viskoznosti odredio na osnovu karakterizacije komercijalno dostupnih in situ oftalmičkih gelova. 
Sva su reološka mjerenja provedena na reometru povezanim s posebnom jedinicom koja 
osigurava točnu temperaturu mjerenja i minimalizira isparavanje uzorka. 
Viskoelastična svojstva in situ gelova ispitivana su testom promjene sile smičnog naprezanja pri 
konstantnoj frekvenciji (eng. strain sweep). Testom promjene frekvencije (eng. frequency sweep) 
procijenila se ovisnost viskoznosti i viskoelastičnih modula o promjeni frekvencije. Evaluacija in 
situ gelova provedena je i pri biorelevantnim uvjetima (nakon razrjeđenja umjetnom suznom 
tekućinom u omjeru 40:7) u svrhu procjene otpornosti formulacije prema razrjeđenju suzama. Za 
procjenu dinamičke viskoznosti razvijenih sustava, u usporedbi s komercijalno dostupnim 
oftalmičkim lijekovima, korišten je rotacijski reološki test u bioreleavantnim uvjetima.  
Robusnost razvijene formulacije prema uklapanju djelatnih tvari ispitana je evaluacijom utjecaja 
djelatnih tvari različitih fizičko-kemijskih svojstava na reološke karakteristike gela. Korištene su 
četiri oftalmičke djelatne tvari (timolol, deksametazon, dorzolamid i tobramicin) u 
koncentracijama i kombinacijama relevantnim za topikalnu oftalmičku primjenu. 
In vitro oslobađanje lijeka ispitano je korištenjem vertikalne difuzijske ćelije. Za određivanje 
djelatne tvari u prikupljenim uzorcima korištena je tekućinska kromatografija ultravisoke 
djelotvornosti (UPLC). Sterilizacija odabranih formulacija provedena je filtracijom te filtracijom 
i autoklaviranjem. Stabilnost sterilizirane formulacije pohranjene u dobro zatvorenim bočicama 
pri sobnoj temperaturi tijekom šest mjeseci evaluirana je mjerenjem ključnih reoloških svojstava. 
Biokompatibilnost razvijenoga optimalnoga in situ gela ispitana je korištenjem MTT testa 
vijabilnosti stanica na 3D HCE-T staničnim modelima rožnice (kultiviranima na filtrima veličina 
pora od γ i 0,4 µm) nakon izloženosti gelu od γ0 minuta. 
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Rezultati: Temeljem eksperimentalnoga plana i mjerenjem Tgel, η* i G' uspješno su dobiveni i 
validirani matematički modeli koji opisuju ovisnost mjerenih zavisnih varijabli o 
koncentracijama P407, P188 i kitozana. Matematičkim modelom za Tgel pokazan je  redoslijed 
učinaka koncentracija na odabranu varijablu: P407 (koeficijent = -13,84) > P188 (koeficijent = 
6,70) > CS (koeficijent = β,74). Negativna vrijednost koeficijenta upućuje na obrnut odnos 
između faktora (koncentracija) i odgovora (Tgel), što za posljedicu ima da porast koncentracije 
P407 rezultira smanjenjem Tgel. Pozitivna vrijednost uočena za koeficijente vezane za 
koncentracije C188 i CS sugerira da povećavanjem njihovih koncentracija dolazi do pomicanja 
Tgel prema višim temperaturama. U svrhu dobivanja matematičkih modela za η* i G', podatci 
dobiveni mjerenjima su logaritmirani. Povećanje koncentracije P188 rezultiralo je smanjenjem 
log(η*) (negativan koeficijent = -1,60), dok povećanje koncentracije P407 za posljedicu ima 
porast log(η *) (koeficijent = 1,5γ). Učinak koncentracije CS na log(η *) statistički se pokazao 
manje značajnim od učinka koncentracija poloksamera. Slično modelu za log(η*), povećanjem 
koncentracije P188 smanjivao se log(G') (koeficijent = -0,76), dok je porast koncentracije P407 
rezultirao porastom odabrane zavisne varijable (koeficijent = 2,16).  
Temeljem dobivenih modela, odabrana su četiri vodeća sustava (PL1-4) koja su u detaljnoj 
reološkoj karakterizaciji pokazala postojanje strukture gela na temperaturi oka, ali i nakon 
razrjeđenja suznom tekućinom. Reološki profil razvijenih sustava sugerirao je na strukture tzv. 
mekanih gelova koji nastaju pri srednjim koncentracijama poloksamera. Uloga kitozana,  
promotora mehaničke čvrstoće gela, dokazana je reološkim testom promjene frekvencije. 
Usporedbom dinamičkih viskoznosti razvijenih sustava s komercijalno dostupnim oftalmičkim in 
situ gelirajućim pripravcima u biorelevantnim uvjetima, utvrđeno je njihovo odgovarajuće 
pseudoplastično ponašanje.  
S obzirom na najmanji udio polimera (P407, P188 i CS od 14,2, 1,7 i 0, 25%, m/m), poželjnim 
reološkim svojstvima (Tgel = γ1,1°C, η* = β,1 Pa  s; niskoj dinamičkoj viskoznosti pri visokim 
brzinama smicanja) te in vitro rezistentnosti na razrjeđenje suznom tekućinom (G’ = β1β,4 Pa 
prije razrjeđenja i 175,γ Pa nakon razrjeđenja), sustav PL1 odabran kao optimalni in situ gel.  
Procijenjen je učinak djelatnih tvari na temeljna reološka svojstva (Tgel, η*, dinamičku viskoznost 
i vrijeme geliranja) odabranog sustava PL1. Sve su djelatne tvari, s iznimkom tobramicina, 
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snizile Tgel. Najizraženiji je učinak imao deksametazon, a taj se učinak može pripisati promociji 
samoorganizacije P407 u sustavima koji sadrže hidrofobne djelatne tvari. Otopljene djelatne tvari 
(dorzolamid i timolol) pokazale su nešto slabiji učinak od deksametazona na snižavanje Tgel. 
Takav se utjecaj djelatnih tvari na Tgel može pripisati efektu isoljavanja. Djelatne tvari nisu 
značajnije utjecale na promjenu η*, dok su produljile vrijeme geliranja optimalne formulacije 
PL1. Međutim, raspon vremena geliranja od 41,1 do 87,4 sekunde prihvatljiv je za oftalmičku 
primjenu.  
U svrhu praćenja oslobađanja modelnoga lijeka iz optimalnoga in situ gela, razvijena je 
odgovarajuća in vitro metoda za ispitivanje oslobađanja. Prikladnost razvijene metode dokazana 
je kroz testove topljivosti, odabir najmanje rezistentne membrane i kroz evaluaciju 
diskriminatornosti metode. Kvantifikacijska (UPLC) je metoda validirana u skladu s ICH 
smjernicama. Dobiveni profil oslobađanja timolola iz in situ gela ukazao je na produljeno 
oslobađanje, značajno sporije od kontrolne otopine timolola, slično oslobađanju lijeka iz gela 
usporedive viskoznosti. Time je potvrđena viskoznost kao najkritičniji parametar što kontrolira 
oslobađanje lijeka iz te vrste pripravaka. 
Ključna reološka svojstva PL1 optimalnoga in situ gela ispitana su prije i nakon filtracije kroz 
filtar pora 0,β µm te nakon filtracije i autokalviranja (β0 minuta na 1β1°C). Filtracija je 
rezultirala smanjenjem Tgel za oko 2°C, dok su vrijednosti η* dobivene u testu promjene 
frekvencije povećane, što se može pripisati već poznatom utjecaju čistoće poloksamera na 
viskoznost njihovih gelova.  
Stabilnost sterilizirane formulacije, pohranjene u dobro zatvorenim bočicama pri sobnoj 
temperaturi tijekom šest mjeseci, procijenjena je ispitivanjem kritičnih reoloških parametara koji 
mogu utjecati na performanse razvijene platforme in vivo. Analize Tgel, η* i G’ ukazale su na 
zadržavanje bitnih reoloških svojstava razvijenoga sustava tijekom ispitanoga razdoblja.  
U svrhu preliminarnoga ispitivanja biokompatibilnosti PL1 optimalnoga in situ gela korišteni su 
γD epitelni modeli rožnice. Izloženost modela in situ gelu u vremenu od 30 minuta, rezultirala je 
smanjenjem vijabilnosti stanica manjoj od β0%, ukazujući na prikladnost razvijenoga sustava za 
oftalmičku primjenu. 
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 Zaključak: Sustavan pristup razvoju in situ gelirajućeg pripravka, proveden u sklopu 
doktorskoga rada, kroz uspješnu primjenu D-optimalnoga statističkoga dizajna, rezultirao je 
sustavom smanjene ukupne koncentracije polimera, temperature geliranja u fiziološki 
relevantnom rasponu, pseudoplastičnog ponašanja te otpornim na razrjeđenje suznom tekućinom. 
Posljedično, zadržana su pozitivna reološka svojstva koja osiguravaju jednostavnost primjene, 
točnost doziranja te izbjegavanje nelagode nakon primjene. Razvijeni se sustav pokazao 
robusnim na uklapanje djelatnih tvari, što ga čini prikladnom platformom za oftalmičku primjenu 
djelatnih tvari različitih fizičko-kemijskih svojstava. Nadalje, razvijeni se sustav pokazao stabilan 
i biokompatibilan te je omogućio kontrolirano oslobađanje modelne djelatne tvari. 
KLJUČNE RIJEČI: oftalmička primjena, kvaliteta uključena u dizajn (eng. QbD), poloksameri, 
kitozan, reologija, geliranje uzrokovano povećanjem temperature, temperatura geliranja. 
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1. INTRODUCTION 
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The anatomical barriers and the tear fluid dynamics in the precorneal area of the eye have a huge 
effect on the eye-related drug bioavailability (1,2). This problem can be overcome by using in 
situ forming ophthalmic gels prepared from polymers that exhibit reversible phase transitions and 
pseudoplastic behavior to minimize interference with blinking, avoid foreign body sensation and 
blurring of vision (3–5). In situ forming ophthalmic gels need to be fine-tuned considering all the 
biopharmaceutical challenges of the front of the eye in order to increase drug residence time at 
the application site resulting in its improved bioavailability and efficacy (6). Such a system 
should be formulated as drug containing liquid suitable for instillation into the eye that shifts to 
the gel phase upon exposure to physiological conditions (7). The optimal in situ forming gel 
should be characterized by: (i) temperature of gelation in physiologically relevant range; (ii) 
pseudoplastic behavior that allows gel to thin during blinking, making it more comfortable and 
easier to spread across the eye surface (8); (iii) suitable gel strength to endure the dilution with 
tears. Moreover, in vivo performance of in situ forming ophthalmic gels is governed also by drug 
release and biocompatibility issues. 
Poloxamers (trade name Pluronic®), a series of closely related block copolymers of polyethylene 
oxide and polypropylene oxide, have been investigated as in situ forming gels (9). At high 
concentrations of poloxamers, the aqueous solutions exhibit a dramatic change of the viscoelastic 
moduli and become soft solids or gels. A phase transition from liquid to gel upon reaching 
physiological temperatures is presently one of the most important phenomenon for their 
applications (10). Poloxamer 407 (P407) was mainly studied for ophthalmic delivery, however, 
concentrated P407 aqueous solutions (>18%, w/w) gel already at the ambient temperature (11). In 
that case, in situ forming ophthalmic gel has to be stored in refrigerator and applied cold (7), and 
therefore, its instillation to the front of the eye can possibly be irritating and painful.  
Use of P407 in mixture with other poloxamers is considered as a strategy to decrease the P407 
concentration, modulate the temperature of gelation and rheological properties of in situ forming 
gel. Among others, poloxamer 188 (P188) was shown to be a good modulator of P407 in situ 
forming gels (11–13). In previous studies, both poloxamers were used in in situ forming 
ophthalmic gels at very high total concentration, e.g. P407 and P188 in concentration of 21% and 
10% (11), 16% and 14% (14), 20% and 11% (15) (w/w), respectively. 
The additional improvements in the biopharmaceutical properties of poloxamer ophthalmic gels 
can be achieved by the presence of different additives in the formulation (16–20). Chitosan, a 
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biocompatible and biodegradable polycationic polymer, has been demonstrated to increase the 
mechanical strength and mucoadhesivness of in situ forming ophthalmic gels (20). In addition, 
there are other benefits of including chitosan in ophthalmic formulations such as improvement of 
eye-related permeability due to its paracellular permeation enhancing effects (21), antimicrobial 
activity (22) and corneal wound healing effect (23). 
The aim of this doctoral thesis was to develop stabile and robust in situ forming ophthalmic 
poloxamers/chitosan gel fine-tuned in terms of polymer content and rheological properties, i.e. 
temperature of gelation, storage modulus and viscosity. Minimizing the total polymer content 
while retaining the advantageous rheological properties has been achieved by means of D-
optimal statistical design. The selection of the leading candidate for drug formulation 
development has been based on the ability to keep its rheological properties upon dilution under 
biorelevant conditions. The robustness of selected mixed system has been evaluated upon 
entrapment of four ophthalmic active pharmaceutical ingredients (1). 
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2. THEORETICAL PART 
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2.1. Ophthalmic drug delivery 
Although evidently exposed organ, in the terms of drug delivery, eye is a specific and extremely 
complex from multiple perspectives. Drugs must be transported across several protective barriers 
regardless of which administration route is utilized (i.e. topical, subconjunctival, sub-tenon’s 
intravitreal, peribulbar and retrobulbar administration). These barriers for effective drug 
absorption exist on physical, chemical and biochemical levels and each of them are active 
depending on the delivery route. Most of these obstacles are anatomical and physiological 
barriers that normally protect the eye from exogenous particles and toxicants (24). Anatomically, 
the eye is divided in anterior and posterior segment. The anterior segment includes approximately 
one-third of the eye consisting of cornea, conjunctiva, pupil, aqueous humor, iris, lens, ciliary 
body and the anterior portion of sclera. The posterior segment consists of vitreous humor, retina, 
choroid, sclera and optic nerve making up the remaining two-thirds in the back of the eye, 
Figure 1 (25). 
 
Figure 1. The anatomy of the eye, picture reprinted with permission from (26). 
 
The anterior and posterior segment of the eye can be affected by various vision impairing 
conditions. Diseases affecting anterior segment include glaucoma, allergic conjunctivitis, anterior 
 13 
 
 
uveitis and cataract while age-related macular degeneration (AMD) and diabetic retinopathy are 
the most prevalent diseases affecting posterior segment of the eye (27). 
2.1.1.  Topical ophthalmic drug delivery 
Topical administration is the most common drug administration route for the treatment of the 
anterior segment of the eye. This is due to the fact that it is the simplest, most convenient, self-
administrable and non-invasive drug administration route for the management of anterior 
segment diseases/disorders. Drugs are delivered locally by this administration route, avoiding the 
blood-aqueous barrier, and the side effects and first-pass metabolism that may occur in some 
systemically administrated drugs. Depending on the formulation and drug physiochemical 
properties, drugs can reach different external (cornea, conjunctiva, sclera) and internal (aqueous 
humor, iris, ciliary body, vitreous humor, retina, etc.) sites in the eye after topical administration 
(28). However, the number of protective mechanisms play the decisive role in the fate of 
topically administrated drugs (Figure 2).  
Ocular absorption of topically applied ophthalmic drugs is limited by: 
(i) rapid precorneal drug elimination 
(ii) corneal/conjunctival epithelial barrier. 
Consequently, eye-related bioavailability of topically administered products is low, typically less 
than 5%. The major fraction of the instilled dose is usually systemically absorbed via the naso-
lacrimal duct or through the conjunctiva. For the treatment of diseases affecting anterior segment, 
the therapeutic concentrations can be achieved by frequent drug administration, however, for 
diseases affecting posterior segment, the intraocular levels achieved are often below minimal 
effective concentrations. Frequent administration is often associated with undesirable side effects 
caused by systemic drug absorption (2,24,29). Anterior segment diseases are mostly treated using 
eye drops (90% of marketed ophthalmic products) and ointments (27,28). 
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Figure 2. Ocular absorption and elimination pathways after topical administration, picture 
reprinted with permission from (28).   
 
Precorneal factors 
Precorneal factors, which include tear fluid dynamics, solution drainage and nonproductive 
absorption, determine the residence time of the drugs on the eye surface and therefore are of great 
importance for eye-related drug bioavailability.  
Tear fluid dynamics 
The tear film is a liquid layer covering the eye surface and acting as a barrier between the eye and 
environment (30). It is created by tears which are a complex aqueous mixture of peptides, 
proteins, electrolytes, lipids and small molecule metabolites (2,28). Immediately after the 
administration, drug/ophthalmic product is mixed with the tear film, which then presents a 
dynamic barrier to drug absorption. It is undergoes a constant renewal and consequently limits 
drug residence time on the eye surface. 
 15 
 
 
 
Figure 3. Schematic representation of tear film, picture reprinted from (31). 
 
It is composed of three layers (Figure 3): the superficial lipid layer, the middle aqueous layer and 
the deep mucous layer. It plays several important roles:  
(i) it is forming and maintaining a smooth refracting surface over the cornea, as it 
moisturizes the environment for the epithelial cells of the cornea and conjunctiva,  
(ii) it helps with transportation of metabolic products (primarily oxygen and carbon dioxide) 
to and from the corneal epithelial cells,  
(iii) it provides a pathway for white blood cells in case of injury, and 
(iv) it is diluting and washing away noxious stimuli and exhibits bactericidal properties (32). 
Lipids in the lipid layer of the tear film are secreted by the Meibomian glands, and they include 
triacylglycerols, free sterols, sterol esters and free fatty acids. The main function of lipid layer is 
to lower the surface tension of the tear fluid and prevent its evaporation. The aqueous portion of 
tear film, containing inorganic salts, glucose and urea, as well as biopolymers, proteins and 
glycoproteins, is secreted by the main and accessory lacrimal glands. The deepest layer of the tear 
film is the mucous layer. The mucous layer contains mucins, which are produced by the goblet 
cells of the conjunctiva. The mucins form a gel-like structure providing an easily wettable surface 
and thus assisting in water re-spreading after blinks (30). The mucus layer of a tear film is 
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restored slowly (~15 to 20 h) while the aqueous component is replaced approximately every 10 
min (33).   
Solution drainage 
Administration of eye drops induces responsive protective mechanisms such as lacrimation and 
blinking, which results in more pronounced drug elimination. Commercially available eye-
droppers provide average drop volume of 40 µl (range 25–56 µl). Available tear volume is about 
7 µl, while conjunctival cul-de-sac can contain around γ0 µl of applied eye drop. After 
administration, drug has a short residence time of approximately 1–2 min at the eye surface, 
because of the permanent production of lacrimal fluid (0.5–β.β µl/min). Even though the tear 
turnover rate is only approximately 1 µl/min, the excess volume of the instilled fluid flows to the 
nasolacrimal duct in a couple of minutes (4).  
Nonproductive absorption 
In addition to tear fluid dynamics and solution drainage, systemic absorption can cause 
nonproductive drug removal instead of ocular absorption. Systemic absorption can occur either 
directly from the conjunctival sac via local blood capillaries or after the solution has arrived into 
the nasal cavity. Tear fluid containing the drug is transported from the lacrimal sac into the 
nasolacrimal duct, which empties into the nasal cavity, where the drug is then absorbed into the 
bloodstream. This absorption leads to drug wastage and, more importantly, possible side effects 
(4,24,34). 
Anatomical barriers 
After the topical administration, there are two main pathways of drug entry into the anterior 
chamber: via the cornea and via the conjunctiva. Small and lipophilic molecules (i.e. most 
clinically used drugs) are absorbed via the cornea, whereas large and hydrophilic molecules (e.g. 
new potential biotech-drugs such as protein and peptide drugs, gene medicines) are preferably 
absorbed through the conjunctiva and sclera. However, as mentioned previously, an important 
route of drug loss from the lacrimal fluid is systemic absorption through the conjunctiva. 
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Cornea 
Cornea (Figure 4) is an optically transparent and avascular tissue which acts as the principal 
refractive element of the eye (34). Its surface and thickness are 1.04 cm
2
 and 0.5 mm, 
respectively. It comprises five layers: epithelium, Bowman’s membrane, stroma, Descemet’s 
membrane and the endothelium layer. The corneal upper layer, the epithelium, is endowed with 
microvilli, and covered by a charged glycocalyx, which maximizes surface area with the tear film 
(33). The epithelium and stroma are significant barriers to drug absorption, while endothelium 
participates only marginally in barrier function (35). 
The permeation of drugs across corneal epithelium is a complex and dynamic process that 
includes passive diffusion through either a cell (transcellular) or intercellular space between the 
cells (paracellular), influx- and/or efflux-mediated transport by membrane proteins, endocytosis 
and transcytosis. Permeation is determined by both the physicochemical properties of the drug 
and barrier properties. Lipophilic drugs permeate via the transcellular route, while hydrophilic 
drugs permeate primarily via the paracellular pathway. The main physicochemical properties that 
determine the passive transport of drugs across cornea are:  
(i) the degree of ionization at the pH of tears; 
(ii) the drug lipophilicity (e.g. the optimal log P for transcorneal absorption is 2–3); and 
(iii) the charge, size and shape of the drug molecule (2). 
The corneal epithelium consists of a basal layer of columnar cells, two to three layers of wing 
cells and one or two outermost layers of squamous polygonal shaped superficial cells (34). 
Epithelium is lipophilic in nature with superficial cells tightly connected by tight junctions. Tight 
junctions serve as a selective barrier for small hydrophilic molecules and they completely prevent 
the diffusion of macromolecules via the paracellular route. They are composed of a belt-like 
bands of intimate strands and the number of tight junction strands seems to be the most important 
determinant of paracellular resistance (34). 
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Figure 4. Schematic representation of corneal layers, picture reprinted with permission from 
(29).   
 
From these reasons, epithelium is major obstacle for permeation of hydrophilic molecules. 
Compared to many other epithelial tissues (intestinal, nasal, bronchial, tracheal) corneal 
epithelium is relatively impermeable, but it is more permeable compared to the stratum corneum 
of the skin (34). 
90% of corneal thickness is stroma, the hydrophilic layer containing collagen fibrils, which, due 
to its structure, blocks the transport of lipophilic molecules (24). 
Monolayer of hexagonal cells forms the corneal innermost layer, the endothelium, separates the 
stroma from aqueous humor, and it is responsible for maintaining normal corneal hydration (24). 
Presence of endothelial leaky tight junctions allows free movements of molecules between 
aqueous compartments (stroma and aqueous humor) (36). From these reasons, corneal 
endothelium does not act as a significant barrier to the transcorneal diffusion of most drugs.  
Conjunctiva 
The conjunctiva of the eyelids and globe is a thin, vascularized mucus membrane which forms a 
continuous surface area of 17.65 cm
2
 (2), which is around 17 times bigger than the surface of 
cornea. Functionality of conjunctiva is related to the formation and maintenance of the tear film 
and in protection of the eye (34). However, in comparison to corneal, conjunctival drug 
absorption is considered to be nonproductive due to the presence of conjunctival blood capillaries 
and lymphatics, which can cause significant drug loss into the systemic circulation and, therefore, 
lower eye-related bioavailability. Tight junctions of the superficial conjunctival epithelium are 
the major barrier for drug penetration across conjunctiva. Intercellular spaces in the conjunctival 
epithelium are, however, wider than those in the cornea1 epithelium and therefore, the 
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conjunctival permeabilities of hydrophilic drugs are higher for an order of magnitude than their 
corneal permeabilities (24,34). 
Sclera 
The sclera constitutes the posterior five-sixths of the globe and provides the structural integrity 
that defines the shape and length of the eye (34). The sclera mainly consists of collagen fibers 
and proteoglycans embedded in an extracellular matrix (24). Permeability through the sclera is 
considered to be comparable to that of the corneal stroma and is inversely proportional to the 
molecular radius of the drug. Also, charge of a drug is important because positively charged 
molecules permeate poorly possibly due to their binding to the negatively charged proteoglycan 
matrix. Drugs penetrate across the sclera through perivascular spaces, through the aqueous media 
of gel-like mucopolysaccharides or through empty spaces within the collagen network (34) to 
reach the anterior segment (trans-scleral pathway).  
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2.2. Topical ophthalmic dosage forms 
The clinical performance of topical ophthalmic drug products is dependent on the interplay of the 
physicochemical factors of drug and delivery system along with physiological and anatomical 
environment of the complex eye surface. Conventional ophthalmic drug products include eye 
drops in form of solution or suspension and ointments mainly of the oleaginous type, and are still 
the mainstream treatment of anterior segment eye diseases.  
Having in mind the complexity of eye surface environment and obstacles to eye-related 
bioavailability, formulation approaches for its improvement are to: 
(i) improve drug concentration within the formulation; 
(ii) extend retention time on eye surface; 
(iii) provide sustained drug release; and/or 
(iv) enhance corneal permeability. 
To improve the drug concentration within the eye drops, the diverse solubility enhancers can be 
used (37). This could also allow a smaller volume of eye drop to be administered, which would 
then be less suspectible to removal from eye surface by solution drainage. The contact time of 
topical ophthalmic solutions with eye increases with the increase of formulation viscosity. 
Several synthetic polymers like polyvinylalcohol, polyvinylpyrrolidone, polyethylene glycol, 
polyacrylic acid, and many cellulose derivatives such as hypromellose and 
hydroxyethylcellulose, are commonly used as viscosity enhancers due to their physiologic 
compatibility and satisfactory physicochemical properties (38). However, increase in viscosity is 
followed by increase in bioavailability only to a certain extent (5).  
Permeation enhancers can also be included into ophthalmic liquid formulations. They include 
preservatives (frequently added to multiple use ophthalmic systems and preventing microbial 
contamination) and surfactants (acting as drug solubilizers, and/or as spreading agents), and they 
modify transcorneal permeability by inducing ultrastructural changes in the corneal epithelium 
(39). Such molecules are, for example, ethylendiaminetetraacetic acid (EDTA), benzalkonium 
chloride (BAK), polyoxyethylene glycol ethers (lauryl, stearyl and oleyl), sodium taurocholate, 
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saponins and cremophor EL (40). However, there are safety concerns related to frequent use of 
these molecules (27). 
Other formulation approaches to improve drug concentration within formulation, extend retention 
time on eye surface and provide sustained drug release include ophthalmic suspensions and 
emulsions. Ophthalmic suspensions are biphasic systems consisting of solid particles dispersed 
throughout a liquid phase (buffer), often with a help od suspending/dispersing agent (41). 
Suspensions are employed to deliver poorly water soluble drugs so frequently, corticosteroids are 
marketed in the form of suspension. Suspension particles retained in conjunctival sac 
subsequently improve drug retention time on eye surface and therefore the duration of action. The 
main challenge in their formulation, stability, efficacy and patient acceptance is the size and size 
distribution of particles. If not adequate, particle size can create several undesirable consequences 
like aggregation and resuspendability related issues. Particles in ophthalmic suspensions need to 
be micronized (less than 10 µm, preferably less than 5 µm) to avoid irritation/foreign body 
sensation (42). Smaller size particle restores the drug absorbed into ocular tissues from 
conjunctival sac, while larger particle size helps retain particles for longer time and provide slow 
drug dissolution (27). Among marketed ophthalmic, suspension of dexamethasone combined 
with tobramycin (TobraDex
®
) is one of the widely used for treatment of ocular bacterial 
infections. Drawbacks of ophthalmic suspensions are relatively high costs and complexity of 
manufacturing process since sterilization can cause physical or chemical instability. From this 
reasons, in some cases, aseptic processing is only viable manufacturing option, which increases 
costs even more (43).  
Ophthalmic emulsions are colloidal pharmaceutical dosage forms consisting of one phase 
(water/oil) dispersed in other (oil/water) with an aid of  surfactants (emulsifiers) (27). An 
example of such system a topical corticosteroid ophthalmic emulsion of difluprednate 
(DUREZOL
®
), indicated for the treatment of inflammation and pain associated with ocular 
surgery, currently available in the US market (44). Positive side of ophthalmic emulsions is their 
lubricating nature, while drawbacks associated to these systems are related to the use of 
surfactants (local toxicity issues) and to physical instability (flocculation).  
Eye ointments are semisolid products usually intended for application to the conjunctiva, cornea, 
or eyelid. Ointments offer advantages over eye drops due to the significantly prolonged retention 
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time on the eye surface, minimization of tear dilution, reduced nasolacrimal drainage which all 
results in the improvement of bioavailability (45). Ophthalmic ointments account for 
approximately 10% of all of the ophthalmic dosage forms in the market (46). They are associated 
to poor patient compliance due to the greasy feeling, discomfort reflex tearing and blurring of 
vision (because of the difference in refractive index between nonaqueous ointment base and 
tears). Therefore, they are mostly applied at night. Furthermore, drawbacks of using ophthalmic 
ointments are related with potential content uniformity and dosing issues (45,46). 
 
2.2.1. Innovative ophthalmic drug delivery systems 
To improve eye-related drug bioavailability, there is a significant effort directed towards new 
drug delivery systems for ophthalmic administration (3,47–49). Innovative delivery platforms 
should lead to reduced dosing frequency, better patient compliance, reduced systemic adverse 
effects and finally improved clinical outcome. These delivery platforms include variety of drug 
delivery nanosystems and hydrogel-based systems. 
Drug delivery nanosystems comprise nanosuspensions, nanoemulsions, polymeric micelles, 
nanoparticles, liposomes, niosomes, cubosomes and dendrimers (25,28,36,50–52). Using the 
nanosystems all the strategies to increase eye- related bioavailability can be tackeled (solubility, 
retention time, sustained release, increased permeability). 
Nanosuspensions consist of nanosized drug particles suspended in an appropriate dispersion 
medium and stabilized by polymer(s) or surfactant(s) (50). In comparison to conventional 
suspensions, nanosuspensions offer advantages such as faster dissolution and improved solubility 
of the drug, enhanced bioavailability, and reduced irritation to the eye. Nanosuspension approach 
provides opportunity to address many of the deficiencies associated with water insoluble drugs.  
Nanoemulsions are biphasic dispersion of two immiscible liquids (most commonly oil-in-water), 
stabilized using an appropriate surfactant, suitable for for the entrapment of hydrophobic drugs 
(51). The direct consequence of their small droplet size (20–200 nm) is their clear or hazy 
appearance and long-term physical stability, which differs them from milky white color and less 
stabile coarse emulsion (51,53). Moreover, nanoemulsions possess higher solubilization capacity 
than simple micellar dispersions. Therefore, nanoemulsion were shown to to improve 
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permeability, retention time and overall eye-related bioavailability (51). The most known 
ophthalmic nanoemulsion is RESTASIS
®
, a cyclosporine nanoemulsion for treatment of dry eye. 
Polymeric micelles (10–200 nm) are based on amphiphilic molecules or block copolymers which 
can generally self-assemble into organized core-corona/supramolecular structures in aqueous 
media at concentrations exceeding their critical micellar concentrations (CMC) (52). Polymeric 
micelles have shown potential for enhancing the solubility and therapeutic efficacy of poorly 
water soluble drugs and for protection of the drugs from degradation. Due to their small size and 
hydrophilic nature, micelles can efficiently permeate the corneal barriers and produce therapeutic 
concentrations both in the anterior as well as the posterior segment of the eye (52). To prolong 
the residence time at the ocular surface, polymeric micelles should intimately contact the mucus 
layer. Positively charged corona of polymeric micelles can enhance the interactions with 
negatively charged mucins at the corneal surface, facilitating precorneal retention (54). 
Nanoparticles are particles consisting of various biodegradable materials which frequently have 
multifunctional surface groups, with a diameter from 10 to less than 1000 nm providing a large 
surface area (28). Drugs can be either encapsulated in the matrix or attached to the surface of the 
particle. They offer a great opportunity for efficient local delivery of drugs to the anterior 
segment such as permeability enhancement across the blood-aqueous barrier and cornea, longer 
drug contact time with ocular tissues, specific/controlled delivery of drugs to the target site and 
protection of drugs from degradation and metabolism. Due to their size, low irritation and 
sustained release properties are expected, as well as less frequent administration (55).  
Liposomes are lipid vesicles with one or more phospholipid bilayers enclosing an aqueous core. 
Liposomes are adequate ophthalmic delivery systems due to the suitable biocompatibility, cell 
membrane-like structure and ability to encapsulate both hydrophilic and hydrophobic drugs (36). 
They have been investigated in ophthalmic drug delivery since 1980's. The earliest applications 
of liposomes were for topical drug delivery in the form of the eye drops and intravitreal injections 
for prolonged action (25). Although liposomes could entrap a wide range of molecules, their use 
is limited in topical ocular delivery because of relatively poor stability (36). Various 
modifications were evaluated to circumvent this drawback and one of the interesting approaches 
appears to be light activated liposomes which enable drug release at specified time and site with 
the projected laser light (25). 
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Niosomes are non-ionic surfactant vesicles structured in bilayers, ranging from 10-1000 nm, 
which can entrap both hydrophilic and lipophilic drugs (36). Niosomes are suitable for topical 
ocular delivery due to the following benefits: chemical stability, ease of surface formation and 
modification because of the functional groups on their hydrophilic heads; improvement of 
bioavailability and effectiveness in the modulation of drug release properties (32,47,55). 
Furthermore, they are biodegradable, biocompatible, and non-immunogenic.  
Cubosomes are defined as nanoparticles of a liquid crystalline phase with cubic crystallographic 
symmetry formed by the self-assembly of amphiphilic or surfactant-like molecules (36). Glycerol 
monoolein is one of the most common surfactants used to make cubosomes. Cubic phases have 
useful properties, such as their ability to solubilize hydrophobic, hydrophilic, and amphiphilic 
molecules, their biodegradability by simple enzyme action and their suitability as sustained 
release delivery systems. Furthermore, the cubic phase is strongly bioadhesive and is thought to 
be a permeation enhancer (57). Several preclinical studies evaluated and showed promise for use 
of cubosomes as ophthalmic drug delivery systems (36,57). 
Dendrimers are nanoscale, highly branched and reactive three-dimensional macromolecules with 
a high degree of molecular uniformity, narrow molecular weight distribution, specific size and 
interesting structural properties like internal voids and cavities and a highly functional terminal 
surface formed by amino, carboxyl and/or hydroxyl groups (28). In addition to the outstanding 
structural control, their unique property is mimicry of globular proteins. They are referred to as 
“artificial proteins”, based on their systematic, electrophoretic, dimensional length scaling and 
their biomimetic properties (58). Several preclinical studies showed their potential for ophthalmic 
use (28). Reports describe multiple use of dendrimers in ophthalmology for delivery of various 
drugs (genes, antioxidants, peptides) (36).  
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2.3. Hydrogels in ophthalmic drug delivery 
 
Aqueous gels or hydrogels formulated using hydrophilic polymers along those based on stimuli 
responsive polymers (in situ forming gels) are in the focus for the ophthalmic drug delivery via 
different routes of administration (Figure 5). Hydrogels allow the incorporation of various 
ophthalmic drugs (hydrophilic, lipophilic and biologicals). An interesting delivery systems based 
on hydrogels are hydrogel contact lenses. Due to their high water content and favourable 
properties they are highly compatible with human tissues (47). They extend the retention time of 
the drug, control and extend its release to several days or even months and enhance its eye-related 
bioavailability to more than 50% in comparison to conventional eye drops (47). Mostly used 
polymers in these lenses are hydroxyethyl methacrylate, methacrylic acid, polyvinyl alcohol and 
silicones. 
In situ forming gels stand out as the main candidates for topical ophthalmic drug delivery and due 
to their unique properties they have great market potential. They are prepared as liquid dosage 
forms (provides dose accuracy) which undergo phase transition on eye surface or conjunctival sac 
to form viscoelastic gel in response to an environmental stimulus following topical 
administration. The environmental stimulus can be of physical (temperature, light), chemical (pH, 
redox potential, ionic strength) and biological origin (inflammation, enzymes) (3,47). 
 
 
Figure 5.  Application sites of hydrogels in ophthalmology, picture reprinted with permission 
from (3). 
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2.3.1. In situ forming ophthalmic gels 
One of the solutions of innovative pharmaceutical science for efficient ophthalmic drug delivery 
are in situ forming ophthalmic gels. They are prepared from polymers that exhibit reversible 
phase transitions and, due to their favorable rheological properties, minimize interference with 
blinking, avoid foreign body sensation and blurring of vision (3–5). Such systems are formulated 
as drug containing liquid suitable for instillation into the eye that shifts to the gel phase upon 
exposure to physiological conditions (7). Till now, for the purpose of ophthalmic delivery 
physical and chemical stimuli such as temperature, pH and ions were investigated (4,59). These 
triggers can be modified to control gel formation, retention time on the eye surface and drug 
release (6). Since they are not performed gels, but (viscous) solutions at administration, dosing is 
easier, more accurate and reproducible in comparison to the application and dosing of preformed 
gels. Additionally, in situ forming gels systems have gained major interest since no organic 
solvents or copolymerization agents are needed to trigger gelation (47).  
Since gelling can be affected by various factors such as salt concentration, ionic strength, pH, 
temperature, presence of a drug, adequate characterization of in situ forming gels is prequisite for 
their ophthalmic application. Pseudoplastic flow characteristics should be demonstrated with 
thixotropic properties which would assure easy spreadability across the ocular surface upon 
blinking and transformation to a more viscous material under low shear rate conditions to prolong 
the ocular residence time. Very important are safety issues which can be addressed with 
appropriate in vitro biocompatibility and in vivo ocular tolerability tests. Desirable properties of 
ideal ophthalmic gels and analytical methodology for their determination are summarized in the 
Table 1. 
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Table 1. Characteristics and mode of investigation of topical ophthalmic gel formulations, 
reprinted with permission and modified from (47). 
Characteristic  Analytical methods 
Clarity and optical transmittance  Visual inspection, refractive index or spectrophotometric analysis 
Safety and good ocular tolerance Observation for possible adverse effects  
Visual acuity 
Ocular tolerance (Draize, HETCAM, BCOP and histology tests)  
Cell-based cytotoxicity assays 
Isotonicity test (osmommeter) 
Suitable pH  Measurement of pH at biorelevant temperature 
Pseudoplastic and thixotropic flow  
Viscoelasticity 
Cone and plate in rotational or oscillation rheometer 
Gelling capacity  Qualitative observation of gel formation in simulated tear fluid 
Mucoadhesive properties  Polymeric mucoadhesion tests (rheometer) 
Bioadhesive force of the gel 
Extended residence time on eye surface Precorneal residence assessed using gamma scintigraphy 
Ease and reproducibility of application  Gel consistency (rheometer), firmness and cohesiveness assessed by 
texture analyzer 
Compatible excipients Fourier transform infrared spectroscopy used to analyse potential 
drug-polymer interactions 
Physical properties  Solid-state properties (X-ray powder diffraction and particle size 
analyzed by dynamic light scattering) 
Sustained/modified drug release  In vitro release studies 
Enhanced transocular permeation  Ex vivo transcorneal and transscleral permeation studies 
Sterility  Direct inoculation method 
Stability Storage stability investigated 
 
Polymers used in these systems are of natural, semisynthetic or synthetic origin, providing the 
unique property of significant structure conversion from viscous solution to gel upon reception of 
physical, chemical or biological stimulus (47). Advantages associated to hydrogels consisting of 
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the polymers of natural origin usually are non-toxicity, biodegradation, interaction with proteins 
and cells non-specific or specific binding (3). However, their potential drawbacks are weak 
mechanical strength, batch-to-batch inconsistency and immunogenicity. On the contrary, 
synthetic polymers offer well defined hydrogels in terms of network architecture, mechanical 
properties and prolonged stability, while they do not inherently interact with proteins or cells and 
their biocompatibility and biodegradability must be thoroughly assessed (3).  
Polymers used in formation of in situ forming gels can be classified, according to the 
environmental stimuli that triggers sol-gel conversion, as temperature-responsive 
(thermoresponsive), pH or ion-responsive system (47). 
Various studies have shown that these drug delivery platforms could improve the treatment of 
diseases affecting the surface and anterior segment of the eye, such as glaucoma, cataracts, dry 
eye disease, uveitis and ocular microbial infections, including conjunctivitis or keratitis. Some of 
these delivery platforms which are already either commercially available, or in clinical trials are 
summarized in the Table 2. Marketed ophthalmic products are indicated mainly for glaucoma, 
dry eye and ocular infections (6). 
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Table 2. In situ forming ophthalmic gels; either commercially available or currently in 
(pre)clinical trials. 
 
Trade name Indication Manufacturer 
Polymer(s) 
(mechansim  of 
gelation) 
Active 
ingredient 
market/status 
Betoptic S
®
 Glaucoma Alcon
®
 
Carbomer (pH-
responsive) 
Amberlite
®
 IRP-69  
(ion exchange resin) 
Betaxolol 
On the US and 
EU market 
Carteol
®
 LP Glaucoma  
Bausch & Lomb, 
Inc. 
Alginic acid  
(ion-responsive) 
Carteolol 
hydrochlorate 
 On the EU 
market  
Timogel
®
 Glaucoma 
Théa PHARMA 
S.A. 
Gellan gum  
(ion-responsive) 
Timolol maleate 
On the EU 
market 
Timolol GFS Glaucoma Sandoz, Inc. 
Gellan gum and 
xanthan gum 
(ion-responsive) 
Timolol maleate  
On the US 
market 
Timoptic XE Glaucoma Merck & CO, Inc. 
Gellan gum  
(ion-responsive) 
Timolol maleate  
On the US 
market 
Timoptol®-LA Glaucoma Santen UK Ltd. Gellan gum  
(ion-responsive) 
Timolol maleate  
On the UK 
market 
Rysmon
®
 TG Glaucoma 
Wakamoto 
Pharmaceutical 
CO., LTD. 
Methylcellulose 
(temperature-
responsive) 
Timolol maleate 
On the 
Japanese 
market 
Refresh 
liquigel
®
 
Dry eye Allergan, Inc. 
Carboxymethylcellul
ose sodium 
(temperature-
responsive) 
/ 
On the US 
market 
REFRESH 
OPTIVE
® 
Gel Drop 
Dry eye Allergan, Inc. 
Carboxymethylcellul
ose sodium  
(temperature-
responsive) 
Glycerin  
 
On the US 
market 
Systane gel 
drops
®
 
Dry eye Alcon
®
 
Hydroxypropyl-guar 
(pH-responsive and 
ion-responsive) 
Polyethylene 
Glycol 400  
Propylene 
Glycol 
On the US and 
EU market 
Systane
® 
Balance 
Dry eye Alcon
®
 
Hydroxypropyl-guar 
(pH-responsive) 
/ 
On the US and 
EU market 
TobraDex 
ST
 Blepharitis Alcon
®
 
Xanthan gum  
(ion-responsive) 
Tobramycine 
Dexamethasone 
On the US 
market 
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Trade name Indication Manufacturer 
Polymer(s) 
(mechansim  of 
gelation) 
Active 
ingredient 
market/status 
AzaSite
TM
  
Bacterial 
conjunctivitis 
Inspire 
Pharmaceuticals, 
Inc. 
Polycarbophil  
(pH-responsive)  
Azithromycin 
Dexamethasone 
On the US 
market 
Besivance
TM
 
Bacterial 
conjunctivitis  
Bausch & Lomb, 
Inc. 
Polycarbophil 
(pH-responsive) 
Besifloxacin  
On the US, 
Argentina and 
Canadian 
market 
AzaSite
TM
 Plus  
Ocular 
infections and 
inflammation  
InSite vision, Inc. 
Polycarbophil 
(pH-responsive)7  
Azithromycin 
Phase III trials 
(US) 
AzaSite Xtra™  Ocular 
infections 
InSite vision, Inc. 
Polycarbophil 
(pH-responsive) 
Azithromycin 
GLP tox 
studies 
finished (US) 
BromSite
TM
  
Ocular 
inflammation 
Sun 
Pharmaceutical 
Industries Ltd. 
Polycarbophil/ 
(pH-responsive)  
Bromfenac  FDA approved 
DexaSite
 TM
  
Ocular pain 
and 
inflammation 
InSite vision, Inc. 
Polycarbophil 
(pH-responsive) 
Dexamethasone 
Phase III trials 
(US) 
 
2.3.2. pH-responsive in situ forming gels 
Ophthalmic formulations containing pH-responsive polymers (polyelectrolytes), which exhibit 
sol-gel phase transition in response to environmental pH changes (47) are promising tool for 
improvement of eye-related bioavailability. These systems exploit the difference of pH of tear 
fluid (7.4) and the pH of formulation. Such gels are composed of polymers with backbones 
containing large number of charged pendant groups (60,61). The sol-gel phase transition results 
from changes in the ionisation state of the weakly acidic (carboxylic or phosphoric) or weakly 
basic (ammonium) groups present in the polyelectrolyte (47). Common characteristic of these 
polyelectrolytes is pKa value between 3 and 10 which renders them suitable for pH-responsive 
systems (62). Most widely used pH-responsive polymers for ophthalmic formulations are 
polyacrylic acid and its derivatives (polymethacrylic acid, polycarbophils), chitosan and cellulose 
acetate phthalate (4).  
Polyacrylic acid (also known as Carbomer, Carbopol) and its derivatives are anionic high 
molecular weight polymers whose acidic aqueous solutions are less viscous, while they are 
transformed into gels upon increasing the pH (Figure 6).  
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Figure 6. pH-dependent ionization poly(acrylic acid), picture reprinted with permission 
from (61). 
Sol to gel transition is related to their polyanionic nature. Upon pH increase, as a result of the 
electrostatic repulsion of the negatively charged groups, polymers swell and gel is formed. Gel 
structure further entraps the drug molecules and delivers them to the environment in controllable 
manner. Sol-gel transitions of polyacrylic acid is dependent on the polymer molecular weight. 
Another beneficial feature of these polymers is mucadhesion, which is a result of physical 
entanglements or secondary bonds (63). Due to these favorable characteristics with positive 
impact on the eye related bioavailability, polyacrylic acid and its derivatives are frequently used  
in ophthalmic formulations (6). 
Cellulose acetate phthalate is another polymer whose solutions show pH dependent gelation. It 
has a potential for sustained drug delivery to the eye because it is a free flowing solution at a pH 
of 4.4 and undergoes gelation when the pH is increased by the tear fluid to pH 7.4. This shift in 
pH results in almost instantaneous conversion of the fluid to a viscous gel. Gelation is triggered 
by neutralization of the acid groups of the polymer chain (4). 
 
2.3.3. Ion-responsive in situ forming gels 
Polymers which solutions undergo phase transition to gel in the presence of different ions are 
known as ion-activated polymers. The ones with the potential for ophthalmic administration are 
those which interact with the ions present in the tear fluid (e.g. sodium, potassium and calcium). 
The most widely used ion-activated polymers in ophthalmic formulations are (deacetylated) 
gellan gum, xanthan gum, carrageenan and alginate (4,64). 
Deacetylated gellan gum (Gelrite
®
) is anionic polysaccharide and it composed of tetrasaccharide 
repeating-units (Figure 7A). Cross-linking of the negatively charged polysaccharide helices by 
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monovalent and divalent cations (Na
+
, K
+
, Ca
2+
) is driving the change of structure form sol to gel. 
Na
+
 was found to be the most gel-promoting ion in vivo and gel formed is liquid crystalline 
comprising three-fold helical chains organized in parallel fashion in an intertwined duplex 
stabilized by hydrogen bonds (65). 
Deacetylated gellan gum and alginate are approved as a pharmaceutical excipients for ophthalmic 
use. Gellan gum is marketed in two controlled-release glaucoma formulation called Timoptic-
XE
® 
(Merck) and Timolol GFS (Sandoz), while alginate, also for glaucoma therapy is marketed 
in France as Carteol LP by Laboratoire Chauvin, a Bausch and Lomb company. 
 
 
Figure 7. Structural formula of gellan gum (A) and alginate with mechanism of gelation in 
presence of Ca
2+ 
(B), reprinted from (66). 
 
Similarly to gellan gum, aqueous solutions of alginate (Figure 7B) (a natural polysaccharide 
extracted from brown sea algae) also form gels when instilled into the eye. Alginates, due to their 
excellent biodegradable, biocompatible and mucoadhesive properties and are often used as 
constituents of numerous drug delivery systems (67). Alginic acid is a linear and anionic block 
copolymer polysaccharide comprising b-D-mannuronic acid and a-L-glucuronic acid residues 
joined by 1,4-glycosidic linkages. Dilute aqueous solutions of alginates form strong gels on 
addition of di- and trivalent cations by a cooperative process involving consecutive glucuronic 
residues in the a-L-glucuronic acid blocks of the alginate chain. 
A) B) 
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Rupenthal et al. characterized several ion-activated polymeric systems in vitro and in vivo (64). 
Among number of anionic polysaccharides (gellan gum, xanthan gum, carrageenan and alginate), 
formulations based on gellan gum and carrageenan exhibited the most favorable characteristics in 
terms of phase transition, rheological and textural properties, as their viscosity significantly 
increased upon contact with cations of the tear fluid, thus prolonging precorneal retention time 
and reducing nasolacrimal drainage (64). All tested polymeric formulations were found to be 
non-irritant and classified as safe for in vivo use. Systems based on gellan gum, xanthan gum and 
carrageenan exhibited the most favorable characteristics in terms of precorneal retention as well 
as delayed release of the model hydrophilic drug (pilocarpine hydrochloride) in vivo (8).  
 
2.3.4. Temperature-responsive in situ forming gels 
The sol-gel transition of this class of in situ forming gels is triggered by a temperature change 
from storage to physiological temperature i.e. temperature of the eye surface. A literature 
overview of the temperature-responsive in situ forming ophthalmic gels is summarized in the 
Table 3. Summarized data show that the major driving force for sol-gel transition for 
temperature-responsive in situ forming gels is predominance of hydrophobic interactions of 
amphiphilic (co)polymer molecules with the temperature increase. 
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Table 3. Temperature-responsive in situ forming ophthalmic gels. 
Temperature 
responsive 
polymer 
Mechanism of gelation upon temperature 
increase 
Polymer 
concentration 
range, w/w, % 
Active ingredient 
(reference) 
PEO–PPO–PEO1 
(Poloxamers) 
Micelle formation occurs at the critical 
micellization temperature as a result of PPO 
block dehydration.  
With increasing temperature, micellization 
becomes more dominant and at a definite point, 
micelles come into contact and no longer move 
(68,69). 
14–42% 
 
fluconazole (70)  
diclofenac sodium (15) 
pilocarpine (71) 
dorzolamide HCl (72) 
acyclovir (18) 
timolol maleate (7) 
rhEGF (14) 
Cellulose 
derivative CMC, 
MC, HPMC
2
 
Hydrophobic interactions among polymer chains 
containing methoxy groups (68,69). 
1–10% 
 
ciprofloxacin 
hydrochloride (73)  
ketorolac tromethamine 
(74) 
Xyloglucan Hydrophobic parts of polymer molecule 
aggregate to minimize the hydrophobic surface 
area contacting the water, causing gelation 
(68,69). 
1.0–2.0% pilocarpine HCl (75) 
ciprofloxacin (76) 
PNIPAAm
3
 Hydrophobic interactions between polymer 
chains become predominant, hydrogen bonds are 
broken and the polymer dehydrates (68,69). 
≈10% epinephrine (77) 
PLGA–PEG–
PLGA
4
 
 
Hydrophobic forces drive the sol-gel transition 
of amphiphilic polymers, to micelles, and upon 
further temperature increase, micelles aggregate 
in gel (68,69). 
15–20% dexamethasone acetate 
(78) 
1
 PEO-polyethylene oxide; PPO-polypropylene oxide 
2
 CMC-Carboxymethyl cellulose; MC-Methyl cellulose; HPMC-Hydroxypropylmethyl cellulose 
3
 Poly N-isopoprylacrilamide 
4
 PLGA-polylactide-co-glycolyde; PEG-polyethylene glycol 
 
Cellulose derivatives (carboxymethyl cellulose (CMC), methyl cellulose (MC) and 
hydroxypropylmethyl cellulose (HPMC)) are polymers of natural origin and their solutions are 
exhibiting temperature triggered sol-gel phase transition (47). As temperature responsive 
systems, they are marketed as artificial tears or lubricating solutions and commercially available 
products are summarized in the Table 2.  
MC and HPMC aqueous solutions form gels at concentrations ranging from 1–10%, while Tgels 
are ranging from 40–50°C and 75–90°C respectively. Tgel of these systems decreases with a 
higher degree of cellulose ether substitution or with the addition of salts or other polymers (47). 
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Therefore, combining cellulose derivatives with other polymers results in systems with enhanced 
properties to favour ophthalmic drug delivery (i.e. lower Tgel, enhanced viscosity) (47).  
Among many other investigated polymers, poloxamers, poly N-isopoprylacrilamide (PNIPAAm) 
and xyloglucan are frequently used as ophthalmic drug delivery systems. Aqueous solution of 
linear polymer PNIPAAm undergoes phase transition (precipitation) when the temperature is 
raised from the room temperature to about 32°C. Based on this polymer, Hsiue and coworkers 
developed and tested two types of glaucoma therapy thermosensitive systems containing 
epinephrine (77). One was the solution of linear PNIPAAm, and the other was the mixture of 
solution of linear PNIPAAm and suspension of crosslinked PNIPAAm nanoparticles. Both 
systems were biocompatible, while the latter system had more appropriate drug release profile. 
Results of the animal (rabbits) experiments demonstrated that the intra ocular pressure-lowering 
effect achieved with investigated systems lasted considerably longer than that achieved with 
conventional eye drops (77).  
Xyloglucan is a polysaccharide which when partially degraded by ȕ-galactosidase exhibits 
thermally reversible gelation in dilute aqueous solution, the sol–gel transition temperature 
varying with the degree of galactose elimination (75). Furthermore, xyloglucan possess properties 
such as mucoadhesivity, biocompatibility, high drug entrapment capacity and high thermal 
stability. This properties led to its application as desirable excipient in ophthalmic drug delivery 
systems (76). Miyazaki and coworkers developed xyloglucan gels with prolonged duration of 
miotic response following release of pilocarpine over a period of at least 4 h (75). 
Biodegradable and water-soluble amphiphilic triblock copolymer of poly–(DL–lactic acid co–
glycolic acid) (PLGA)–polyethylene glycol (PEG)–PLGA (PLGA–PEG–PLGA) has been 
applied in temperature responsive in situ forming gel formulations and has been widely used in 
parenteral delivery systems (69). Gao et al. evaluated its use for ophthalmic delivery of 
dexamethasone acetate (78). The results of rabbit ocular pharmacokinetics indicated that the 
PLGA–PEG–PLGA temperature-responsive in situ forming gel achieved significantly enhanced 
bioavailability in the anterior segment in comparison to conventional eye drops. 
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2.4. Poloxamer-based in situ forming ophthalmic gels 
Poloxamers (trade name Pluronic
®
), a series of closely related block copolymers of polyethylene 
oxide (PEO) and polypropylene oxide (PPO) with the general formula 
HO(C2H4O)a(C3H6O)b(C2H4O)aH, have been investigated as in situ forming gels (9). At high 
concentrations of poloxamers, the aqueous solutions exhibit a dramatic change of the viscoelastic 
moduli and become soft solids or gels. A phase transition from liquid to gel upon reaching 
physiological temperatures is presently one of the most important phenomenon for their 
applications (79).  
Poloxamer block copolymers are available in a range of molecular weights and PPO/PEO 
composition ratios. An attractive poloxamer as in situ forming ophthalmic gel is Poloxmer P407 
(P407), also known as Pluronic F127. P407 has approximate block lengths of a = 101 (≈ 70% of 
PEO) and b = 56 (≈ γ0% of PPO) and average molecular weight of about 12 600 (9840– 14,600) 
Da, with PEO/PPO ratio of 2:1 (80,81). It has a greater solubility in cold water relative to warm 
water, because of greater hydrogen bond interactions and solvation at lower temperatures (47). 
As a result of these molecular properties, upon temperature increase P407 converts into a 
colorless, optically clear and transparent gel which makes it attractive as a delivery platform for 
ophthalmic drugs. Ophthalmic, topical and injectable P407 formulations have shown 
advantageous properties by promoting stabilization and solubilization of many active 
pharmaceutical ingredients (APIs) (82). However, concentrated P407 aqueous solutions (>18 %, 
w/w) gel already at the ambient temperature (11). In that case, in situ forming ophthalmic gel has 
to be stored in refrigerator and applied cold (7) which makes its instillation to the front of the eye 
possibly irritating and painful. 
Use of P407 in mixture with other poloxamers is considered as a strategy to decrease the P407 
concentration, modulate the temperature of gelation and rheological properties of in situ forming 
gel. Among others, poloxamer 188 (P188) was shown to be a good modulator of P407 in situ 
forming gels (11–13). P188, also known as F68, has less hydrophobic properties in comparison to 
P407, and average molecular mass about 8400 (7680–9510) Da, while block lengths are a = 80 (≈ 
80% of PEO) and b = β7 (≈ β0% of PPO), providing PEO/PPO ratio of 4:1 (81).  
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Studies focused on the development of in situ forming ophthalmic poloxamer gels are 
summarized in the Table 4 . 
Table 4. In situ forming ophthalmic poloxamer gels. 
Components in 
poloxamer based 
in situ forming 
ophthalmic gels 
Concentration 
range of polymers, 
w/w, % 
Total polymer 
concentration in 
optimal in situ 
forming gel 
w/w, % 
Active ingredient (reference) 
P407 18% – 25% 22% Forskolin (83) 
P407 12 – 20%, 
30% rhEGF (14) 
P188 10 – 30% 
P407 0 – 20% 
20% 
Fluorescein sodium 
P188 0 – 20% Ofloxacin (84) 
P407 15 – 25% (w/V, %) 
33%, 38% Ketorolac tromethamine (85) 
P188 5 – 15% (w/V, %) 
P407 13.65% 
21.61% Dorzolamide HCl (72) 
P188 3.41% 
Miranol C2M 4.55% 
Triacetin 7.80% 
P407 14 – 26%, 
31.1% Diclofenac sodium (15) P188 8 – 11% 
Carbopol 940 0.1 – 0.3% 
P407 15 – 20% 
21.1% Fluconazole (86) Tween 80 0.5 – 1.5% 
Carbopol 934 0.1 – 0.3% 
P407 15 – 25% 
18% Timolol maleate (7) 
HPMC
1
 2% 
MC
1
 3% 
CMC
1
 2.50% 
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Components in 
poloxamer based 
in situ forming 
ophthalmic gels 
Concentration 
range of polymers, 
w/w, % 
Total polymer 
concentration in 
optimal in situ 
forming gel  
w/w, % 
Active ingredient (reference) 
P407 18 – 25% 25% without an active ingredient 
(87) 
PEG 6000 2 – 5 % 
P407 15% 27% Acyclovir (18) 
P188 10 – 15% 
Hyaluronic acid  0.5 – 2% 
P407 21% 31% labeled with Technetium-99m-
diethylen triaminepentaacetic 
acid (11) 
P188 10% 
Sodium hyaluronate  0. 2% 
P407 16% 17% Fluconazole (70) 
CS
2
 0.5 – 1.5% 
P407 18% 18% Pilocarpine HCl (88) 
Gellan gum 0.1 – 1% 
P407 15 – 20%;   17.2% Betaxolol HCl (89) 
HPMC
1
 0.5 – 1.0% 
P407 P407 25% 28%, 30% Pilocarpine (71) 
HPMC
1
 HPMC 3% 
MC
1
 MC 5% 
1 
HPMC-Hydroxypropylmethyl cellulose; MC-Methyl cellulose; CMC-Carboxymethyl cellulose 
2
 CS - Chitosan 
Although poloxamers are widely investigated as potential in situ forming gel systems, they suffer 
from a drawback of having weak mechanical strength, which can lead to rapid gel erosion (7,20). 
To promote mechanical strength of poloxamer gels and consequently prolong their residence time 
and therefore eye-related bioavailability, different polymers/additives are added to their systems 
(7). Furthermore, since P407 mucoadhesivness, a very important parameter for effective 
ophthalmic delivery, is low (90), it is frequently combined with mucoadhesive polymers such as 
polyacrylic acid (Carbopol) (91) and hyaluronic acid (18). 
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Gratieri et al. developed (20) ophthalmic in situ forming gel by combining poloxamer P407 and 
chitosan. Chitosan was added to the P407 in order to obtain adequate gel strength. The developed 
system had adequate mechanical and mucoadhesive properties. They demonstrated that 
poloxamer/chitosan formulations in a concentration of 16% of poloxamer and 0.5 – 1.5% of 
chitosan showed optimal gelation temperatures (Tgel≈γβ°C) and were able to withstand low 
shearing forces at 35°C. The mechanical properties of these formulations, especially the one 
containing 1% of chitosan, indicated high hardness and adhesiveness, besides showing prolonged 
retention. This group subsequently incorporated the antifungal agent, fluconazole, in the 
developed systems which resulted in prolonged API release when compared to the chitosan 
solution (70). The drawback of developed platform was its low resistance to dilution with 
simulated tear fluid. Namely, after dilution, rheological analysis revealed that the system behaved 
as viscoelastic solution at 35C, indicating possible issues with controlled drug delivery.  
Wei et al. evaluated the influence of P188 on P407 ophthalmic gels in concentration range from 
16 – 24% for P407 and 0 – 20% for P188 (11). The mixed poloxamer solution containing 21% 
P407 and 10% P188 was free flowing liquid below β5°C and converted to a gel under 
physiological conditions. Gamma scintigraphic results demonstrated that the clearance of the in 
situ forming gel encapsulating label molecule (Technetium-99m-diethylentriamine pentaacetic 
acid) was significantly delayed with respect to the phosphate buffered solution, while at least a 
threefold increase of the precorneal retention time was achieved. 
Asasutjarit et al. developed diclofenac sodium in situ ophthalmic gel based on P407. P188 was 
added to modified Tgel and Carbopol 940 as mucoadhesive agent (15). The optimized in situ gel 
formulation obtained from this study contained 20%/11%/0.1% (w/w/w) of P407/P188/Carbopol. 
It could be easily applied at the room temperature and transformed to a gel exhibiting 
pseudoplastic flow behavior at the precorneal temperature. In vitro and in vivo eye irritation test 
showed that it could be accepted as safe for ophthalmic use. In addition, in vivo evaluation of 
ophthalmic absorption indicated that formulation could increase ophthalmic bioavailability of 
diclofenac sodium in rabbits and reduce the frequency of administration significantly compared 
to a commercial product. 
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Fathalla et al. developed two optimal P407/P188 gels having polymer concentrations 23%/10% 
(w/V) and 23%/15% (w/V), respectively (85). These in situ gels appeared to be a promising 
ophthalmic delivery system for ketorolac.  
In all these studies both poloxamers were used in in situ forming ophthalmic gels at very high 
total concentration, e.g. P407 and P188 in concentration of 23% and 10% and 23% and 15%, 
(w/V) (85) 21% and 10% (11); 16% and 14% (14); 20% and 11% (w/w) (15), respectively. 
Decreasing the total polymer concentration would surely have significant positive implications on 
economic issues and possible toxicity issues related to chronic use of poloxamer-based in situ 
forming ophthalmic gels.  
 
2.5. Considerations for formulation development of poloxamer-based in 
situ forming ophthalmic gels 
 
In situ forming ophthalmic gels need to be fine-tuned considering all the biopharmaceutical 
challenges of the front of the eye in order to increase drug residence time at the application site 
resulting in its improved bioavailability and efficacy (Table 1).  
The optimal poloxamer-based in situ forming gel should be characterized by: (i) temperature of 
gelation in physiologically relevant range; (ii) pseudoplastic behavior that allows gel to thin 
during blinking, making it more comfortable and easier to spread across the eye surface (8); (iii) 
suitable gel strength to endure the dilution with tears. Beside these crucial properties related to in 
situ forming gel performance, the formulation has to meet strict requirements of biocompatibility 
and sterility. Further criteria which can have influence on in vivo performance of in situ forming 
gel or patient acceptance include suitable pH, osmolality and refractive index. The eye can 
tolerate products over a range of pH values from about 3.0 to about 8.6, however normal tears 
have a pH of about 7.4 (38). Ophthalmic products may be tolerated over a fairly wide range of 
tonicity (0.5%–5% sodium chloride, equivalent to about 171–1711 mOsm/kg). Hypotonic 
solutions are better tolerated than hypertonic solutions (38). Refractive index measurements 
detect possible impairment of vision or discomfort to the patient after administration of eye 
drops. Refractive index of tear fluid is 1.340–1.360. It is recommended that eye drops should 
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have refractive index values not greater than 1.476 (72). However, it should be kept in mind that 
additives that regulate the formulation pH or osmolality can influence the rheological properties 
of in situ forming gels and the effects of their addition have to be investigated and controlled.  
Additional criteria are related to the active ingredient incorporation, its availability and stability 
(3). Availability relates to the capability of delivering drugs at the right dose and it is closely 
related to the drug release rate form the formed gels. The drug release rate is mostly defined by 
the physicochemical properties of the active ingredient, polymer concentration, gel rheological 
properties and the affinity of active ingredient for the polymer network.  
Last but not least, the stability of developed formulation represents a critical quality parameter, 
and therefore the storage conditions to insure stability and the shelf life have to be determined. 
As seen from previously listed studies (Table 4), poloxamer systems show remarkable potential 
as in situ forming ophthalmic gels, however they were used at very high total concentrations. In 
addition to decrease the total polymer concentration, improvements in the biopharmaceutical 
properties of poloxamer ophthalmic gels can be achieved by the presence of different additives in 
the formulation (16–18,20,92), such as chitosan. These improvements of poloxamer systems 
result in enhanced viscoelastic properties and mechanical strength of in situ forming gels which 
consequently prolong drug residence time at site of administration (18) and could promote system 
resistance to dilution by tears. 
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2.6. Chitosan in ophthalmic drug delivery 
 
Chitosan is a biocompatible and biodegradable polycationic polymer with pKa of 6.5. Its 
mucoadhesive properties, important for ophthalmic delivery systems, are related to the fact that 
below its pKa, chitosan is positively charged and electrostatically interacts with negatively 
charged epithelial surfaces (48). It is a heteropolymer containing both glucosamine and 
acetylglucosamine units (Figure 8). This polymer distincts from other commonly available 
polysaccharides due to the presence of nitrogen (93). It is not considered as one chemical entity 
since it can be found in a variety of forms differing in size (average molecular weight and 
molecular weight distribution) and degree of deacetylation (DD) and this diversity is 
exponentially increased by the numerous chemical modifications that have been investigated 
(94).  
 
 
Figure 8. Structure of chitosan 
Chitosan has already been demonstrated to increase the mechanical strength and 
mucoadhesivness of poloxamer in situ forming ophthalmic gels (20). Furthermore, there are other 
benefits of including chitosan in ophthalmic formulations such as improvement of eye-related 
permeability due to its paracellular permeation enhancing effects (21), antimicrobial activity (22) 
and corneal wound healing effect (23). 
Chitosan does not cause allergic reactions due to its biocompatible character and ophthalmic 
safety of chitosan is well documented in literature (95,96). Pioneering work in chitosan 
ophthalmic safety was done by Felt and coworkers (95). They studied and reported excellent 
ocular tolerance of chitosan in rabbit model following topical instillation of its solutions using 
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confocal laser scanning ophthalmoscopy combined with corneal fluorescein staining. Their 
conclusion was that chitosan is a well-tolerated polymer suitable for the development of 
ophthalmic formulations intended for topical use. There are a significant number of other studies 
demonstrating the ocular biocompatibility of chitosan. In addition, Pepić and coauthors studied 
the potential of poloxamer/chitosan micelle system as ophthalmic dexamethasone delivery 
system (96). In vivo study in rabbits showed no ocular damage or clinically abnormal signs in the 
cornea, conjunctiva or iris. 
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2.7. Rheological characterization of in situ forming gels 
 
Hydrogels are defined by International Union of Pure and Applied Chemistry as a polymer 
networks that are expanded throughout their whole volume by water (97). When considering 
ophthalmic preparations, it is difficult to clearly draw the line between highly viscous solutions 
and the actual gels. One of the interesting definitions of gels is that they are systems at the upper 
limit of viscous preparations which are formed when high molecular weight polymers and/or high 
polymer concentrations are incorporated into the formulation (5). 
Another definition has been made that the term ’’gel’’ should be limited to the systems which 
fulfil the following phenomenological characteristics:  
(i) they consist of two or more components one of which is a liquid, present in substantial 
quantity and 
(ii) they are soft, solid, or solid-like materials (98).  
The term 'rheology' is derived from the Greek word rheos meaning to stream or flow. Rheology 
is the science of the flow and deformation of materials and describes the response of different 
materials to stress or shear. Many of solid materials will behave as liquids at very long times and 
most liquids will respond like solids at short times. They cover the spectrum of ’’viscoelastic 
materials’’. Rheological characterization of these materials is very important, since it provides 
unique insights into their microstructure (99). Characterization of the microstructure and flow 
properties of semisolid and liquid pharmaceuticals is essential for understanding and controlling 
their rheological behavior. 
Moreover, definition of the solid-like characteristics of gels in terms of the dynamic mechanical 
properties (tested by oscillatory rheological tests) have been proposed, viz. a storage modulus, G', 
which exhibits a pronounced plateau extending to times at least of the order of seconds and a loss 
modulus, G", which is considerably smaller than the storage modulus in the plateau region (98). 
Storage Modulus (G', Pa) is a measure of the deformation energy stored by the sample during the 
shear process. After the load is removed, this energy is completely available, now acting as the 
driving force for the reformation process which will compensate partially or completely the 
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previously obtained deformation of the structure. G' presents the elastic behavior of a sample 
(100). Loss Modulus (G", Pa) is a measure of the deformation energy used up by the sample 
during the shear process and therefore afterwards, it is lost for the sample. This energy is spent 
during the process of changing the material's structure, i.e. when the sample is flowing partially 
or completely. G'' represents the viscous behavior of a material (100). Quotient of the lost and the 
stored deformation energy is called the loss factor or damping factor – tanδ (tangent value of the 
phase angle): 
tanδ =G’’/G’                                                                                                                            (Eq. 1)                                                                           
According to Thomas Mezger’s The Rheology Handbook, gels are defined as viscoelastic 
materials which, in oscillation rheological testing, exhibit G’>G’’ with tanδ<1, while minimal 
adequate G’ values for gel structures would be around 5 Pa (100). Moreover, Kojarunchitt et al. 
defined soft gels as viscoelastic systems where G’=G’’ (101). From all the definitions and 
arguments mentioned, conclusion can be made that gels can hardly be adequately defined without 
appropriate rheological characterization. 
Two types of tests rheological tests are usually employed in investigations of viscoelastic 
materials- shear tests and oscillatory tests.  
In order to gain reliable results, the structure of a gel must not be disturbed during its rheological 
characterization. Therefore, shear stress is a crucial parameter and needs to be precisely adjusted 
and controlled. This inherently excludes rotational rheometers from any kind of investigations on 
either gel formation or gel structure characteristics (102). From this reason oscillatory, tests 
(Figure 9) are employed. They are important since they explore the viscoelasticity of a sample 
providing a microstructural fingerprint that can be used to quantify stability and to sensitively 
refine critical aspects of product performance (103). 
During the oscillatory testing the sample is subjected to a relatively small shear force or 
displacement applied in the form of a sinusoidal wave (Figure 9A). Oscillatory rheometers are 
specified to apply the bi-directional movement of the upper geometry, relative to the lower, that 
is required to achieve this (103). When performing full rotation, the wheel is turning over rotation 
angle of 360°. This corresponds to a complete oscillation cycle of the time dependent functions 
(t) (shear stress), Ȗ(t) (shear deformation/strain) and (shear rate) Ȗ(t). Ever during continuous . 
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rotation, when the wheel is passing the angle positions of 0° and 180°, the upper plate is showing 
the zero position and therefore, Ȗ(t) =0 and also (t)=0 (100). 
 
 
Figure 9. Oscillatory rheological test: A) two plates model to illustrate oscillatory shear 
tests, picture reprinted from (104); B) oscillatory tests: shear force ▫F, deflection 
path ▫s and deflection angle ▫φ in the shear gap h, picture reprinted with 
permission from (100).  
The velocity, however, is at maximum where Ȗ(t)= Ȗmax. At the angle postion of 90°, the upper 
plate shows maximum deflection to the right, and at 270° occurs the maximum deflection to the 
left. Therefore, Ȗ(t) = Ȗmax and also   (t)=  max or Ȗ(t) = -Ȗmax and also   (t)= - max, respectively 
(100). 
A principle of oscillatory testing originates from the year 1676 when Robert Hooke (1635-1703) 
wrote law which described the proportionality of force and deformation for solids (ideally elastic 
materials):  
Deformation of solids is proportional to the applied force, i.e. the force needed to extend or 
compress a spring by some distance is proportional to that distance. Resulting relation is the 
spring law: 
 C = F / s                                                                                                                               (Eq. 2) 
Where F is the force acting on deflection path s on a spring with a constant C (measure of a 
stiffness). When performing oscillatory test on ideally elastic materials Hooke’s law applies as 
follows: 
(t) *)(  Gt                                                                                                                      (Eq. 3) 
with the complex modulus (G*) and the time dependent values of sinusoidal functions of  and Ȗ. 
G* can be described as the resistance against deformation (rigidity of material). Since 
- F + F
s s
   ϕ    ϕ
h
A B 
. . 
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consttG  (t) /)(*  , the  (t) curve is always in phase with the Ȗ(t) curve i.e. both curves are 
occurring without any delay between preset and a response in the form of sine curves (100).  
On the contrary to ideally elastic materials, in the oscillatory test, ideally viscous samples (or 
Newtonian) exhibit flow behavior described by the viscosity law or Newton's law:    
(t) *   )(  t                                                                                                                    (Eq.4) 
With the complex viscosity * and the time dependent values of the sine functions of  and Ȗ. 
Complex viscosity, *, can be imagined as the viscoelastic flow resistance of a sample. Since   
η* = / Ȗ = const, the  (t) curve is always in phase with the Ȗ(t) curve, i.e. both curves are 
appearing without any delay between preset and the response, showing the same frequency. If the 
Ȗ(t) curve is presented as a sine curve, both the  (t) curve and the Ȗ(t) curve are occurring as 
cosine curves. For samples showing ideally viscous behavior, there is a delay between the  (t) 
curve and the Ȗ(t) curve with the phase shift angle δ of 90° (δ=π/2 rad) (100). Therefore, based on 
their rheological behavior, viscoelastic liquids have phase angle equal or higher to 90° 
(Figure 11, Table 5)  and exhibit higher G’’ than G’ values in G’ G’’ plateau region (Figure 10). 
 
 
Figure 10. Typical oscillatory test (frequency sweep) data for samples behaving as a 
viscoelastic solid (as a gel or as a viscoelastic liquid), (picture reprinted from 
(103)). 
All gel systems are viscoelastic materials since they are exhibiting viscous and elastic behavior 
simultaneously.  
Viscoelasticity is the property of materials that exhibit both viscous and elastic characteristics 
when undergoing deformation. The viscous portion behaves according to Newton's law and the 
elastic portion behaves according to Hooke's law.  
. 
. 
. . 
. 
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Gels, as viscoelastic solid materials, display a time-dependent, delayed response, whether a stress 
or a strain are applied as well as when the stress/strain are removed. These materials have a phase 
angle (late in phase response to stress or strain) between 0 and π/β radians (0 and 90°, Figure 11,  
Table 5) (100) and in G’ G’’ plateau region exhibit higher G’ values (Figure 10). 
 
Figure 11. Shear stress vs. shear strain and resulting phase angle for elastic (δ=0°), 
viscoelastic (0°< δ<90°) and viscous (0≥90°) materials, (reprinted from (103)). 
On the other hand, ideally elastic materials do not have a shift in phase angle (δ = 0, Table 5).  
Table 5. Flow behavior of different materials with respect to G’, G’’, δ and tanδ,  
reprinted with permission from (100). 
Ideally viscous 
flow behavior 
Behavior of 
viscoelastic 
liquid 
Viscoelastic 
behavior showing 
50/50 ratio of the 
viscous and elastic 
portions 
Behavior of 
viscoelastic 
gel or a solid 
Ideally elastic 
deformation 
behavior 
δ=90° 90°>δ>45° δ=45° 45°>δ>0° δ=0 
tanδ→ ▪ tanδ>1 tanδ=1 tanδ<1 tanδ→ 0 
(G'→ 0) G''>G' G''=G' G'>G'' (G''→ 0) 
 
Two types of oscillatory tests which are commonly used for in depth characterization of gels are 
strain and frequency sweep analyses. 
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In the strain sweep (also known as amplitude sweep test) test oscillation is performed at variable 
strain amplitudes, while the frequency and temperature are kept at a constant value. These tests 
are carried out to determine the limit of linear viscoelastic (LVE) range and to evaluate 
mechanical spectra (G’ and G’’). LVE range is the range where stress () is directly proportional 
to strain (Ȗ). This term derives from the proportionality of pre-set and measured parameters (e.g. 
shear strain and shear stress). In a diagram, e.g. the G’-curve occurs as a straight line (100).  
 
 
Figure 12. Schematic representation of strain sweep test (reprinted from (105)).  
After determination of LVE of the sample, frequency sweep tests are commonly performed, since 
they provide an insight on the behavior of GƟ, GƠ and * as a function of angular frequency, 
while strain (Ȗ) is kept constant in the previously determined LVE range (Figure 13). From 
frequency sweep analysis information about a time dependent behavior is obtained. Short term 
behavior is simulated by rapid motion, while long term behavior is simulated by low frequencies 
(100). 
 
Figure 13. Schematic representation of frequency sweep test (reprinted from (106)).  
 
In rotational tests the rheological properties of materials can be characterized in a steady simple 
shear flow with homogeneous regime of deformation. Basically there are two different regimes of 
deformation: imposition of constant rotational speed or constant torque, corresponding to 
controlled shear rate and controlled shear stress, respectively (107). Rotational rheology is used 
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to characterize the mostly complex, non-Newtonian, flow behavior of liquids, solutions, melts 
and dispersions. With most of the rheometers, the bob is the rotating part of the measuring 
system, but there are also types where the cup or the lower plate of the measuring system is set in 
rotational motion. 
 
Figure 14. Rotational rheological test (reprinted from (108)). 
 
Possible resulting curves, depending on nature of the tested material, are summarized in the 
Figure 15. Characterization and manipulation of the flow behavior of in situ forming gels in the 
experimental set up simulating conditions before and after administration to the eye surface 
assures their optimal performance. 
 
Figure 15. Typical flow curves for Newtonian, shear thinning and shear thickening (dilatant) 
fluids: (a) shear stress as a function of shear rate; (b) viscosity as a function of 
shear rate (picture reprinted from (107)). 
 
As mentioned previously, gels are pseudoplastic materials. Since they are exhibiting a shear-
thinning behavior, their viscosity depends on the degree of the shear load (such as blinking) – it 
decreases with increasing shear load, and with time, it is restored to a certain extent when the 
load is removed. 
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2.8. Quality by Design and Design of Experiments in pharmaceutical 
development 
 
The term Quality by Design (QbD) was suggested by the regulatory authorities (FDA, EMA) at 
the beginning of the new millennium, recognizing that “quality cannot be tested into products, i.e. 
quality should be built in by design”. This was a direct acknowledgment of the significance of 
quality theory in pharmaceutical development (109). QbD concept is acknowledged in 
pharmaceutical development due to its advantages on assurance of high quality drug products 
without extensive regulatory oversights (110). Implementation of this approach increases 
development efficiency with a successful product optimization and a robust manufacturing 
process, improves the communication between regulatory agencies and industry providing 
regulatory relief and flexibility, reduces post-approval changes and enables real-time quality 
control (110). 
Quality by Design is defined as a systematic approach to development that begins with 
predefined objectives and emphasizes product and process understanding and process control, 
based on sound science and quality risk management (111).  
Pharmaceutical QbD is a systematic, scientific, risk-based, holistic and proactive approach to 
pharmaceutical development that begins with predefined objectives and emphases product and 
processes understanding and process control. It means designing and developing formulations 
and manufacturing processes to ensure predefined product quality objectives. QbD identifies 
characteristics that are critical to quality from the perspective of patients, translates them into the 
attributes that the drug product should possess, and establishes how the critical process 
parameters can be varied to consistently produce a drug product with the desired characteristics 
(112). 
Design of Experiments (DoE) is the main component of the statistical toolbox to use QbD in both 
research and industrial settings. It is considered the main systematic approach requiring the 
implementation of statistical thinking at the starting point of pharmaceutical development. 
Experimental design is a structured, organized method for determining the relationships between 
factors affecting a process and the output of that process. DoE, in short, means achieving process 
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knowledge, through the establishment of mathematical relationships between process inputs and 
its outputs (109) (Figure 16).  
 
Figure 16. Schematic representation of process (reprinted with permission from (109)). 
Quality target product profile (QTPP) forms the basis of design for the development of the 
product. Considerations for the QTPP could include intended use in clinical setting, route of 
administration, dosage form, delivery systems, dosage strength(s), container closure system, drug 
release or delivery and attributes affecting pharmacokinetic characteristics (e.g., dissolution) 
appropriate to the drug product dosage form being developed; drug product quality criteria (e.g., 
sterility, purity, stability and drug release) appropriate for the intended marketed product (111). 
Critical Quality Attribute (CQA) is a physical, chemical, biological, or microbiological property 
or characteristic that should be within an appropriate limit, range, or distribution to ensure the 
desired product quality. CQAs are generally associated with API, excipients, intermediates (in-
process materials) and drug product. Potential drug product CQAs derived from the quality target 
product profile and/or prior knowledge are used to guide the product and process development. 
Relevant CQAs can be identified by an iterative process of quality risk management and 
experimentation that assesses the extent to which their variation can have an impact on the 
quality of the drug product (111). 
Risk Assessment is a valuable science-based process used in quality risk management that can aid 
in identifying which material attributes and process parameters potentially have an effect on 
product CQAs. Risk assessment is typically performed early in the pharmaceutical development 
process and is repeated as more information becomes available and greater knowledge is obtained 
(111). 
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Design Space is the relationship between the process inputs (material attributes and process 
parameters) and the critical quality attributes (111). 
Control Strategy is designed to ensure that a product of required quality will be produced 
consistently (111). 
2.8.1. DoE workflow 
The general purpose of DoE is the relation of the critical process/formulation parameters (CPP, 
CFP) (x1, x2, xi) with the CQAs (yi) through mathematical functions y = f (x), as depicted in 
Figure 16. Such relationships enable the: 
 determination of the most influential factors (CPPs, CFPs) among many; 
 identification of optimum factor settings leading to enhanced product performance and 
assuring CQA values lying within specifications with minimum variability; 
 elucidation of interactions between the factors, an important advantage over the 
conventional way of experimentation, where each factor is studied independently of the 
others (One-Factor-At-a-Time or OFAT experimentation)(109). 
Execution of an experimental design requires seven distinct phases: 
(i)      Setting solid objectives: clear definition of the Quality Target Product Profile (QTPP) 
should be done, using the knowledge base from scientific literature and technical 
experience, critically evaluated under the Quality Risk Management approach. 
(ii)       Selection of process variables (factors) and responses (Critical Quality Attributes - 
CQAs): this choice is justified based on the DoE objective and should assure that the 
whole design is executable and appropriate for satisfying its scope. 
(iii)        Selection of an experimental design: based on DoE objectives, screening, 
characterization or optimization of process and formulation, different types of designs can 
be chosen 
(iv)      Execution of the design: the generated design matrix should be accurately executed, 
assuring that parameters not included in the design are identified and kept constant 
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(v)       Checking that the data are consistent with the experimental assumptions: DoEs are 
exceptionally effective in identifying outliers, arising from potential poorly executed 
trials. 
(vi)  Analyzing the results: ANOVA and graphical tools are very helpful in identifying 
main effects of the significant factors and interactions thereof. The results are evaluated 
not only on a statistical basis but also versus the established theories and practically lead 
to process knowledge. 
(vii) Model building and validation - use and interpretation of the results at this step, the 
evaluation of the DoE outcome can support scientifically sound decision making on 
following actions, such as executing confirmatory runs, augmenting designs, or further 
proceeding with scale up and technology transfer activities (109). 
Traditionally, formulations were manufactured to meet quality control tests outlined in product 
specifications. If the product is expected fit for commercial purpose, then it should meet quality 
control tests. In case of a batch failure to comply with these tests, it is reprocessed or rejected, 
which opens doors for regulatory questions and obvious cost related issues.  Enhanced product 
stability decreases the amount of rejected products and reduces costs. For patients, robust 
pharmaceutical products increase efficacy and minimize side effects. Meanwhile, it makes it 
easier for governments to implement management, regulation, and supervision in the research, 
development, manufacturing, storage and clinical use of drugs (113). 
In summary, QbD principles, when implemented, lead to a successful product development, 
subsequent prompt regulatory approval, reduce intensive validation burden, and significantly 
reduce post-approval changes (114). 
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2.9. Ocular tolerability assessment 
In addition to the tests evaluating performance, early assessment of biocompatibility or ocular 
tolerability is crucial in development of novel ophthalmic products. The cornea and conjunctiva 
are susceptible to injuries and adverse ocular effects either from the administered drug or 
excipients used in the finished ophthalmic product. For the purpose of ocular tolerability 
assessment, it is important to establish adequate tests. Non clinical models used in pharmaceutical 
development include in vitro and ex vivo models and in vivo i.e. animal models.  
Several tests and assays used to determine the ocular toxicity and irritation potential of 
ophthalmic delivery systems are recognized by regulatory agencies (47). 
“Draize rabbit eye irritation test” uses live rabbits for the determination of range of possible eye 
irritation effects from chemical substances. It is accepted by the regulatory agencies. The 
irritation responses recorded are redness, swelling, edema, cloudiness, discharges, hemorrhage 
and blindness (47). The tested materials are classified based on a subjective scoring, from non-
irritating to severely irritating, for their effect on the cornea, iris and conjunctiva. The main 
shortcomings of the Draize test is its subjectivity, poor reproducibility and the differences 
between the rabbit eye and the human eye (47). 
“Low-volume eye irritation test” (LVET), was developed to circumvent issues related to the 
Draize test. The test is a modified Draize test in which the number of test material is reduced 
while maintaining the same scoring system of the Draize test (47).  
Tests based on animal models are often criticized by public and scientific community due to the 
ethical concerns. Therefore, regulatory agencies have provided a set of in vitro and ex vivo tests 
that can potentially replace the aforementioned controversial in vivo eye irritation tests (47).  
In vitro and ex vivo models of eye barriers enable safe and efficacious screening of formulations 
(48). First models are commonly based on the cells and the latter are based on tissues (115). 
Prerequisite for these tests is accuracy and reproducibility without the use of live animals (47).  
Examples of irritation assays are the isolated/enucleated organ method such as the Bovine 
Corneal Opacity and Permeability (BCOP) test, the non-ocular organotypic models such as Hen's 
Egg Test on the Chorioallantoic Membrane (HET-CAM) (a conjunctival model), and the cell-
 56 
 
 
based cytotoxic colorimetric methods such as Red Blood Cell (RBC) lysis and protein 
denaturation, Neutral Red Uptake (NRU) and Sulforhodamine B (SRB) assays (47). 
Drawbacks related to tissue based (ex vivo) models are low throughput and insufficient 
standardization, ethical concerns and moreover, the relation from animal to human tissue is 
questionable (2). The cell-based models that have the correct balance between their predictability 
and throughput have the potential to be routinely used for assessment of of eye-related 
biocompatibility (2,115,116). In vitro models may also provide mechanistic understanding of 
toxicity at the cellular /molecular level. Furthermore, they are capable of creating a broader range 
of toxicology testing capabilities such as multiple endpoints, concentrations, exposure methods 
and times to be better controlled and tailored accordingly (117).  
Currently, most of the ocular tolerability testing is performed using cell monolayers i.e. two-
dimensional (2D) cell models. Such models do not reflect 3D structure of tissues (118). Use of 
inadequate cell models during development can lead to selection of wrong candidates and/or 
formulations which can lead to great expenses in late development. Implementation of 3D cell 
based models, which simulate better in vivo physiological environment is key for successful  
pharmaceutical development, that is right screening of drug candidates during early phase of 
research and development (119). 
For chemicals tested for ocular biocompatibility, as a general rule, when the cell viability of 
rabbit corneal epithelial cell line is ≤70% at two concentration levels (5% and 0.5% ), tested 
chemical is classified per United Nations Globally Harmonized System of Classification and 
Labeling of Chemicals (UN GHS) as Category 1. This category includes chemicals inducing 
serious eye damage or irreversible effects on the eye. However, when cell viability is >70% at 
both concentrations, a test chemical is classified as UN GHS No Category, meaning that tested 
chemicals do not require classification for eye hazards (116). 
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3. AIMS OF THESIS 
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In situ forming gels attract great attention as the formulation candidates for the improvement of 
bioavailability and efficacy of topical ophthalmic drugs. The mixtures of poloxamers 407 
(gelation agent) and 188 (gelation modifier) are of interest for the development of in situ forming 
ophthalmic gels. Despite many beneficial properties of poloxamers as ophthalmic excipients, 
their performance is associated to weak mechanical strength, which leads to rapid erosion 
(7,18,20). The improvement of the mechanical strength of poloxamer gels can be achieved by the 
inclusion of chitosan. Chitosan is well known for its biocompatible, biodegradable and 
mucoadhesive properties, rendering it suitable for ophthalmic use (95). 
The aim of this doctoral thesis was to develop in situ forming ophthalmic P407/P188/CS gel fine-
tuned in terms of polymer content, temperature of gelation, storage modulus and viscosity.  
Specific aims of a thesis were to optimize the formulation parameters by implementation of DoE 
to assure: 
(i)  temperature of gelation (Tgel) in physiologically relevant range; 
(ii)  pseudoplastic behavior; 
(iii) suitable viscosity and storage modulus of in situ gel; 
(iv) resistance to dilution with simulated tear fluid; 
(v)  robustness against entrapment of drugs with diverse physicochemical properties; 
(vi) controlled release of model drug. 
A systematic approach (DoE) to in situ forming gel development has the potential to result in 
robust formulation characterized by ease of administration, accuracy of dosing, avoidance of eye-
related discomfort and prolonged residence at the eye surface. These benefits will lead to better 
patient compliance, improved eye-related bioavailability and, finally, improved therapeutic 
outcome.  
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4. MATERIALS AND METHODS 
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4.1. Materials 
 
Poloxamers P407 (Kolliphor P407; EO98PO69EO98; average molecular weight (Mw) 13,498 
g/mol) and P188 (Lutrol micro F68; EO80PO27EO80; average Mw 8902 g/mol) were purchased 
from BASF SE (Ludwigshafen, Germany). More than 90% deacetyled ultrapure PROTASAN
TM
 
chitosan salt (Protasan UP CL 214; Mw 150,000-400,000 g/mol; viscosity 20-200 mPa  s) (CS) 
was obtained from NovaMatrix
®
 (Sandvika, Norway). 
Water for injection (WFI) was donated by PLIVA Croatia Ltd (Zagreb, Croatia). Ultrapure water 
for chromatographic analyses was produced by Ultra Clear
TM 
UV Plus (SG Wasseraufbereitung 
und Regenierstation GmbH, Barsbüttel, Germany). 
NaCl, NaHCO3, KCl, Na2HPO4, NaH2PO4, MgSO4  7H2O, NaOH, KH2PO4, and CH3COONa  
3H2O, were obtained from Kemika (Zagreb, Croatia). CaCl2  2H2O, acetonitrile (ACN), HEPES 
and D-glucose monohydrate were acquired from Merck (Darmstadt, Germany).  
Timolol maleate (TIMO), dexamethasone (DEX), dorzolamide hydrochloride (DORZO) were 
kindly donated by TEVA Pharmaceutical Industries Ltd. Tobramycin (TOBRA) standard was 
purchased from the USP (Rockville, MD, USA).  
Simulated tear fluid (STF) pH 7.4 was prepared by dissolving the following substances in double-
distilled water: KCl (1.4 mg/ml), NaCl (6.8 mg/ml), NaHCO3 (2.2 mg/ml) and CaCl2  2H2O 
(0.08 mg/ml) (65). 
Krebs-Ringer buffer (KRB) pH 7.4 was prepared by dissolving the following substances in 
double-distilled water: KCl (0.4 mg/ml), NaCl (6.8 mg/ml), NaHCO3 (2.1 mg/ml), MgSO4 × 
7H2O (0.4 mg/ml), D-glucose monohydrate (1.1 mg/ml), CaCl2 × βH2O (0.52 mg/ml), NaH2PO4 
× βH2O (0.158 mg/ml) and HEPES (3.575 mg/ml) (115). 
50 mM phosphate buffer (PB) was prepared by dissolving KH2PO4 (6.81mg/ml) and NaOH  
(1.56 mg/ml) in double-distilled water (120). 
Hank’s balanced salt solution (HBSS, pH 6) was prepared by dissolving the following substances 
in double-distilled water: MgSO4 × 7H2O (100 mg/l), KCl (400 mg/l), NaHCO3 (350 mg/l), NaCl 
(8000 mg/l ), D-glucose monohydrate (1100 mg/l) , CaCl2 × βH2O (185 mg/l) (Sigma–Aldrich), 
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MgCl2 × 6H2O (100 mg/l),) KH2PO4 (60 mg/l) , Na2HPO4 × βH2O (60 mg/l), and HEPES (7150 
mg/l). 
Final step in STF, KRB, PB and HBSS preparation was filtration of solutions (Whatman
TM
 
membrane filters, 0.β µm, RC58, GE Healthcare Limited, Buckinghamshire, UK). 
Regenerated cellulose membranes pore size of 0.β µm and 0.45 µm (RC 0.β and RC 0.45), 
polyethersulfone pore size 0.45 µm membranes (PESU 0.45) and cellulose acetate membranes 
with 0.8 µm pore size (CA 0.8) were obtained from Sartorius Stedim Biotech (Göttingen, 
Germany). Hydrophilic polyethersulfone (PES) Supor
®
 0.1 µm pore size membrane filters where 
purchased from PALL (Ann Arbor, MI, USA).  
Commercially available two API-free preformed gels, TIMO-loaded in situ forming gel, 
Dexpathenone-loaded in situ forming gel and DEX/TOBRA-loaded in situ forming gel were 
purchased and used for analyses. All materials were used as received. 
4.2. Methods 
4.2.1. Preparation of in situ forming ophthalmic gels 
In situ forming ophthalmic gels were prepared by slightly modified cold method (121). Briefly, 
appropriate amounts of all materials were weighed in a glass bottle and defined amount of 
previously refrigerated WFI was added. Samples were stirred (speed 400-600 rpm) in an ice bath 
until clear solution was obtained. In case when CS was used in mixed systems, after ice bath, 
additional means of ultrasound at 20-β5°C (Bandelin Sonorex digital 10P, BANDELIN electronic 
GmbH & Co. KG, Berlin, Germany) were applied to aid its dissolution. The concentration of 
P407 was in the range of 10.25 – 19.30 % (w/w) while the concentration of P188 was in the range 
of 0 – 7.66 % (w/w). The concentration of CS was in the range of 0 – 1.29 % (w/w). Sodium 
chloride was used in suitable range to achieve isotonicity. 
Out of four active pharmaceutical ingredients (APIs), six API-loaded in situ forming ophthalmic 
gels were prepared, namely mixed P407/P188/CS system containing: 2 % (w/w) DORZO, 0.5 % 
(w/w) TIMO, 2 % (w/w) DORZO and 0.5 % (w/w) TIMO, 0.1 % (w/w) DEX, 0.3 % (w/w) 
TOBRA, 0.05 % (w/w) DEX and 0.3 % (w/w) TOBRA. All in situ forming ophthalmic gels were 
isotonized taking into account NaCl equivalent for each API.  
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4.2.2. Osmolality, pH and transparency determination 
 Osmolality was determined by the freezing point depression method (Advanced
®
 3D3 Single-
Sample Osmometer, Advanced Instruments Inc, Norwood, Massachusetts, USA). pH was 
measured using PHM240 pH/Ion-Meter (Radiometer Analytical SAS, Villeurbanne, France). 
The transparency of in situ forming ophthalmic gels was determined by measuring the refractive 
index (RE40 Refractometer, Mettler-Toledo, LLC, Columbus OH, USA)(122). 
4.2.3. Measurement of temperature of gelation and complex viscosity 
The temperature sweep test was performed to determine the temperature of gelation (Tgel), 
storage modulus (G’), loss modulus (G’’) and complex viscosity (*) (18,20). The rheological 
measurement was performed using Rheometer Anton Paar Physica MCR 301 (Figure 17A, Anton 
Paar GmbH, Graz, Austria) with parallel plate (PP50, Figure 17B) measuring system equipped 
with H-PTD 200 Truly Peltier-temperature-controlled hood (US Patent 6,571,610). Peltier 
heating element was connected to circulating water bath (F25-ME Refrigerated/Heating 
Circulator, JULABO GmbH, Seelbach, Germany). This system reduced the amount of water 
evaporating during the heating phase and allowed a more homogeneous temperature distribution. 
Samples were placed carefully on the lower plate of rheometer, measuring bob was placed in the 
measuring position and sample was equilibrated for 5 minutes at 5 °C. Angular frequency and 
strain applied were fixed at 1 s
-1
 and
 
1 %, respectively while gap was d = 0.5 mm. Data was 
calculated by Rheoplus
TM
 software (Anton Paar). 
G’, G’’ and * were recorded in the temperature range of 5–85 °C with a rate of 10 °C/min. Tgel 
is defined as the temperature point at which intersection of G’’ and G’ curves occurs (18,100). 
All measurements were done in triplicate. 
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Figure 17. A) Anton Paar Rheometer Physica MCR 301 with H-PTD 200 Truly Peltier-
temperature-controlled hood (picture reprinted from: (123)); B) parallel plate 
measuring system with a gap (H) and radius (R) (picture reprinted from (100)). 
 
4.2.4. Design of experiments 
Quality by Design (QbD) principles were employed to optimize formulation parameters and 
evaluate their impact on Tgel, G’ and *. Statistical software JMP® version 12.0.1 (SAS Institute 
Inc., Cary, North Carolina, USA) was used to set experimental design, establish the mathematical 
model and analyze the collected data. Designs were generated within the class of optimal designs 
and D-optimality criterion was selected based on the particularities of the experimental situation. 
The independent variables were the concentrations P407 (10.59 – 19.1%, w/w), P188 (0 – 7.66%, 
w/w) and CS (0.08 – 1.29% (w/w), while dependent variables were Tgel , G’ and *. Sequential 
approach to experimentation was applied through screening, refining and optimizing designs 
(Table 6). Data set was expanded with the results of preliminary screening, consisting of five 
samples, which contained only P407. For the subsequent design of experiment, a new factor was 
added in order to explore influence of concentration levels of CS on the responses and include it 
into the model. Finally, preparation reproducibility was addressed in DoE by addition of three 
replicated samples in the last step (Table 6: Sample 23 was replicate for Sample 14; Sample 24 
was replicate for Sample 15 and finally Sample 25 was replicate for Sample 16). This was done 
for two reasons - to evaluate the error of mixed system preparation as well as the error of the 
measurement. 
A B 
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Table 6. Samples prepared for DoE. 
DoE Sample
*
 
 
P407 P188 CS 
(%, w/w) (%, w/w) (%, w/w) 
Preliminary screening 1ο 11.40     
2ο 13.80 
3ο 15.20 
4ο 16.90 
5ο 19.30 
Screening 6• 11.32 0.87 
7• 19.10 0.80 
8• 15.80 0.84 
9• 14.12 4.01 
10• 14.61 4.24 
11• 18.39 4.64 
12• 10.59 7.40 
13• 15.49 7.66 
Refining step (addition of CS) 14Ƥ 16.40 0.85 0.08 
15Ƥ 10.93 4.20 0.08 
16Ƥ 15.92 3.97 0.08 
17Ƥ 13.61 2.51 0.66 
18Ƥ 11.16 0.95 1.29 
19Ƥ 16.20 0.92 1.22 
20Ƥ 10.80 4.18 1.25 
21Ƥ 15.70 3.96 1.18 
22Ƥ 11.31 0.89 0.10 
Replicate step 23 (14)ƥ 16.40 0.84 0.09 
24 (15)ƥ 10.93 4.21 0.09 
25 (16)ƥ 15.88 3.97 0.08 
*ο-preliminary screening, •-screening, Ƥ-screening with addition of CS, ƥ-optimization step 
Multiple regression and analyses of variance (ANOVA) were used to evaluate experimental 
results (JMP
®
 version 12.0.1). Factorial models were set to determine all main effects and 
interactions for the factors of interest i.e. concentrations of P407, P188 and CS. Significance of 
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the regression models was assessed with ANOVA. Level of significance for all tests was  = 
0.05.  
Factor Profiling platform (JMP
®
) was utilized to explore and visualize estimated models, e.g. 
explore the shape of the response surface, find optimum settings of the factors and simulate 
response data. 
To validate the models, the experimental values of Tgel, G’ and * of four optimal mixed 
P407/P188/CS systems were statistically compared to their predicted responses. 
 
4.2.5. Oscillatory rheological characterization – strain sweep, frequency sweep and 
gelation time testing 
The viscoelastic behavior of in situ forming ophthalmic gels was investigated by strain 
(amplitude) sweep and frequency sweep test using the rheometer system with cone-and-plate 
(CP50, Figure 18) geometry with 1° incline. Gap of the measuring configuration was d = 0.05 
mm.  
 
Figure 18. Cone and plate measuring system with a radius (R), gap a); and incline (α) (picture 
reprinted from (100)). 
 
For strain sweep analysis, the angular frequency was set at 62.8 rad/s and the strain was varied 
from 0.001 to 1000 %. The linear viscoelastic range (LVE) at γ5°C was identified as the region 
in which the moduli (G’ and G’’) are independent of the strain.  
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For frequency sweep analyses strain was set at 1%, which was in the linear viscoelastic range, 
while the angular frequencies were in the range of 0.628-199 rad/s.  
The evaluation of in situ forming ophthalmic gel under biorelevant conditions was performed by 
sample dilution with STF (40:7). The STF diluted samples were submitted to strain and 
frequency sweep analysis at γ5°C. 
Gelation time was determined as the time point at which intersection of the curves of measured 
G’’ and G’ occurred (100). The samples were placed at rheometer plate preheated at γ5°C. Strain 
(1%) was constantly in LVE range, while applied frequency was 1 Hz throughout the test. 
4.2.6. Rotational rheological characterization 
In order to study and compare dynamic viscosities of developed in situ forming gel formulations 
with commercially available ophthalmic products from US and EU market, rotational test with 
controlled shear rate (CSR) was developed and applied.  
The same rheometer, Anton Paar Physica MCR 301 with cone plate (CP50, Figure 18) measuring 
system, Peltier element and special temperature isolated hood, as in oscillatory tests was used. 
Gap was d=0.05 mm and angle 1°. Temperature was γ5°C and samples were allowed to 
equilibrate for 5 minutes.  
Viscosity profiles of samples in biorelevant conditions (diluted with STF 40:7) were measured in 
the shear rate range of 0.1s
-1
 – 1000 s-1. Similar measuring methodology was reported before  
(15). 
4.2.7. Sterilization 
Sterilization of selected in situ forming gel was evaluated by filtration and flitration and 
autoclaving. In case of sterilization by filtration samples were filtrated 0.β µm through syringe 
filter (Spartan RC 0.β µm). Filtrated samples, placed in non-siliconized 20 ml (15 R) Type I clear 
glass vials sealed with Teflon 2 coated chlorobutyl rubber stoppers (Schott
®
), were sterilized by 
steam at 1β1°C for β0 minutes using Systec V-95 autoclave (Systec GmbH, Sandvsweg, 
Germany). 
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4.2.8. Physical stability of samples at room temperature 
Selected samples of in situ forming gel placed in non-siliconized 20 ml (15 R) Type I clear glass 
vials sealed with Teflon 2 coated chlorobutyl rubber stoppers sterilized by filtration and filtration 
and autoclaving, as well as non sterilized control samples, were stored for 6 months at 
β5°C/60%RH. Key rheological properties, i.e. Tgel and (*) were evaluated and compared at 
initial and 6 months time point. 
 
4.2.9.  In vitro release testing  
In vitro release (IVR) testing was performed using the Vision Microette (Hanson, Chatsworth, 
CA, USA), a commercial Franz diffusion cells apparatus equipped with six static vertical 
diffusion cell with 12 ml volume and 15 mm orifice (providing area for release of 1.767 cm
2
), an 
AutoFill sample collector and circulating water bath (Figure 19). Donor part of vertical cell 
consisted of open cell top with cap which is suitable for retaining less viscous liquids. 
Temperature was maintained at γ5°C and stirring speed of 400 rpm assured homogenized sample 
in the receptor medium (STF). Sink conditions were assured. An aliquot of 2.5 ml of sample was 
placed on the testing membranes in donor compartment.  
IVR testing of in situ formulations was performed during 24 hours. 1 ml of receptor medium was 
collected automatically at predetermined time intervals. System’s rinsing volume was set at 1.5 
ml to assure no carryover of an API prior each sampling point. 
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Figure 19. A) Franz diffusion cells apparatus used in IVR test (picture reprinted from (124)); 
B) Special top for less viscous fluids (picture reprinted from: (125)). 
 
A 
B 
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4.2.9.1. Solubility testing and choice of IVR medium 
Medium for IVR testing should provide sink conditions (126), meaning that medium volume 
should be 3-10 times the saturation solubility of the drug.  
In order to evaluate the influence of different salts and buffers providing pH of solutions of 7.4 
on API solubility, saturation solubility testing was performed in the following media:  
1. Simulated tear fluid, STF 
2. Krebs-Ringer buffer solution, KRB 
3.  50 mM phosphate buffer, PB  
API was added in the flasks containing 20 ml of corresponding medium. Flasks were sealed and 
placed on a thermostatic orbital shaker at γ5°C (GFL® orbital shaker γ0γ1, GFL Gesellschaft für 
Labortechnik GmbH, Burgwedel, Germany) and stirred at 75 min
-1
 throughout 48 h. Testing was 
performed in triplicate for each tested medium. pH values were checked and, when needed, 
adjusted to 7.4 during the test. 
Supernatants of saturated solutions were taken after 24 and 48 h and filtered through 0.2 µm 
filters (Spartan RC 0.β µm, GE Healthcare Life Sciences, Freiburg, Germany), diluted with tested 
medium and analyzed by UPLC method.  
4.2.9.2. Membrane selection study 
Five membranes summarized in Table 7 were evaluated for suitability for the IVR testing. 
Table 7. Membranes in IVR study.  
Membrane  pore size 
(µm)  
regenerated cellulose (RC) 0.2 
regenerated cellulose (RC) 0.45 
polyethersulfone (PESU) 0.45 
cellulose acetate (CA) 0.8 
Hydrophilic polyethersulfone (PES) 0.1 
Membranes were presoaked in the release medium for 12 hours before starting the test. Three 
tests were performed in order to choose the most suitable membrane. In the first, membranes 
 70 
 
 
were screened for API adsorption at two concentration levels of API solutions in STF (0.0801 
mg/mL and 0.4005 mg/mL). API solutions were filtrated through the membranes; filtrated and 
non-filtrated solutions were analyzed by UPLC and ratio of their areas was calculated.  
Secondly, influence of membranes on drug release from the in situ forming gel formulation was 
tested. Finally, for lead candidates, membrane’s resistance to diffusion of drug from the API 
solutions in STF at two concentration levels (0.01 mg/mL and 2.5 mg/mL) was tested. 
4.2.9.3. Data presentation and statistical analysis 
 
For the purpose of statistical analysis for evaluation of discriminative nature of the developed 
IVR method, for each tested cell results were expressed as amount of drug released per 
membrane area (µg/cm2) versus the square root of time. The slope of the resulting line is a 
measure of the drug release rate.  
For the purpose of this study, slopes of tested samples were calculated on at least five sampling 
points and samples were considered to be similar only if their slope ratios passed the first level 
acceptance criteria as described in the USP chapter <1724> (127,128). 
For the first stage comparison of the batches, Mann-Whitney U test was used to calculate and 
evaluate the 90% confidence interval for the ratio of the slopes between the two batches (127). 
Each T (test sample) slope is compared to each R (reference sample) slope by calculating T/R 
slope ratios. If 6 cells for T and R batch are available, the 36 individual T/R ratios are then 
ordered from the lowest to the highest. The 8
th
 and 29
th
 T/R ratios represent the lower and uppler 
limits of the 90% confidence interval for the ratio of test to reference release rates. To pass first 
stage testing, these ratios, when converted to percents by multiplying by 100, must be within the 
range of 75–133.33% (127,129).  
4.2.10. UPLC analyses  
Quantification of an API was done by ultra-performance liquid chromatography (UPLC). Three 
types of UPLC instruments were used: Agilent Infinity 1290 (Agilent, Santa Clara, CA, USA), 
Waters ACQUITY UPLC H and Waters ACQUITY UPLC I Class (Waters, Milford, MA, USA). 
Data were acquired and processed with the Empower 2 software (Waters, Milford, MA, USA). 
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The chromatographic separation was done on a Waters Acquity UPLC BEH Shield RP18 column 
(β.1x100mm, 1.7µm particle size) with the mobile phase consisting of 60% of 5 mM sodium 
acetate buffer (pH 4.5) and 40% ACN (v/v). Volume of injection was 5 µL and elution was 
isocratic. Sample temperature was maintained at 15°C, while column temperature was set at 
50°C. Flow of the mobile phase was 0.6 ml/min and detection was done at β96 nm wavelength 
(Photodiode Array detector (PDA) was part of Waters systems and Diode Array (DAD detector) 
was used in the Agilent instrument).  
For each sequence, standard solutions were prepared in duplicate and injected alternately. At least 
five standard solution injections were done in each injection sequence. System suitability was 
evaluated according to following criteria: relative standard deviation (RSD) of the detector 
response factor for all standard solution injections in the sequence is not more than 3.0%, and 
tailing factor of API peak is not more than 2.0.  
4.2.10.1. Validation of UPLC method 
The objective of validation of an analytical procedure is to demonstrate that it is suitable for its 
intended purpose (130). Validation of UPLC method for TIMO quantification was assessed by 
demonstration of specificity, linearity, accuracy, range, repeatability and standard/sample 
stability. 
Specificity of developed method was performed by comparing chromatograms obtained with 
standard solution, sample solution, placebo solution, in vitro release medium, and mobile phase. 
The linearity of an analytical method is its ability to elicit test results that are directly, or by a 
well-defined mathematical transformation, proportional to the concentration of analyte within a 
given range (130). The linearity study was designed to cover the range of about 1% to about 
100% of the working concentration from IVR test. Evaluation was performed by injecting in 
duplicate standards spiked with P407 (14 %, w/w), P188 (2 %, w/w), NaCl (0.9%, w/w) and 
chitosan (0.3%, w/w) at seven concentration levels by in the range from 0.00516–0.05170 mg/ml. 
The accuracy of a method expresses the closeness of agreement between true value (a reference 
value or a conventional true value) and the value found by analytical procedure. In practice this is 
related to the closeness of agreement between added (spiked) and found amount of analyte of 
interest (130). Method accuracy was evaluated through recovery experiment from the recovery 
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solutions prepared in triplicate for each level in the same concentration range as for linearity 
study (1%-100%).  
Placebo solution containing P407 (14 % w/w), P188 (2 %, w/w), NaCl (0.9%, w/ w) and CS 
(0.3%, w/ w) was added to all recovery solutions. Each of three solutions, prepared for each of 
seven concentration levels, was injected once. 
The concentration range for which the standard linearity and accuracy study met the acceptance 
criteria was taken as the range of the method. 
Repeatability of UPLC method was established by relative standard deviation of injections of 
standard solutions.  
The stability study was designed to evaluate the suitability of storing the standard and sample 
solutions at working and room temperature to ensure that they are sufficiently stable to complete 
the analysis within a reasonable time frame. The stability of the standard solution and sample 
solution was evaluated over an appropriate period of time (at least 24 houurs) against freshly 
prepared standard solution.  
4.2.11. In vitro biocompatibility study 
The biocompatibility was assayed using corneal epithelial models based on the immortalized 
human corneal epithelial cell line (HCE-T) (RIKEN Cell Bank, Tsukuba, Japan). In situ forming 
gel was applied directly onto cell-based models. After the 30-minute treatment at γ7°C, treated 
models were incubated at the room temperature for 5 minutes to induce formulation gel-sol 
transition. The cell surface was rinsed with Hank’s balanced salt solution and exposed to air-
liquid interface for the following 24 h. The cell viability was assessed by MTT test. 
4.2.11.1. Cell culture conditions 
HCE-T cells were cultivated in DMEM/F12 medium (Lonza, Basel, Switzerland) supplemented 
with fetal bovine serum (5%, Biosera, Boussens, France), insulin (5 μg/ml, Sigma-Aldrich), 
dimethyl sulfoxide (0.5%, Applichem), epidermal growth factor (10 ng/ml, Sigma-Aldrich) and 
penicillin/streptomycin/amphotericin B (Lonza) in a humidified atmosphere containing 5% CO2 
at γ7 °C (48). The cells were subcultured at 80–90% confluence. The culture medium was 
changed every 48 h. 
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4.2.11.2. Cultivation of the HCE-T cell-based model 
The HCE-T cell-based models were cultivated according to the protocol by (115). Brifely, 
Transwell
®
 polycarbonate membrane cell culture inserts (0.4 and γ.0 μm pore size, surface area 
1.12 cm
2
, Corning B.V. Life Sciences, Amsterdam, The Netherlands) were coated with rat tail 
type I collagen (ββ5 μg/well; Sigma-Aldrich) and human fibronectin (4 μg/well; Sigma-Aldrich). 
HCE-T cells were seeded onto the coated polycarbonate filter and were cultivated submerged in 
the medium until a sharp increase in transepithelial electrical resistence (TEER) was observed, 
after which they were exposed to the air-liquid interface (ALI) for the following 3 days. The 
culture medium was changed every 2 days during the submerged conditions and every day during 
exposure to the ALI. 
4.2.11.3. MTT Assay 
MTT assay was performed on the HCE-T cell-based models according to the protocol by Pauly et 
al. (131). The culture medium for basolateral compartment was aspirated, and the wells were 
transferred to a clean 12-well cell culture plate (Corning B.V. Life Sciences). The MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, Sigma-Aldrich) solution in culture 
medium (0.5 mg/ml, 700 L) was applied to both the apical and basolateral compartments, and 
the cells were incubated for 4 h at γ7 °C. After the removal of the MTT solution, formazan 
crystals were dissolved by the addition of isopropanol (700 μL) to both compartments. The 
absorbance was measured at 570 nm by using microplate reader (1420 Multilabel counter 
VICTOR3, Perkin Elmer, Waltham, MA, USA). 
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5. RESULTS AND DISCUSSION 
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5.1. In situ forming ophthalmic gel development and optimization using a 
Design of Experiments 
 
QbD approach was applied in order to determine the minimal total concentrations of P407, P188 
and CS that would yield an optimal in situ forming ophthalmic gel with the potential to ensure the 
defined formulation characteristics i.e., Tgel in physiologically relevant range, storage modulus 
and complex viscosity which would provide controlled (prolonged) release of model drug, 
pseudoplastic flow behavior;  which would preserve gel structure in biorelevant conditions and 
which would be robust against entrapment of drugs with diverse physicochemical properties. 
For the establishment of the mathematical model, it was necessary to generate the data of Tgel, G’ 
and * of the sample based on the independent variables (Table 8). This was achieved by the 
temperature sweep test (Figure 20). In the first screening step of the applied sequential approach, 
influence of concentration levels of two factors (independent variables; P407 and P188 
concentration) on Tgel, G’ and * (dependent variables) was tested. Selected independent 
variables were evaluated at their low, medium and high levels, which were selected based on the 
preliminary experiments. Based on the particular experimental conditions, a custom D-optimal 
design was applied to provide estimates for the effect testing with smallest standard errors, as it 
maximizes the information in the selected set of experimental runs with respect to a model stated 
(132). Two center points were included in the experimental runs to allow the testing for non-
linear factor effects and estimation of the pure experimental error, and to increase the power of 
the experiment. A total of eight experimental runs were generated for the evaluation of the main 
effects and possible interactions. Accordingly, eight samples, varying in concentrations of P407 
(10.59 – 19.1%, w/w) and P188 (0.8 – 7.66%, w/w) were prepared, and their Tgel, G’ and * were 
determined (Table 8). Collected data were analyzed, and significant cause-and-effect relationship 
was identified. Data set was expanded with the results of preliminary screening, consisting of 
five samples, which contain only P407 (11.4 – 19.3%, w/w)(1). 
In the subsequent, refining step, CS concentration was added as an additional independent 
variable. Concentration ranges of factors P407 and P188 were selected based on the result 
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obtained in screening step, and CS concentration was evaluated in the range of 0.08 – 1.29% 
(w/w) based on the literature data (20,133).  
D-optimal statistical design with one center point was applied. Nine experimental runs were 
required for analyzing the main effects and all second level interactions. Additionally, to evaluate 
error of mixed P407/P188/CS system preparation and measurement, three replicated runs were 
added to the experimental sequence (replicate step, Table 8). Based on this approach, three 
mathematical models were established, i.e. Tgel, G’ and * models, as the prerequisite for the 
optimization of in situ forming P407/P188/CS ophthalmic gel (1). 
All prepared formulations had an ophthalmically acceptable osmolality, which was achieved by 
the addition of appropriate amounts of NaCl to the solution. Osmolality was determined by the 
freezing point depression method (Advanced® γDγ Single-Sample Osmometer, Advanced 
Instruments Inc, Norwood, Massachusetts, USA). For CS free solutions it was in the range of 
295.4 – 301.8 mOsm/kg, while for CS containing solutions it was in the range of 310.4 – 332.0 
mOsm/kg. pH of tested systmes was in the range of 5.8 for CS containing solutions to 6.5 for CS 
free solutions (1). The transparency of in situ forming ophthalmic gels was determined by 
measuring the refractive index and determined values of all systems were in the ophthalmically 
suitable range for eye drops (i.e. not greater than 1.476) (72). 
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Figure 20: Typical temperature sweep profile of temperature responsive in situ forming gel 
(G’- squares, G’’- triangles and η* - circles). Tgel is marked with an arrow at 
intersection of G’ and G’’ curves. 
Tgel 
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Table 8.  Sample sequence from design of experiment (DoE) and corresponding 
experimental temperature of gelation (Tgel), complex viscosity (*), storage 
modulus (G’) and damping factor (tan), reprinted with permission from (1). 
DoE Sample* P407 P188 CS Tgel *1 log* G'1 logG Damping 
factor
1
 
(tanδ) 
Form 
(%, 
w/w) 
(%, 
w/w) 
(%, 
w/w) 
(°C) (Pas) (Pa) 
Preliminary 
screening 
1ο 11.4     33.4 0.05 -1.34 3.56 0.55 0.825 gel 
βο 13.8 24.4 19.5 1.29 119 2.08 0.259 gel 
γο 15.2 24.3 702 2.85 4320 3.64 0.206 gel 
4ο 16.9 20.7 1520 3.18 9360 3.97 0.197 gel 
5ο 19.3 15.1 2430 3.39 15200 4.18 0.101 gel 
Screening 6• 11.32 0.87 31.6 0.44 -0.36 2.45 0.39 0.494 gel 
7• 19.1 0.8 15.1 2370 3.37 14700 4.17 0.142 gel 
8• 15.8 0.84 22.5 277 2.44 1660 3.22 0.315 gel 
9• 14.12 4.01 29.8 2.17 0.34 13.2 1.12 0.248 gel 
10• 14.61 4.24 33.4 1.21 0.08 7.01 0.85 0.413 gel 
11• 18.39 4.64 22.5 131 2.12 794 2.90 0.271 gel 
1β• 10.59 7.4 49.4 0.02 -1.68 n.d. n.d. 1E+30 solution 
1γ• 15.49 7.66 35.1 0.48 -0.32 4.3 0.63 0.685 gel 
Refining step 
(addition of 
CS) 
14Ƥ 16.4 0.85 0.08 23.8 169 2.23 975 2.99 0.425 gel 
15Ƥ 10.93 4.2 0.08 52.5 0.02 -1.61 0.0156 -1.81 9.46 solution 
16Ƥ 15.92 3.97 0.08 31.1 7.77 0.89 46.4 1.67 0.327 gel 
17Ƥ 13.61 2.51 0.66 33.5 0.54 -0.27 9.17 0.96 0.748 gel 
18Ƥ 11.16 0.95 1.29 54.8 0.4 -0.4 0.273 -0.56 9.09 solution 
19Ƥ 16.2 0.92 1.22 26.3 26.2 1.42 229 2.36 0.201 gel 
β0Ƥ 10.8 4.18 1.25 47.7 0.49 -0.31 0.927 -0.03 3.14 solution 
β1Ƥ 15.7 3.96 1.18 33.5 3.32 0.52 35.6 1.55 0.46 gel 
ββƤ 11.31 0.89 0.1 38.2 0.04 -1.4 n.d. n.d. 2.37 solution 
Replicate 
step 
βγ (14)ƥ 16.4 0.84 0.09 23.9 1245 3.1 7270.000 3.86 0.2745 gel 
β4 (15)ƥ 10.93 4.21 0.09 52.4 0.02 -1.63 0.029343 -1.53 12.4 solution 
β5 (16)ƥ 15.88 3.97 0.08 31.1 2.36 0.37 21.2 1.33 0.2935 gel 
1* G’ and tanδ at γ5°C, determined by temperature sweep test (angular frequency and strain were 1 s-1 and 1%, respectively);  
n.d = not deterrmined 
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5.2. The model of temperature of gelation 
Within the established Tgel model, the response of interest is represented by following regression 
equation (1):  
 �ܶ�� = ͵ͷ.Ͷ͸ − ͳ͵.ͺͶ ×  ܲͶͲ͹̅̅ ̅̅ ̅̅ ̅  +  ͸.͹Ͳ × ܲͳͺͺ̅̅ ̅̅ ̅̅ ̅ +  ʹ.͹Ͷ × �ܵ̅̅̅̅  + ͹.Ͳ͹ ×  ܲͶͲ͹ ̅̅ ̅̅ ̅̅ ̅̅ ×  ܲͳͺͺ  ̅̅ ̅̅ ̅̅ ̅̅  + ͻ.ͳ͸ × ܲͶͲ͹ ̅̅ ̅̅ ̅̅ ̅̅  ×  ܲͳͺͺ  ̅̅ ̅̅ ̅̅ ̅̅ ×  �ܵ ̅̅ ̅̅           (Eq. 5) 
where factors denoted as overlined represent centered factors, that are reduced by mean value and 
divided by the half of the factor range. This way of representation allows for easier interpretation 
of the regression results and comparison of regression coefficients (the magnitude of the factor 
effect). The obtained coefficient of determination between the experimental and predicted values 
of Tgel was R
2
 = 0.93 (Figure 21A).  
Statistical analysis of the collected data revealed significant effects of P407, P188 and CS 
concentrations on the Tgel (p <0.05). The concentration effect impacts Tgel in following order: 
P407 (coefficient = -13.84) > P188 (coefficient = 6.70) > CS (coefficient = 2.74). The negative 
value of the coefficient indicates an inverse relationship between the factor (concentration) and 
the response (Tgel), showing that increase of the P407 concentration will result in a decrease of 
Tgel. The positive value of the coefficient observed for P188 indicates that increasing the 
concentration of P188, shifts Tgel to higher values, as already reported in the literature (12,15). 
Similarly to P188, but to a lesser extent, the increase in CS concentration increases Tgel. 
Evidently, CS affects the onset of gelling but it does not interfere with the formation of in situ 
gel, thus, making it a suitable additive in this mixed poloxamer system (1). In the similar 
concentration range, CS was already shown not to induce marked changes in the Tgel of 
poloxamer systems (20). 
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Figure 21. A) Experimental vs. predicted values of Tgel. B) Interaction profiles for Tgel. 
Factors at the borders of the concentration range tested. Red lines: lower limits of 
the tested concentration range (P407 10.25, P188 0, CS 0.08%, w/w); blue lines: 
upper limits of the tested concentration ranges (P407 19.1, P188 7.66, CS 1.3%, 
w/w), reprinted with permission from (1) 
Significant higher order terms include the interaction between P407 and P188 (coefficient = 7.07) 
and the interaction among P407, P188 and CS (coefficient = 9.16). These interactions show that 
the effect of one factor may vary depending on the level of the other factor. P407 and P188 
interaction profile suggests that the impact of P407 on the Tgel decrease is more pronounced at the 
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lower level of P188 (Figure 21B). At the other side, higher level of P407 assures more 
pronounced effect of P188 on the Tgel increase. Parallel lines on the Figure 21B indicate lack of 
significant interactions at lowest and highest concentration levels of the independent variables 
(i.e. P407 and CS, P188 and CS) (1).  
 
Figure 22. Response surface of the effects of the concentration of P407, P188 and CS on the 
Tgel. A) The 3-D response surface plot at varying concentration of P407 (10.25 – 
19.1 %, w/w) and P188 (0 – 7.66 %, w/w). B) The 3-D response surface plot at 
varying concentration of P407 (10.25 – 19.1%, w/w) and CS (0.08 – 1.30%, w/w). 
C) The 3-D response surface plot at varying concentration of P188 (0 – 7.66%, 
w/w) and CS (0.08 – 1.30%, w/w), reprinted with permission from (1). 
The response surface and contour plots shown in Figure 22 are three-dimensional feature of 
Figure 21B, depicting relationship of the independent variables on the response. As it can be seen 
in the Figs. 21B and 22A, relationship of the P407 and P188 on Tgel is not a straightforward. 
Curvatures shown on the Fig. 22A indicate that this relation is not linear (1).  
These interactions reveal the complexity of interplay of the components in the measured mixed 
systems. This complexity of interplay is highly related to the concentration of P188 in the system 
as suggested by Zhang et al. who revealed the formation of two distinct populations of micelles in 
mixed P407/P188 systems, depending on the concentrations of polymers, as presented on the 
Figure 23 (12). They suggested that P188 micellization was responsible for the Tgel increase 
(Figure 23). 
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Figure 23. A) Proposed mechanism for micelle organization P407 (at concentration levels of 20, 
17 and 16%, w/w). B) Proposed mechanism for micelle organization for mixed 
solutions of P407/P188 (at 19/1,18/2 and 17/3, % w/w). Micellization of P188 may 
also occur in the segregated mixtures. The crystalline P407 phase is predominant at 
high temperature. C) Proposed mechanism for micelle organization for mixed solution 
of P407/P188 (at 10/10 and 5/15, % w/w) when P188 concentrations were higher than 
the CMC in the range of investigated temperature (picture modified and reprinted with 
permission from (12)). 
 
A 
B 
C 
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5.3.  Models of rheological properties: complex viscosity and storage 
modulus 
Critical attribute that determines the dosing accuracy, retention time, and drug release from in 
situ forming ophthalmic gels is formulation rheological behavior. The systems with fine-tuned 
rheological properties would withstand the high shear rates and tear dilution thus preventing the 
drainage of an API from the site of the absorption (5)  
Oscillatory rheological tests provide insight into the gel microstructure. Complex viscosity is 
described by the ratio of the complex modulus G* and the angular frequency ω (100).  η∗ = G∗ω                                                                         (Eq. 6) 
Complex modulus consists of two parts - G’ and G” and their relationship is described via 
Pythagoras theorem (100): |G*| = √G'2 + G''2                                                                                              (Eq. 7) 
Consequently, this relation is similar for the complex viscosity: |*| = √'2 + ''2                                                                       (Eq. 8) 
Complexity of this term comes from the fact that it is combination of its real part depicting 
viscous behavior (’) and imaginary part (”) which represents elastic behavior (100). 
5.3.1. The model of complex viscosity 
Influence of different P407, P188 and CS concentration levels on the measured * at γ5°C and 
angular frequency of 1s
-1
 (6.28 rad/s) was investigated and mathematically described. Prior to the 
statistical analysis, * data were checked for normality. It was confirmed by Kolmogorov test 
that data follows the log-normal distribution. Thus, log transformation was applied on the 
measured * data (1).  
In this mathematical approach, the response of interest log(*) is represented by following 
regression equation: log(η*) = -Ͳ.͵͹ + ͳ.ͷ͵ × PͶͲ͹̅̅ ̅̅ ̅̅ ̅-ͳ.͸Ͳ × Pͳͺͺ̅̅ ̅̅ ̅̅ ̅-Ͳ.ͷͷ × PͶͲ͹̅̅ ̅̅ ̅̅ ̅ × Pͳͺͺ̅̅ ̅̅ ̅̅ ̅-Ͳ.͹͸ × PͶͲ͹̅̅ ̅̅ ̅̅ ̅ × CS̅̅ ̅ +Ͳ.͹Ͳ × CS̅̅ ̅ × CS̅̅ ̅ + ͳ.ͷ͸ × PͶͲ͹̅̅ ̅̅ ̅̅ ̅ × PͶͲ͹̅̅ ̅̅ ̅̅ ̅ × Pͳͺͺ̅̅ ̅̅ ̅̅ ̅           (Eq. 9) 
Developed * model shows good fit between experimental and predicted logarithmic values of 
* with resulting coefficient of determination R2 = 0.97 (Figure 24A). 
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Figure 24. A) Experimental values vs. predicted values of log(*). B) Interaction Profiles for 
log10(*). Factors at the borders of the concentration range tested. Red lines-
lower limits of the tested concentration range (P407 10.25, P188 0, CS 0.08%, 
w/w); blue lines: upper limits of the tested concentration ranges (P407 19.1, P188 
7.66, CS 1.3%, w/w), reprinted with permission from (1). 
 
Statistical analysis of the collected data revealed significant effects of P188 and P407 
concentrations on log(*) (p <0.05). The increase of P188 concentration results in the decrease of 
log(*) as revealed by its negative coefficient (coefficient = -1.60). On the contrary, the increase 
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of P407 concentration results in the increase of log(*)(coefficient = 1.53). The complexity of 
interactions is noticed on the response surface and contour plots of P407 and P188 (Figure 25A) 
and P407 and CS (Figure 25 B), while less complex relationship is noticed for P188 and CS on 
the response (Figure 25 C; which is in agreement with the linear lines on the Figure 24B ). 
Namely, the interaction between P407 and CS (coefficient = -0.76) as well as between P407 and 
P188 (coefficient = -0.55) was observed. Concomitantly, two higher order terms were found with 
the positive effect on the response, namely the interaction among P407, P407 and P188 
(coefficient = 1.56) and CS and CS (coefficient = 0.70) (1).  
At higher level of P188, the effect of P407 on increase of log(*) is less pronounced 
(Figure 25B). In contrary, the omission of P188 from the system results in faster increase of 
log(*) when increasing P407 concentration (1).  
 
 
Figure 25. Response surface of the effects of the concentration of P407, P188 and CS on the 
log(*). A) The 3-D response surface plot at varying concentration of P407 (10.25 
– 19.1%, w/w) and P188 (0 – 7.66%, w/w). B) The 3-D response surface plot at 
varying concentration of P407 (10.25 – 19.1%, w/w) and CS (0.08 – 1.30%, w/w). 
C) The 3-D response surface plot at varying concentration of P188 (0 – 7.66%, 
w/w) and CS (0.08 – 1.30%, w/w), reprinted with permission from (1). 
 
CS and P407 interaction profile suggests that the impact of P407 on the log(*) increase is more 
pronounced at the lower level of CS (Figure 24B). Similarly to the data presented on the 
Figure 24B, complexity of interactions is noticed on the response surface and contour plots of 
P407 and P188 (Figure 25A) and P407 and CS (Figure 25B), while less complex relationship is 
noticed for P188 and CS on the response; which is depicted by the linear lines on the Figure 24B 
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and Figure 25C. As it can be seen by comparing the response surface and contour plots images of 
the Tgel model and log(*) model (Figure 22 and Figure 25), higher degree of complexity, i.e. 
curvatures, was found in the log(*) model. This indicated the absence of linear relationship 
between the concentrations of three tested polymers to a response (1). 
 
5.3.2. The model of storage modulus 
As for the model of log(*), influence of different independent variables (P407, P188 and CS 
concentration levels) on the measured response G’ at γ5°C and angular frequency  of 1s-1 was 
tested and mathematically described. Again, Kolmogorov test confirmed that data follows the 
log-normal distribution, therefore log transformation was applied on the measured G’ data (1).  
Log (G’) is described by following regression equation (1): 
 logሺ�′ሻ = ͳ.ͳ͵ + ʹ.ͳ͸ × ܲͶͲ͹̅̅ ̅̅ ̅̅ ̅   − Ͳ.͹͹ × ܲͳͺͺ̅̅ ̅̅ ̅̅ ̅ − Ͳ.ʹ͸ ×  ܲͶͲ͹ ̅̅ ̅̅ ̅̅ ̅̅ ×  �ܵ  ̅̅ ̅̅ ̅ + Ͳ.ͷ͸ ܲͳͺͺ ̅̅ ̅̅ ̅̅ ̅̅ ×  �ܵ ̅̅ ̅̅  
                                                                                                               (Eq. 10) 
 
Developed log (G’) model exhibits suitable fit between experimental and predicted logarithmic 
values of G’ with resulting coefficient of determination R2 = 0.93 (Figure 26A) (1). 
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Figure 26. A) Experimental values vs. predicted values of log(G’). B) Interaction Profiles for 
log(G’). Factors at the borders of the concentration range tested. Red lines-lower 
limits of the tested concentration range (P407 10.25, P188 0, CS 0.08%, w/w); 
blue lines: upper limits of the tested concentration ranges P407 19.1, P188 7.66, 
CS 1.3%, w/w), reprinted with permission from (1). 
 
Statistical analysis of the acquired data revealed significant effects of P407 and P188 
concentrations on log(G’) (p <0.05), with P407 concentration having stronger effect on the 
response. As expected, similarly to model for log(*), the increase of P188 concentration results 
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in the decrease of log(G’) due to its negative coefficient (coefficient = -0.76). On the contrary, the 
increase of P407 concentration results in the increase of log (G’) (coefficient = β.16) (1). 
  
 
Figure 27. Response surface of the effects of the concentration of P407, P188 and CS on the 
log(G’). A) The γ-D response surface plot at varying concentration of P407 (10.25 
– 19.1 %, w/w) and P188 (0 – 7.66 %, w/w). B) The 3-D response surface plot at 
varying concentration of P407 (10.25 – 19.1 %, w/w) and CS (0.08 – 1.30 %, 
w/w). C) The 3-D response surface plot at varying concentration of P188 (0 – 7.66 
%, w/w) and CS (0.08 – 1.30 %, w/w), reprinted with permission from (1). 
 
As seen on the Figure 27 (A; B) relation between P407 and P188 and P407 and CS on the 
response in model appears to be relatively simple. More complex relation of P188 and CS on the 
log (G’) was found to be statistically significant interaction with positive effect on the dependent 
variable (coefficient = 0.56) (Figure 27C) (1). 
Figure 26B (2D view of the Figure 27) shows that the increase of P188 at lower level of CS 
results in decrease of log(G’), while this effect is not observed when CS is at highest level (1.3%, 
w/w). The increase in CS at low level of P188 lowers the response of interest. However, this 
effect is opposite at higher level of P188 (7.66%, w/w) (1). 
Another interaction included in the model, but with no statistical significance, was interaction 
between P407 and CS having a negative impact on the response (coefficient = -0.26). Same 
interaction with significant negative effect was noticed in the model for log(*) (1). 
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5.4. Selection of rheologically improved in situ forming ophthalmic gel  
Tgel of innovative ophthalmic in situ forming gels is the most critical parameter related to efficacy 
and safety as well as patient compliance since it influences the accuracy of dosing, (dis)comfort 
associated with the instillation and residence time at the eye surface. Namely, if the system gels 
at room temperature, dosing would be hindered. Storage at low temperature would diminish this 
problem, however, the instillation of cold formulation can possibly be irritating and painful. 
Therefore, the optimal Tgel of in situ forming ophthalmic gel should be between β5°C, the 
average ambient temperature, and γ5°C, the eye surface temperature (20). In this study, the 
optimal range of Tgel was set to 28 – γβ °C (1). 
Viscosity is one of the key attributes for innovative ophthalmic in situ forming gels defining the 
residence time at the eye surface and drug release profile. The optimal range of viscosity is much 
more difficult to select in relation to Tgel. A wide range of viscosities reported for poloxamer-
based in situ forming ophthalmic gels have suitable in vivo response (7,14,20).Therefore, we 
characterized the commercially available in situ forming ophthalmic gels with rotational test with 
controlled shear rate to enable the recognition of leading candidates. Oscillatory tests of selected 
leading candidates reveled the lower limit for η* (at γ5°C and 1s-1) at 1.2 Pa  s (1).  
G' presents the elastic behavior of a sample and it assures adequate gel stability. As minimal G’ 
values for gel structures are around 5 Pa (100), this value was set as minimal value for this 
dependent variable.  
Considering the optimal Tgels, G’ and * suggested by corresponding models, four mixed 
P407/P188/CS systems were selected (Table 9). The additional criterion of the selection was the 
lowest possible total polymer content in in situ forming ophthalmic gel. To validate the data 
obtained by the models, mixed P407/P188/CS systems were prepared. Tgel, G’ and η* were 
determined by temperature sweep test and compared with predicted values (Table 9) (1). 
Furthermore, damping factor (tanδ) factor was obtained in these measurements and values lower 
than 1 for all samples at γ5°C, indicate presence of gel state (100). 
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Table 9. Selected mixed P407/P188/CS systems, corresponding experimental and predicted temperature of gelation (Tgel), 
complex viscosity (η*), storage modulus (G’) and dumping factor (tan)1, reprinted with permission from (1). 
 
Sample P407 
(%, 
w/w) 
P188 
(%, w/w) 
 CS 
(%, 
w/w) 
Exp. Tgel 
 (°C) 
Pred. Tgel
 
 (°C) 
 Tgel 
recovery 
(%)  
Exp. log(*)1 Pred. 
log(*) 
log(*) 
recovery 
(%)  
Exp. 
log(G')1 
Pred. log(G')  log(G') 
recovery 
(%)  
Damping 
Factor 
(tan) 
PL1  14.2 1.7 0.25 31.10 ▫ 
0.01 
31.27  
(29.72-32.82) 
99.5 0.32 ▫ 0.06 0.62 
(0.28-0.96) 
52.4 1.15 ▫ 
0.17 
1.50 
(1.26-1.74) 
76.6 0.β9 ▫ 0.0γ  
PL 2 15.0 2.0 0.5 β6.γ0 ▫ 
0.01 
28.87 
(27.00-30.74) 
109.77 0.81 ▫ 0.06 0.60 
(0.06-1.14) 
73.8 1.60 ▫ 
0.06 
1.75 
(1.48-2.02) 
91.5 0.β1 ▫ 0.00 
PL3 14.2 1.7 1.01 29.90 ▫ 1.7 35.30 
(32.45-38.15) 
118.06 0.66 ▫ 0.0β 0.53 
(0.09-0.97) 
80.2 1.44 ▫ 
0.09 
1.18 
(0.74-1.62) 
122.4 0.β6▫ 0.01  
PL4 14.2 1.7 0.5 28.70 ▫ 
0.01 
32.60 
(30.90-34.30) 
113.59 0.61 ▫ 0.09 0.30 
(-0.23-0.83) 
48.9 1.40 ▫ 
0.02 
1.42 
(1.14-1.70) 
98.5 0.23 ▫ 0.01  
 
Exp., experimental, presented as mean ▫ SD 
Pred., predicted, presented as mean; values in brackets represent lower and upper limits of 95% confidence interval 
1* (Pa  s) and G’ (Pa) at 35C determined by temperature sweep test (angular frequency and strain were 1 s-1 and 1 %, respectively)
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High coefficient of determination (R
2
 = 0.93)
 
and the overall recovery of experimental to 
predicted Tgel (110.23  0.08%; relative standard deviation (RSD) = 7.02%) confirmed the 
suitability of Tgel model. Similar agreement was found for log (G’) model (R2 = 0.93) with the 
average recovery of experimental to predicted of 97.25  19.07%, having slightly higher 
variability (RSD = 19.61%) (1). In case of log(*) model, even better coefficient of determination 
(R
2
 = 0.97)
 
 was observed, and despite the lower overall recovery of experimental to predicted 
log(*) (63.83  0.16%; RSD = 24.3%), the developed model enabled the development of mixed 
P407/P188/CS system with targeted viscosity (> 1.2 Pa  s) (1). The higher variability of this 
model could be related to the heating rate-dependent kinetics of gel formation. Mixed P407/P188 
systems exhibit very complex rheological behavior with internal relaxations and slow 
reorganizations taking place in the temperature range preceding or following the Tgel (Figure 23) 
(12). However, when ophthalmic in situ forming gel is applied, formulation is quickly spreaded 
throughout the surface of the eye and actually dramatic and the fast temperature change from 
room temperature (storage condition) to biologically relevant temperature is occurring in vivo.  
5.4.1. In depth rheological characterization of in situ forming ophthalmic gel – 
oscillatory tests 
In depth rheological characterization of selected mixed P407/P188/CS systems structure was 
performed by oscillatory rheological tests. 
Oscillatory tests explore the viscoelasticity of a sample providing a microstructural fingerprint 
that can be used to quantify stability and to sensitively refine critical aspects of product 
performance (103). 
Mixed P407/P188/CS systems are viscoelastic materials and they are showing viscous and elastic 
behavior simultaneously. Depending on their rheological behavior, viscoelastic liquids differ 
from viscoelastic solids. Namely, as mentioned previously, viscoelastic solid materials (such as 
gels) have a phase angle (δ) between 0 and π/β radians (0 and 90°) and consequently tanδ 
(dumping factor, loss tangent) < 1 (100). 
Two types of oscillatory tests were used to characterize developed mixed systems - strain and 
frequency sweep analyses. In the strain sweep test oscillation is performed at variable amplitudes, 
while the frequency and temperature are kept at a constant value. These tests are carried out to 
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determine the limit of LVE range, i.e. the range where stress () is directly proportional to strain 
(Ȗ); and to evaluate mechanical spectra (G’ and G”) (100). 
Strain sweep analysis of developed mixed P407/P188/CS systems at γ5°C are presented on the 
Figure 28.  
 
Figure 28. Strain sweeps (shear strain amplitude sweep) with controlled shear deformation 
(CSD) of selected mixed P407/P188/CS systems (PL1, PL2, PL3 and PL4) before 
(empty symbols, red) and after (filled symbols, blue) dilution with simulated tear 
fluid (STF). Storage modulus (G’) is represented by square while loss modulus 
(G”) by triangle. 
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Analyzing the data obtained by strain sweep studies, a typical gel-like behavior is observed, with 
the LVE range being maintained up to almost 3% of applied strain (Figure 28). For all samples, 
G’ is significantly higher than G’’, indicating that at γ5°C elastic character of the sample is 
dominant and gel structure is present.  
After determination of LVE of the samples, developed mixed P407/P188/CS systems were 
subjected to the frequency sweep analysis, which gave an insight on the behavior of GƟ, GƠ and 
* as a function of angular frequency, while strain (Ȗ) is kept constant in the previously 
determined LVE range. Frequency sweep analysis provides information about a time dependant 
behavior of samples. Short term behavior is simulated by rapid motion (high frequencies), while 
long term behavior is simulated by low frequencies (100). 
Frequency sweep measurements for all four mixed P407/P188/CS systems indicated that G’ was 
higher than G’’ revealing suitable gel stability (Figure 29). Moreover, the presented rheological 
profile suggests the existence of soft gels known to be formed at moderate poloxamer 
concentration (134). This phenomenon has been ascribed to the weak attraction of spherical 
micelles as the solvent becomes poorer on heating. 
To determine the influence of CS on the gel mechanical strength, frequency sweep analysis was 
carried out also for the respective control systems without CS (Figure 29). As expected, the 
presence of CS in mixed systems resulted in higher G’ and G’’ values indicating increased gel 
mechanical strength (1). It was already suggested that the elastic characteristic of the system 
increased owing to an effect on microscopic diffusion within gel structure which facilitated the 
accommodation of unbound water and consequently micelle packaging (20).  
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Figure 29. Rheological properties of selected mixed P407/P188/CS systems (PL1, PL2, PL3 
and PL4) and respective controls under biorelevant conditions. Frequency sweeps 
analysis before (circles) and after (squares) dilution with STF: 40:7 at γ5°C. G’ 
filled symbols, G” empty symbols. Control sample for PL1, PLγ and PL4 is 
labeled CPL1,3,4; control sample for PL2 is labeled CPL2, reprinted with 
permission from (1). 
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Since dilution of ophthalmic product with tears is inevitable after administration in vivo, it is 
essential to evaluate their key properties in biorelevant conditions. An optimal gel system should 
keep its structure despite the dilution with tears. From this reasons, mixed systems were further 
characterized under biorelevant conditions. Therefore, dilution with STF at the ratio of 40:7 
mimicking their mixing with tear fluid after instillation was done (11). Despite the dilution, 
mixed systems retained their ability to form gel at temperature lower than 35C (i.e., the sample 
PL2 formed gel at 28.7C, while PL1, PL3 and PL4 formed gel at 33.5C). The observed increase 
in Tgel relative to undiluted systems can be related to both, the decrease in the total concentration 
of polymers and the modification of the physicochemical properties of the hydrogels in the 
presence of STF electrolytes (20,135). 
The dilution of all mixed systems with STF resulted in no change in G’ to G” ratio or their 
overall profile (Figure 29). Furthermore, there was no significant change in the absolute values of 
G’ and G” in case of samples prepared with the same poloxamer concentration and different CS 
concentration (Figure 29; PL1, PL3 and PL4). On the contrary, comparing the mixed system PL2 
(P407/P188/CS 15.0/2.0/0.5%, w/w) with PL4 (P407/P188/CS 14.2/1.7/0.5%, w/w), it may be 
observed that the small increase in poloxamers concentration influenced the resistance to dilution. 
Figure 30 shows the relationship of * and angular frequency of selected mixed P407/P188/CS 
systems. The decrease of * values with the increase of angular frequency arguments suitable 
pseudoplastic behavior of in situ forming ophthalmic gels (Figure 30). The viscosity profiles of 
all mixed systems did not change significantly upon dilution with STF suggesting the 
maintenance of their pseudoplastic behavior. 
 
 
 
 
 
 96 
 
 
 
Figure 30. Complex viscosity (*) of selected mixed P407/P188/CS systems as a function of 
angular frequency (ω) before (red, empty symbols) and after (blue, filled symbols) 
dilution with STF, reprinted with permission from (1). 
 
Moreover, there was no marked change in the absolute values of * upon dilution except, again, 
in the case of PL2 sample (1). 
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Comparing mixed P407/P188/CS systems developed in this study with mixed P407/CS system 
developed by Gratieri et al. in terms of resistance to dilution, it may be concluded that P188 
significantly contributed to gel stability (20). In mixed P407/CS system the concentration of P407 
was higher (16%, w/w and 14%, w/w, upon dilution with STF) than in case of mixed 
P407/P188/CS system (14.2%, w/w and 12.09%, w/w, upon dilution with STF). However, upon 
dilution mixed P407/CS system behaved as viscoelastic solution at 35C and decreased 
frequencies while mixed P407/P188/CS system behaved as soft gel(1).  
5.4.2. Dynamic viscosity evaluation by rotational rheology 
In DoE study in this thesis, oscillatory tests were used to study gel formation in order to gain 
reliable and conclusive results. For this purpose, the structure of a gel must not be disturbed 
during its rheological characterization. Therefore, shear stress is a crucial parameter and needs to 
be precisely adjusted and controlled. Oscillatory tests are superior to rotational tests when comes 
to investigations on gel formation or gel structure characteristics (102), i.e. to explore the 
viscoelasticity of a sample providing a microstructural fingerprint that can be used to quantify 
stability and to sensitively refine critical aspects of product performance.  
Commercially available ophthalmic products and in situ forming gel formulations developed in 
this study are based on different polymers. Therefore, their gelation mechanisms differ which 
consequently results in difference in the linear viscoelastic (LVE) range and in other 
characteristics tested by oscillatory tests. In order to compare developed formulations with 
commercially available products, rotational test with controlled shear rate (CSR) was developed.  
Viscosity profile of samples in biorelevant conditions (diluted with STF 40:7) was measured in 
the shear rate range of 0.1 – 1000 s-1. Similar measuring methodology was reported before (15). 
Results of measurments are presented in the Table 10.  
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Table 10. Dynamic viscosity results of commercially available ophthalmic formulations and 
P407/P188/CS mixed systems after dilution with STF. 
Shear 
Rate 
[1/s] 
API-free 
Preformed 
gel 1* 
API-free 
Preformed 
gel 2* 
TIMO-
loaded  
in situ 
forming 
gel* 
Dexpanthe
nol loaded 
in situ 
forming 
gel* 
DEX/ 
TOBRA-
loaded in 
situ 
forming 
gel* 
PL 1 
P407/ 
P188/ 
CS 
(%, w/w 
14.2/1.7/
0.25) 
PL 2 
P407/ 
P188/ 
CS 
(%, w/w 
15/2/ 
0.5) 
PL 3 
P407/ 
P188/ 
CS 
(%, w/w 
14.2/1.7/
1.01) 
PL 4 
P407/ 
P188/ 
CS (%, 
w/w 
14.2/1.7/
0.5) 
Polyme
r 
Gellan gum  Hydroxypr-
opyl guar 
Carbomer HP-guar 
(agar gum) 
Xanthan 
gum 
Mixed systems  
0.1 2.035 
▫0.007 
3.545  
▫ 0.7β8 
4.160  
▫β.γ05 
1.033  
▫0.816 
10.170 
▫0.608 
49.900 
▫7.γγ0 
34.500 
▫0.849 
46.450 
▫9.970 
15.000 
▫4.γ84 
0.278 1.690 
▫0.099 
1.550  
▫0.γβ5 
1.395  
▫0.67β 
0.254  
▫0.0β8 
6.110 
▫0.ββ6 
26.950 
▫4.17β 
16.000 
▫1.414 
27.650 
▫4.596 
8.785 
▫0.757 
0.774 1.255 
▫0.1β0 
0.701  
▫0.1γβ 
0.675  
▫0.β7γ 
0.100  
▫0.0βγ 
3.365 
▫0.078 
9.025 
▫0.148 
5.940 
▫γ.βγ9 
13.150 
▫β.899 
3.730 
▫0.4γ8 
2.15 0.841 
▫0.108 
0.338  
▫0.050 
0.325  
▫0.19γ 
0.066  
▫0.0β0 
1.690 
▫0.0β8 
2.000 
▫0.11γ 
2.425 
▫1.β09 
5.220 
▫0.495 
1.183 
▫0.β79 
5.99 0.629 
▫0.04γ 
0.179  
▫0.0ββ 
0.096  
▫0.01β 
0.035  
▫0.005 
0.789 
▫0.011 
0.542 
▫0.βββ 
0.496 
▫0.15γ 
0.863 
▫0.4γ4 
0.312 
▫0.0β6 
16.7 0.401 
▫0.0γ1 
0.097  
▫0.010 
0.064  
▫0.01β 
0.035  
▫0.01γ 
0.351 
▫0.004 
0.131 
▫0.010 
0.196 
▫0.1γ4 
0.287 
▫0.058 
0.107 
▫0.010 
46.4 0.240 
▫0.01γ 
0.058  
▫0.004 
0.038  
▫0.005 
0.019  
▫0.011 
0.152 
▫0.001 
0.082 
▫0.019 
0.131 
▫0.056 
0.188 
▫0.011 
0.078 
▫0.00β 
129 0.134 
▫0.006 
0.037  
▫0.00β 
0.025  
▫0.00β 
0.009  
▫0.001 
0.067 
▫0.001 
0.063 
▫0.009 
0.100 
▫0.0β8 
0.155 
▫0.004 
0.067 
▫0.000 
359 0.072 
▫0.00γ 
0.025 
▫0.001 
0.017 
▫0.001 
0.008 
▫0.000 
0.031 
0.000 
0.053 
▫0.00β 
0.084 
▫0.015 
0.133 
▫0.001 
0.059 
▫0.000 
1000 0.039 
▫0.00β 
0.017 
▫0.000 
0.012 
▫0.000 
0.006 
▫ 0.001 
0.016 
0.000 
0.048 
▫0.001 
0.075 
0.009 
0.111 
▫0.00γ 
0.054 
▫0.001 
Values are mean [Pa·s]  ▫ SD (n = γ) 
Simulated tear fluid (STF) 
 
As already noticed in case of oscillatory shear rheological tests, viscosities of developed mixed 
systems, recorded in rotational test, showed suitable pseudoplastic behavior. Dynamic viscosities 
of P407/P188/CS systems were higher at lower shear rates compared to commercially available 
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formulations, indicating adequate suitability of developed mixed systems to retain potential APIs. 
On the contrary, at high shear rates, viscosities dropped significantly rendering them adequate for 
ophthalmic use. 
Based on minimal polymer content (P407, P188 and CS concentration of 14.2, 1.7 and 0.25%, 
w/w, respectively), favorable rheological characteristics (Tgel = 31.1 °C, * = 2.1 Pa  s; low 
dynamic viscosity at high shears) and in vitro resistance to tear dilution (G’ β1β.4 Pa and 175.γ 
Pa before and after dilution, respectively), the PL1 was selected as optimal in situ forming gel 
(1). 
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5.5. Effect of active pharmaceutical ingredients on temperature of 
gelation and complex viscosity 
 
The addition of APIs in the mixed P407/P188/CS system is expected to cause a modification of 
the physicochemical properties of in situ forming gels. Four ophthalmic APIs were selected in 
order to gain understanding of their effects on Tgel and * of selected PL1 in situ forming gel (1).  
APIs were tested in the concentrations and combinations relevant for topical ophthalmic use.  
In situ forming ophthalmic gels containing TIMO, DEX and DORZO were prepared in the same 
way as API free systems. For preparation of systems containing TOBRA, API was first dissolved 
in defined aliquot of WFI and then mixed with P407/P188/CS solution. pH vas adjusted to 5.8 
since addition of TOBRA increased pH of the solution. All prepared formulations had an 
ophthalmically acceptable osmolality, which was achieved by the addition of appropriate 
amounts of NaCl to the solution (1). 
API-loaded P407/P188/CS systems were characterized for Tgel and * before and after dilution 
with STF (Table 11). Additionally, rotational test was performed in order to evaluate the 
influence of APIs on dynamic viscosity profile (1).   
Table 11. Effect of APIs on temperature of gelation (Tgel) and complex viscosity (*), 
reprinted with permission from (1). 
Sample Before dilution with STF
1
 After dilution with STF 
Tgel (°C) ŋ* (Pa  s) 2 Tgel (°C) ŋ* (Pa  s) 2 
PL1 - DORZO β7.50 ▫ 1.70 7.88 ▫ 1.18 γγ.50 ▫ 0.01 0.67 ▫ 0.06 
PL1 - TIMO β6.γ0 ▫ 0.01 4.90 ▫ 0.54 β9.90 ▫ 1.β0 β.44 ▫ 1.50 
PL1 - DORZO/TIMO β8.70  ▫ 0.0β 4.8β ▫ 1.07 32.90 ▫ 0.80 0.64▫ 0.10 
PL1 -TOBRA γ0.γ0 ▫ 1.40 1.5β ▫ 0.66 γ1.10 ▫ 0.01 0.5β ▫ 0.10 
PL1 - DEX ββ.60 ▫ 1.70 6.11 ▫ 0.70 β8.70 ▫ 0.01 1.56 ▫ 1.16 
PL1 - DEX/TOBRA βγ.65 ▫ γ.18 6.88 ▫ 1.59 γ1.15 ▫ 0.07 0.6γ9 ▫ 0.β1 
PL1 γ1.10 ▫ 1.40 β.10▫ 0.74 γγ.50 ▫ 0.70 0.37 ▫ 0.15 
1
 Simulated tear fluid (STF) 
2 # * at γ5°C determined by temperature sweep test (angular frequency and strain were 1 s-1 and 1 %, respectively) 
Values are mean ▫ SD (n = γ) 
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All APIs, except TOBRA, notably decreased Tgel in comparison with Tgel of PL1. This effect was 
highest for DEX showing the decrease of the Tgel for 8.5°C (1). DEX has already been shown to 
decrease the Tgel of P407 based in situ forming gels (136,137). Such an effect can be ascribed to 
the promotion of P407 self-assembly in the presence of hydrophobic drug allowing the formation 
of gel at lower temperatures (138). The Tgel of the mixed P407/P188 systems was also reported to 
be affected by the addition of hydrophobic APIs; the Tgel decreased with increasing the pH-
dependent hydrophobicity of API in the systems (139). Smaller Tgel decrease was observed for 
the systems containing dissolved APIs, namely Tgel decreased for 4.8 and β.4 °C in case of TIMO 
and DORZA, respectively. As anticipated by other authors, the decrease of Tgel induced by 
dissolved APIs could be related to the API salting out effect (140,141). Their presence could shift 
the concentration and/or temperature at which micelles are formed to lower values and, 
moreover, could affect the close-packing of micelles, resulting in Tgel decrease (135,139). 
However, despite the decrease of Tgel by the addition of APIs, all the samples except those with 
DEX formed gels at temperature higher than 25C (1).  
The * values for API-loaded PL1 were in the range of 1.52 – 7.88 Pa  s indicating no 
pronounced influence of API entrapment on gel viscosity (Table 11) (1).  
Dilution with STF, as expected, led to the increase in Tgel and certain decrease in * for all the 
API-loaded PL1. All the samples retained their gel structure after dilution as suggested by the 
frequency sweep analysis (Figure 31) (1). 
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Figure 31. Storage (filled symbols) and loss modulus (empty symbols) of API-loaded PL-1 
formulations after dilution with STF 40:7 at γ5°C: A) PL1-DEX, B) PL1-
TOBRA, C) PL1- DEX/TOBRA; D) PL1-DORZO; E) PL1-TIMO; F) PL-
DORZO/TIMO 
 
 
A B 
C D 
E F 
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5.5.1. Evaluation of dynamic viscosity of systems containing APIs 
 
After dilution with STF in the ratio 40:7, dynamic (shear) viscosity profiles of mixed systems 
containing different APIs were recorded. Viscosity profiles of all samples showed suitable 
pseudoplastic behavior after dilution with STF at 35°C (Table 12). 
 
Table 12. Dynamic viscosity obtained by rotational test for PL1 based formulations after 
dilution with STF. 
Shear 
Rate 
PL1 PL1 - 
DORZO 
PL1 - 
TIMO 
PL1 - DORZO/ 
TIMO 
PL1-
TOBRA 
PL1 - 
DEX 
PL1 - 
DEX/ 
TOBRA 
[1/s] [Pa  s] [Pa  s] [Pa  s] [Pa  s] [Pa  s] [Pa  s] [Pa  s] 
0.1 49.90 
▫7.γγ0 
25.65 
▫5.γ0γ 
57.7 
▫11.597 
37.7 
▫β.687 
20.050 
▫6.010 
51.45 
▫14.779 
4γ.6▫ 
11.314 
0.278 26.950 
▫4.17β 
16.75 
▫6.β9γ 
22.7 
▫4.667 
19.8 
▫6.505 
9.275 
▫0.β05 
23.15 
▫γ.748 
β0.7▫ 
4.95 
0.774 9.025 
▫0.148 
4.52 
▫1.909 
8.38 
▫γ.705 
6.84 
▫1.44β 
3.465 
▫1.γ08 
10.6 
▫0.β8γ 
8.58 
▫0.β8γ 
2.15 2.000 
▫0.11γ 
1.022 
▫0.γ9γ 
2.44 
▫0.γ68 
1.315 
▫0.γ18 
1.085 
▫0.γ61 
2.705 
▫1.45 
2.695 
▫1.011 
5.99 0.542 
▫0.β22 
0.274 
▫0.076 
0.503 
▫0.γβ5 
0.36 
▫0.1γ9 
0.4075 
▫0.0ββ 
0.388 
▫0.151 
0.305 
▫0.146 
16.7 0.131 
▫0.010 
0.061 
▫0.007 
0.075 
▫0.01 
0.116 
▫0.006 
0.12525 
▫0.077 
0.114 
▫0.07γ 
0.091 
▫0.048 
46.4 0.082 
▫0.019 
0.052 
▫0.00γ 
0.055 
▫0.006 
0.081 
▫0.00β 
0.0683 
▫0.1β4 
0.058 
▫0.01γ 
0.056 
▫0.011 
129 0.063 
▫0.009 
0.049 
▫0.00β 
0.048 
▫ 0.00β 
0.067 
▫0.001 
0.053 
▫0.00β 
0.05 
▫0.006 
0.046 
▫0.00γ 
359 0.053 
▫0.00β 
0.047 
▫0.001 
0.045 
▫0.000 
0.062 
▫0.00β 
0.0443 
▫0.00γ 
0.047 
▫0.004 
0.041 
▫0.001 
1000 0.048 
▫0.001 
0.045 
▫0.001 
0.043 
▫0.000 
0.058 
▫0.00β 
0.0398 
▫ 0.00γ 
0.045 
▫0.00γ 
0.039 
▫0.001 
Values are mean ▫ SD (n = γ). 
 
Dynamic viscosity results indicate adequate pseudoplastic behavior of developed systems in 
biorelevant conditions - after dilution with STF (40:7) at γ5°C.  
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5.5.2. Gelation time 
 
To gain insights in APIs influence on gelation, gelation time, namely the time point at which 
intersection of the curves of measured loss modulus (G”) and the storage modulus (G’) occurrs, 
was determined for PL 1 systems containing APIs (1). Results are presented in the Table 13.  
Table 13. Results of gelling time for PL1 and of PL1 systems containing APIs.  
 
Sample Gelation time (s) 
PL1 - DORZO 68.γ5 ▫ γ.89 
PL1 - TIMO 41.05 ▫ γ.09 
PL1 - DORZO/TIMO 87.γ7 ▫ β1.70 
PL1 -TOBRA 51.0γ ▫ 1γ.74 
PL1 - DEX 45.5γ ▫ 1γ.7 
PL1 - DEX/TOBRA 0.00 ▫ 0.00 
PL 1 5.00 ▫ 5.00 
Values are mean ▫ SD (n = γ). 
 
The addition of APIs in the mixed P407/P188/CS system prolonged the gelation time in all cases 
except for DEX/TOBRA (1). However, the obtained gelation time values were still in the 
appropriate range (41.1-87.4 s) for ophthalmic administration (142,143).  
Results of in depth rheological characterization (oscillatory and rotational) indicate the robustness 
of selected PL1 in situ forming gel against entrapment of APIs with different physicochemical 
characteristics. All samples acted as gels upon dilution and preserved pseudoplasticity (1). The 
decrease in Tgel caused by API entrapment open the possibility to further decrease the 
concentration of poloxamers required to obtain in situ forming gels with appropriate 
biopharmaceutical properties (144). 
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5.6. Drug release from in situ forming gels 
In vitro release tests (IVRs) are a important tool for measuring changes in critical physical 
properties of semisolid products that may be related to their topical bioavailability (127,145). 
Origin of these changes could be the physicochemical characteristics of the drug substance, 
excipients, formulation manufacturing process, shipping and storage effects, aging and other 
formulation and/or process factors. Although IVRs are valuable, it is necessary to stress out that 
these tests cannot predict directly in vivo performance of the drugs because they cannot mimic 
physiologic reality of the biological membranes, like cornea of the eye or stratum corneum of the 
skin, which are usually in vivo rate limiting barriers to drugs bioavailability (127). 
From regulatory perspective, currently the only required use of the IVR test is to determine the 
acceptability of minor process and/or formulation changes in approved semisolid dosage forms 
(129). Recently, for complex generic drugs, regulatory agencies suggest extensive in vitro 
equivalence testing as adequate substitute for expensive in vivo bioequivalence studies. 
Discriminative IVR methodology plays a critical role in this characterization package (146–148) 
Furthermore, for application in pharmaceutical industry method needs to be standardized and 
cost-effective (126). For assessment of in vitro drug release from nano-sized and gelling 
ophthalmic delivery system a variety of membrane diffusion techniques were implemented such 
as simple dialysis methods, dialysis methods using modified Apparatus 1 and 2 and Franz 
diffusion cells (126). Aim of this part of the study was to develop robust, precise and 
discriminative method for testing drug release from developed in situ ophthalmic gel 
formulations. From this reason, TIMO was used as a model ophthalmic drug and vertical 
diffusion (Franz diffusion) cell system was selected as apparatus, due to its applicability for 
assessment of drug release from semisolids (127).  
When drug is dissolved in the drug product, as it is the case in of PL1- TIMO samples, resulting 
release kinetics from semisolids is described by Higuchi model (127): ܳ = ʹ × �� √��   
                                                                                                                                               (Eq.11). 
 
where Q is the amount of drug released into the sink (medium) per cm
2
, Co is the drug 
concentration in the releasing matrix, and D is the drug diffusion coefficient through the matrix. 
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Viscosity, dominantly the ratio of the viscous and elastic properties of prepared gels, is the major 
critical attribute that would influence drug diffusion/release from in situ ophthalmic gels. Drug 
release would, obviously, be reversely proportional to matrix viscosity.  
Parameters considered during development of IVR test in this study were: choice of IVR 
medium, membrane selection, sampling points and discriminatory power of the method.  
 
5.6.1. Validation of UPLC method for quantification of TIMO 
In order to adequately asses TIMO determination in IVR study, prior to the IVR testing, 
quantification method for TIMO using ultra performance liquid chromatography was developed, 
optimized and validated. Validation was designed to cover following parameters: 
 specificity, 
 linearity,  
 accuracy,  
 range,  
 repeatability and  
 standard/sample stability. 
 
Specificity 
During the specificity study chromatograms of mobile phase, in vitro release medium (STF) and 
placebo solution were evaluated to ensure that there is no interference with TIMO peak. 
Results are presented on the Figure 32(A-E). 
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Figure 32: Chromatograms of A) mobile phase solution , B) STF, C) Placebo solution,  
D) TIMO standard solution and of E) IVR sample solution. 
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From all chromatograms obtained in the specificity study it is evident that STF, mobile phase and 
placebo do not interfere with TIMO retention time.  
Linearity  
Linearity of the detector response was evaluated in the concentration range of 0.00516 – 0.05170 
mg/ml (Table 14). Following regression equation was obtained, with coefficient of determination 
R
2
 > 0.999: 
 y = 11462861.374 x + 56163.742                                                                                         (Eq. 12)                                                                                               
Table 14. Linearity results. 
Level Area Concentration 
(mg/ml) 
1% 58897.937 0.0052 
1% 63885.278 0.0052 
10% 619685.978 0.0516 
10% 695850.980 0.0516 
20% 1201809.472 0.1034 
20% 1224370.385 0.1032 
40% 2476425.186 0.2068 
40% 2522467.191 0.2064 
70% 4245772.080 0.3619 
70% 4286297.129 0.3619 
90% 5432830.553 0.4653 
90% 5378213.778 0.4643 
100% 5948429.986 0.5159 
100% 5828232.691 0.5170 
SLOPE 11462861.37436 
INTERCEPT 56163.7 
The 95% confidence interval of the y-intercept (-9709.11, 122036.59) includes zero, which 
indicates that the intercept is not statistically significant. Obtained results demonstrated a linear 
relationship between the detector response and the TIMO concentration in the tested range.  
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Accuracy, range and repeatability of UPLC method 
Method accuracy was evaluated through recovery experiment from the solutions prepared in 
triplicate in the same concentration range as for linearity evaluation. Placebo solution was spiked 
with TIMO. Results presented in the Table 15 indicate that method, with recoveries from 99-
105% and RSDs from 1-5% was found accurate for named purpose. 
Table 15. Accuracy study results. 
Level Average 
recovery 
(%) 
RSD 
(%) 
1% 102 4 
10% 105 5 
20% 101 1 
40% 103 3 
70% 101 1 
90% 101 1 
100% 99 1 
Repeatability was demonstrated by evaluating RSD (<3.0%) of standards injected throughout the 
sequences. Based on the linearity and accuracy results, the range of the developed UPLC method 
was found to be from 0.5 µg/ml do 516.9 µg/ml. 
Sample and standard stability 
Stability of standard and sample solutions (from IVR test) was evaluated after 24 hours ( 
Table 16). Both sample and standard recovery results were within the acceptance criteria for 
standard ( 98.0-102.0 %) and sample (95-105%), at 24 stability time point. 
Table 16. Stability of standard and sample solution. 
Time/h RF recovery for  
standard solution (%) 
mg/ml recovery for  
sample solution (%) 
24 100.4  1.1 101.2  0.9 
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5.6.2. Development of in vitro release method 
5.6.2.1. Selection of receptor medium – solubility testing 
 
TIMO is highly soluble in water (149), therefore aqueous media were chosen as receptor media 
for IVR, namely STF, KRB and PB. During shake flask solubility testing for all investigated 
media, in the tested volume of 20 ml, it was not possible to achieve saturated TIMO solution 
conditions. After 48 hours of tests and large amounts of API spent, testing was stopped, and the 
solutions were filtrated through 0.β µm filters, diluted with corresponding medium and quantified 
by the UPLC. 
pH of the media was measured throughout the test and it did not change significantly after 48 
hours in all evaluated media. Since equilibrium conditions could not be achieved, results are 
expressed as soluble more than stated mg/ml values (Table 17). Solubility results in all three 
media are comparable.  
Table 17. Results of estimated TIMO solubility testing after 48 hours. 
medium STF KRB PB  
estimated solubility –  
 mg/ml 
>214.2 >189.3 >201.7 
 
On account of no significant difference in solubility of TIMO in tested media, simulated tear 
fluid was chosen as receptor medium, due to the highest similarity to the tears in vivo in 
comparison to other media. 
5.6.2.2. Membrane selection 
 
Membranes in IVR should provide inert support for sample, they must not interfere with API by 
adsorbing it or by impacting or controlling its release. Permeability of the membrane is described 
by following equation (150): 
P = D*kp / hm                                                                                                                         (Eq. 13) 
where D is diffusional coefficient of drug through the membrane, kp is partition coefficient 
between the membrane and receptor medium (fluid) and hm is membrane thickness. Membrane 
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and its corresponsive stationary layer present certain diffusional resistance and therefore impact 
the drug release to a certain extent. It is important for a membrane to be very thin and highly 
porous in order to impact diffusion as little as possible.  
In order to find the most appropriate membrane, five membranes were evaluated in our study. 
Results of the influence of tested membranes on the TIMO recovery for API adsorption are 
presented in the Table 18. Acceptance criterion was that recovery of filtrated solution compared 
to the non-filtrated solution to be 95-105%. As it is seen from the Table 18, none of the five 
tested membranes adsorbed significantly TIMO at both concentration levels tested (0.0801 and 
0.4005 mg/ml). 
Table 18. TIMO recoveries after membrane filtration.  
Membrane TIMO 
recovery (%)  
at 0.0801 
mg/ml 
TIMO 
recovery  
(%)  
at 0.4005 
mg/ml 
RC 0.2 103 98 
RC 0.45 101 100 
PESU 0.45 101 101 
PES 0.1 102 103 
CA 0.8 101 105 
 
During an in vitro release experiment, drug migration from gel to receptor occurs as a series of 
successive diffusional steps. Since the physical properties of the product itself are of interest in 
IVR, diffusion/release through semisolid must be the rate limiting step of the process. From this 
reason, it is very important, as emphasized, that the membrane, together with the receptor 
medium, is highly permeable for the drug  (151). 
In order to choose membrane with will have lowest resistance to drug diffusion, all five 
membranes were used in IVR test of the PL1 formulation (0.2% TIMO). Test was done in 
triplicate for each membrane and results of obtained release rates (slopes) are summarized in the 
Table 19.   
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Table 19.  TIMO release rates (slopes) using different membranes obtained in first 2 hours of  
test.  
Membrane slope ± SD 
RC 0.2  7β.7β ▫ β.48 
RC 0.45 68.17 ▫ 14.β6 
PESU 0.45  109.05  ▫ γ1.61 
PES 0.1  96.11 ▫ 1.γ5 
CA 0.8 117.18 ▫ β.β0 
 
Regenerated cellulose membranes (RC 0.2 and RC 0.45) had highest resistance to TIMO release 
rate, while with the use of CA 0.8 highest slopes were obtained. PESU 0.45 showed higher 
variability compared to other tested membranes (Table 19). 
Based on data obtained in first two studies (low absorption, high diffusivity and lower 
variability), PES 0.1 and CA 0.8 were selected as two lead membranes of choice, and were used 
for study which evaluated resistance to diffusion from the TIMO solutions at two concentration 
levels (0.01 mg/ml and 2.5 mg/ml). For this purpose, data was evaluated by plotting % the in 
vitro released drug from the solutions versus time. Results are depicted on the Figure 33.  
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Figure 33. Influence of PES 0.1 (diamonds) and CA 0.8 (squares) on TIMO release at 0.01 
mg/ml (filled) and 2.5 mg/ml (unfilled) concentration levels 
 
Since higher and complete release was obtained with CA 0.8 membranes at both concentration 
levels, it can be concluded have that they have smaller influence on the diffusion of TIMO from 
solutions compared to PES 0.1 membranes. Therefore, CA 0.8 membranes were chosen as the 
most appropriate membranes for IVR testing. 
 
5.6.2.3. Discriminatory power of the method 
 
As emphasized, drug release form the gels would mainly depend on its diffusivity through the gel 
matrix. To evaluate influence of viscosity, six formulations, presented in the Table 20, were 
investigated during IVR method optimization. 
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Table 20. Formulations tested in IVR development. 
Formulation P407  
(%, w/w) 
P188  
(%, w/w) 
CS  
(%, w/w) 
TIMO  
(%, w/w) 
Tgel 
(°C) 
ŋ*1  
(Pa  s) 
PL1  14.2 1.7 0.25 0.1 γ1.1 ▫ β.0 1.β ▫ 0.γ 
PL1 -0.1 14.2 1.7 0.25 0.1 β9.β ▫ 1.6 1.6▫ 0.β 
PL1 -0.3 14.1 1.7 0.25 0.3 β8.7 ▫ 0.5 1.γ▫ 0.5 
C1 14.2 - 0.25 0.2 β6.9 ▫ β.β 4.1β ▫ 1.β 
C2 11.4 - - 0.2 γ1.1 ▫ 1.7 0.097 ▫ 0.07 
C3 17.8 - - 0.2 β1.4 ▫ 1.5 1690 ▫7.1 
1
 * at γ5°C determined by temperature sweep test (angular frequency and strain were 1 s-1 and 1%, respectively) 
 
In order to evaluate the influence of different concentrations of P407 in formulation on drug 
release, two formulations, containing 0.2% of the TIMO, were compared – C2, containing 11.4% 
P407 and C3 which contained 17.8% P407. Formulation C3 was already gel at ambient 
conditions. Results are presented on the Figure 34. 
 
Figure 34. IVR of TIMO from C2 (11.4% P407, triangles) and C3 (17.8% P407, squares) 
(mean ▫RSD). 
In vitro release of TIMO from C2 was very fast, yielding slope (N=5) 637.73  55.06 in first 30 
minutes of the test, indicating that viscous property of the formulation is dominant and 
comparable to TIMO solutions in STF. On the contrary, slope of the formulation C3 (N=6) was 
69.10  8.15, indicating predominance of elastic properties, which confirmed visual observation; 
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sample appeared as a firm gel at ambient conditions. This predominantly elastic nature of a 
formulation ensured sustained release of API into the receptor. Consequently, lower and upper 
limits of 90% confidence interval (30 and 45.73%, respectively) were out of preset limits (75-
133.33%) and absence of release rate similarity of tested formulations was indicated. 
To evaluate method’s sensitivity to discriminate formulations containing different concentrations 
of the API while amounts of excipients are kept the same, IVR testing was done on the 
formulations containing 0.1 (PL1-0.1%) and 0.3% (PL1-0.3%) of TIMO. Results are presented 
on the Figure 35. Again, Mann-Whitney’s U test was used to calculate and evaluate the 90% 
confidence interval for the ratio of the slopes between the two batches and with the lower limit 
23% and upper 52.73%, developed method successfully eliminated similarity between two tested 
batches differing in TIMO’s concentration (151). 
 
Figure 35. IVR of  in situ forming gels containing different amount of TIMO: PL1-0.1% 
(diamonds, filled) vs PL1-0.γ% (square, empty) formulations (mean ▫ RSD). 
  
Since the developed method was able to discriminate formulation differing in physicochemical 
properties, it was found to be suitable for assessing in vitro release of PL1 based in situ 
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5.6.3. Evaluation of IVR from the optimal in situ forming gel 
As emphasized, IVR is prerequisite tool for measuring changes in critical physical properties of 
gels products that may be related to their topical bioavailability. Optimal in situ forming 
ophthalmic gel should exhibit adequate/prolonged release profile of the API to promote eye-
related bioavailability. Viscosity is crucial attribute affecting the drug release from gel matrices. 
If  increased, viscosity results in slower diffusion of the drug across the gel matrix and into the 
receptor medium (64). 
Purpose of IVR study was to evaluate the influence of viscosity and/or Tgel related to the 
functional excipient concentration on the drug release rate. 
The optimal in situ forming gel (PL1) was characterized in term of its influence on TIMO release 
profile. Control in situ forming gel C1 was characterized by * comparable to PL1, while control 
in situ forming gel C2 was characterized by Tgel comparable to PL1 (Table 20). TIMO solution 
was used as the control sample. The in vitro release profiles of PL1 and respective controls are 
shown in Figure 36.  
 
Figure 36. Release profiles of TIMO from PL1 (circles) and control in situ forming gel C1 
(squares) with ŋ* comparable to PL1, control in situ forming gel C2 (triangle) 
with Tgel comparable to PL1 and TIMO solution (inverse triangle). The data are 
expressed as the mean  SD, reprinted with permission from (1). 
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In vitro release of TIMO from PL1 and C1 was significantly slower that form C2 and TIMO 
solution, confirming the viscosity as the critical factor which is governing the drug release from 
the gel matrix (1). Confidence interval of the slopes obtained for PL1 and C1 was calculated (75-
131.2%) and confirmed similarity of drug release of tested formulations at first stage of the test. 
Similar observations were already reported for in situ forming ophthalmic gels (64,70). 
5.7. Sterilization  
 
Due to specific use, ophthalmic products have the same or similar quality/safety requirements as 
injectables and implants (38). The goal of the sterilization process is inactivation of the bioburden 
without adversely affecting product quality attributes (152). Ocular infections are extremely 
dangerous and can rapidly lead to the loss of vision (153). Moreover, eyebaths, droppers and all 
other dispensers should also be sterile and controlled if packaged with the drug product (153).  
Therefore, manufacturing under validated conditions which assure sterility in the final container 
for the shelf life of the product is a prerequisite for ophthalmic products. 
Commonly used methods of sterilization are steam sterilization (autoclaving), dry-heat 
sterilization/depyrogenation, gas sterilization, sterilization by ionizing radiation and sterilization 
by filtration (152). Terminal sterilization of ophthalmic products in their final containers should 
be adopted wherever possible. If the product is susceptible to degradation by terminal 
sterilization, then filtration under aseptic conditions should be considered, usually performed 
using a filter pore size of 0.ββ µm or less (153). Wherever possible, all components used for 
aseptic manufacture should be sterile, or should meet a low specified bioburden control limit 
(153).  
Autoclaving (terminal sterilization) is the first choice for most ophthalmic solutions because of its 
convenience for large-scale production. However, the suitability of autoclaving in relation to 
physicochemical formulation stability needs to be assessed (15). Filtration is commonly used 
procedure in sterile production because it lowers the risk of presence of bioburden and 
particulates. A combination these methods is frequently used in sterile production. 
Ease of formulation preparation, solubilization ability as a surfactant, a final aqueous solution and 
the ability for sterile filtration have made poloxamer P407 an interesting candidate for developing 
sterile products, specifically when controlled release of the drug is required (80).  
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To determine the appropriate sterilization methods, key rheological properties of the PL 1 
optimal in situ forming gel were inspected prior and after filtration through 0.β µm filter, and 
after filtrating and autoclaving (β0 minutes at 1β1°C). Results are presented in the Table 21.  
 
Table 21. Key rheological properties of PL 1 optimal in situ forming gel prior and after 
sterilization. 
Sample Tgel (°C)1 η*1 
Pa  s 
G' 
1
 
(Pa) 
PL 1 31.1 ▫ 0.01 2.1 ▫ 0.36 14.1 ▫ 5.2 
PL 1 filtrated 28.7 ▫ 0.03 2.6 ▫ 0.41 15.9 ▫ 6.0 
PL 1 filtrated and autoclaved 28.5 ▫ 0.02 2.8 ▫ 0.40 16.8 ▫ 5.7 
1
 Tgel, η* and G’ presented as mean ▫ SD at γ5°C, determined by temperature sweep test (angular frequency and 
strain were 1 s
-1
 and 1%, respectively). 
 
Filtration and filtration and autoclaving induced certain decrease of Tgel of the PL1 in situ 
forming gel (Tgel decreased approximately for 2°C). Moreover, certain increase in G’, G” and η* 
measured in the frequency sweep test was noticed for filtrated sample in comparison to non 
filtrated one (Figure 37). Subsequent autoclaving did not induce further changes in G’, G” and 
complex viscosity in comparison to the filtered sample. 
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Figure 37. Frequency sweeps of PL 1 optimal in situ forming gel after sterilization. A) G’ 
(filled symbols) and G” (non filled symbols) of non-filtered (red squares) and 
filtered (blue circles) sample, filtrated and autoclaved sample (green diamonds). 
B) * as function of angular frequency for non-filtered (red squares) and filtered 
(blue circles) sample, filtrated and autoclaved (green triangles). 
 
This phenomenon could be related to the presence of impurities or foreign particles in the in situ 
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by filtration process. The use of the purer poloxamers, namely the ones with removed low 
molecular weight copolymer species and consequently with more uniform molecular mass 
distribution, was related to higher poloxamer gel viscosity (80).  
In our case, impurities which are impacting the micellization and are removed by filtration 
process could originate from synthesis materials and from the glass or plastic packaging or other 
contact areas during poloxamers or in situ gels manufacturing.  
Filtration and autoclaving process did not affect viscosity of the PL1 compared to filtration 
process alone, suggesting that autoclaving is applicable for the P407, as reported before (82).  
In conclusion, optimal PL1 in situ forming gel retained its beneficial rheological properties after 
sterilization process, while more detailed structure analysis revealed stronger gel characteristics 
in comparison to non sterilized sample. These findings support applicability of developed in situ 
gel for ophthalmic use. 
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5.8. Stability study 
Sterilized PL 1 optimal in situ forming gel, stored in well stopped glass vials, was subjected to 
preliminary stability study. After 6 months storage at room temperature (20-β5°C), temperature 
and frequency sweeps were performed on an aged sample. Results are presented on the Figure 38 
and Figure 39.  
 
  
Figure 38. Temperature sweeps (G’ filled symbols and G’’ empty symbols) for PL 1 optimal 
in situ forming gel at initial point (blue squares) and at 6 months stability of 
filtered and autoclaved sample (red, diamonds). 
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Figure 39. Rheological characterization of PL 1 optimal in situ forming gel after stability 
testing. A) Frequency sweep, G’ (filled symbols) and G’’ (empty symbols): initial 
point (blue circles) vs. 6 months stability sample autoclaved (red squares). B) 
Frequency sweep, * initial point (blue circles) vs. 6 months stability sample 
filtered and autoclaved (red squares).  
 
Results of the preliminary stability study results revealed that no significant change in key 
rheological properties (Tgel, *) was noticed for the filtered and autoclaved sample. Moreover, 
the rheological profiles acquired by the temperature and frequency sweeps at initial point are 
comparable to the results obtained for an aged sample.  
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5.9. Biocompatibility assessment of in situ forming ophthalmic gel 
 
Immortalized human corneal epithelial cell line (HCE-T) is one of the most studied human 
derived cell lines in terms of transcorneal passive transcellular and paracellular transport, 
transporter expression and metabolic enzymes (115). In the preliminary ocular biocompatibility 
studies of developed in situ forming gel, simple 2D HCE-T monolayer was used to assess the 
formulation biocompatibility. However, exaggerated toxicity was found in comparison to in vivo 
studies (154). In vitro 2D models are generally characterized by certain shortcomings, such as a 
more pronounced susceptibility to cytotoxicity, as they replicate only a limited segment of tissue 
structure/function (119). Consequently, the concentration of polymers/formulation that can be 
safely applied to such models may be reduced in comparison to the in vivo system.  
Despite the fact that HCE-T cell line is well defined and characterized, obstacles regarding its 
routine use were reported. From this reasons, Juretić et al. investigated and described two 
disctintive phenotypes of HCE-T models, depending on the pore size of polycarbonate 
membrane. Model I was multilayered HCE-T epithelium cultivated on filters with 0.4 m pores 
and Model II consisted of an apical lipophilic HCE-T epithelial monolayer and a basolateral 
lipophilic monolayer of migrated HCE-T cell cultivated on filters with 3 m pores. A 
polycarbonate membrane with a γ μm pore size (Model II) was proved to be better than a 
polycarbonate membrane with a 0.4 μm pore size (Model I) for tight barrier formation with HCE-
T cells (115). 
In order to better predict the ocular tolerability, we employed more complex 3D corneal epithelial 
models to determine the formulation biocompatibility, namely Model I and Model II (115).  
Cell viability was determined with the colorimetric MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide assay (48,67,115,116). This assay measures the activity of the 
mitochondrial enzyme succinate dehydrogenase, which is expressed only in living cells. Acquired 
signal is proportional to the number of metabolically active (viable) cells (131). 
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Results of biocompatibility screening revealed, contrary to HCE-T epithelial monolayer, that 3D 
models showed biocompatibility of the tested formulation (1). Namely, 30-minute treatment 
resulted in decrease in 3D model cell viability lower than 20% (116).  
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6. CONCLUSIONS 
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In this doctoral thesis, a QbD approach was applied in order to determine the minimal total 
concentrations of P407, P188 and CS that would yield an in situ forming ophthalmic gel with the 
potential to ensure the defined formulation characteristics. D-Optimal design was selected based 
on the particularities of experimental situation, while sequential approach to experimentation was 
applied through screening, refining and optimizing designs. Analysis of collected data identified 
significant cause and effect relationships. Mathematical models describing Tgel, η* and G’ with a 
suitable fit between experimental and predicted values were established. Subsequently, all 
established models were validated. Concentrations of poloxamer polymers (P407 and P188) were 
found to have most significant effect on all responses of interest. Decrease of Tgel was related to 
the increase of P407 concentration while the increase of Tgel when increasing P188 concentration 
was related to micellization of P188. Significant higher order terms in the model for Tgel included 
the interactions between P407 and P188 and among P407, P188 and CS. Model obtained for 
log(η*) had higher degree of complexity in comparison to mathematical model for Tgel. Increase 
of P188 concentration resulted in the decrease of log(η*) while on the contrary, the increase of 
P407 concentration resulted in the increase of log(η*). Surprisingly, impact of CS concentrations 
on log(η*) in the obtained model was hindered by poloxamers effect. Complexity of this model 
was depicted by the several interactions - two interactions with negative effect on the response 
(between P407 and CS and as well as between P407 and P188) and two interactions with the 
positive effect on the response log(η*) (among P407, P407 and P188 and between CS and CS). 
Mathematical model for log(G’) revealed significant effects of P407 and P188 concentrations on 
log(G’) with P407 concentration having stronger effect on the response. The increase of P188 
concentration resulted in the decrease of log(G’) and on the contrary, the increase of P407 
concentration resulted in the increase of the response. One statistically significant interaction with 
positive effect on the G’ was between P188 and CS, while another interaction included in the 
model was one between P407 and CS with a negative impact on the response, similar to the 
model for log(η*). 
Based on the models established, four lead in situ forming gel platforms were selected and in 
depth rheologically characterized. PL1 was revealed as optimal in situ forming gel since it had 
lowest polymer content and rheological characteristics suitable for in situ forming gels. 
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Robustness of selected PL1 in situ forming gel against entrapment of APIs with different 
physicochemical characteristics was assessed by the in depth rheological characterization 
(oscillatory and rotational) in biorelevant conditions. Results indicated that all samples acted as 
gels upon dilution and preserved pseudoplasticity suggesting robustness of the platform against 
API entrapment. The decrease in Tgel caused by API entrapment opens the possibility to further 
decrease the concentration of poloxamers required to obtain in situ forming gels with appropriate 
biopharmaceutical properties. 
A discriminative and selective in vitro release method was developed for characterization of the 
optimal in situ forming gel PL1 as a platform containing TIMO as model drug. Results of in vitro 
release suggested prolonged release related to viscosity of the in situ forming gel. 
Evaluation of sterilization process by filtration and filtration and autoclaving showed no 
significant effect on PL1 quality attributes. 
After 6 months storage at room temperature (20-β5°C), temperature and frequency sweep 
analysis of aged sterile sample revealed no change in these critical parameters indicating 
adequate stability.  
Biocompatibility of the optimal in situ forming gel (PL1) was shown on two 3D cell-based 
corneal epithelial models, namely multilayered HCE-T epithelium cultivated on filters with 0.4 
µm pores and model consisting of an apical lipophilic HCE-T epithelial monolayer and a 
basolateral lipophilic monolayer of migrated HCE-T cell cultivated on filters with γ µm pores.  
In conclusion, a systematic approach to in situ forming gel development implemented in this 
thesis resulted in a stable and robust formulation characterized by ease of formulation 
preparation, ability for sterile filtration and autoclaving, ease of administration, accuracy of 
dosing, avoidance of eye-related discomfort, biocompatibility and prolonged residence at the eye 
surface. These benefits will lead to better patient compliance, improved eye-related 
bioavailability and, finally, improved therapeutic outcome. 
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a b s t r a c t
In situ forming ophthalmic gels need to be ﬁne tuned considering all the biopharmaceutical challenges of
the front of the eye in order to increase drug residence time at the application site resulting in its
improved bioavailability and efﬁcacy. The aim of this study was to develop in situ forming ophthalmic
poloxamer P407/poloxamer P188/chitosan gel ﬁne tuned in terms of polymer content, temperature of
gelation, and viscosity. Minimizing the total polymer content while retaining the advantageous rheo-
logical properties has been achieved by means of D-optimal statistical design. The optimal in situ forming
gel was selected based on minimal polymer content (P407, P188, and chitosan concentration of 14.2%,
1.7%, and 0.25% w/w, respectively), favorable rheological characteristics, and in vitro resistance to tear
dilution. The optimal in situ forming gel was proved to be robust against entrapment of active phar-
maceutical ingredients making it a suitable platform for ophthalmic delivery of active pharmaceutical
ingredients with diverse physicochemical properties.
© 2018 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.
Introduction
The anatomical barriers and the tear ﬂuid dynamics in the
precorneal area of the eye have a huge effect on the eye-related
drug bioavailability.1 This problem can be overcome by using in
situ forming ophthalmic gels prepared from polymers that exhibit
reversible phase transitions and pseudoplastic behavior to mini-
mize interference with blinking and avoid foreign body sensation
and blurring of vision.2-4 In situ forming ophthalmic gels need to be
ﬁne tuned considering all the biopharmaceutical challenges of the
front of the eye in order to increase drug residence time at the
application site resulting in its improved bioavailability and efﬁ-
cacy.5 Such a system should be formulated as drug containing liquid
suitable for instillation into the eye that shifts to the gel phase upon
exposure to physiological conditions.6 The optimal in situ forming
gel should be characterized by: (1) temperature of gelation (Tgel) in
physiologically relevant range; (2) pseudoplastic behavior that
allows gel to thin during blinking, making it more comfortable and
easier to spread across the eye surface7; (3) suitable gel strength to
endure the dilution with tears. Moreover, in vivo performance of in
situ forming ophthalmic gels is governed also by drug release and
biocompatibility issues.
Poloxamers (Pluronic®), a series of closely related block
copolymers of polyethylene oxide and polypropylene oxide, have
been investigated as in situ forming gels.8 At high concentrations of
poloxamers, the aqueous solutions exhibit a dramatic change of the
viscoelastic moduli and become soft solids or gels. A phase tran-
sition from liquid to gel upon reaching physiological temperatures
is presently one of the most important phenomena for their
applications.9 Poloxamer 407 (P407) was mainly studied for
ophthalmic delivery, however, concentrated P407 aqueous solu-
tions (>18%, w/w) gel already at the ambient temperature.10 In that
case, in situ forming ophthalmic gel has to be stored in refrigerator
and applied cold,6 and therefore, its instillation to the front of the
eye can possibly be irritating and painful.
The use of P407 in mixture with other poloxamers is considered
as a strategy to decrease the P407 concentration and to modulate
the temperature of gelation and rheological properties of in situ
forming gel. Among others, poloxamer 188 (P188) was shown to be
a good modulator of P407 in situ forming gels.10-12 In previous
studies, both poloxamers were used in in situ forming ophthalmic
This article contains supplementary material available from the authors by request
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gels at very high total concentration, for example, P407 and P188 in
concentration of 21% and 10%,10 16% and 14%,13 20% and 11%14
(w/w), respectively.
The additional improvements in the biopharmaceutical prop-
erties of poloxamer ophthalmic gels can be achieved by the pres-
ence of different additives in the formulation.15-19 Chitosan, a
biocompatible and biodegradable polycationic polymer, has been
demonstrated to increase the mechanical strength and mucoad-
hesivness of in situ forming ophthalmic gels.19 In addition, there are
other beneﬁts of including chitosan in ophthalmic formulations
such as improvement of eye-related permeability due to its para-
cellular permeation enhancing effects,20 antimicrobial activity,21
and corneal wound healing effect.22
The aim of this study was to develop in situ forming ophthalmic
poloxamers/chitosan gel ﬁne tuned in terms of polymer content
and rheological properties, that is, temperature of gelation, storage
modulus, and viscosity. Minimizing the total polymer content while
retaining the advantageous rheological properties has been ach-
ieved by means of D-optimal statistical design. The selection of the
leading candidate for drug formulation development has been
based on the ability to keep its rheological properties upon dilution
under biorelevant conditions. The robustness of selected mixed
system has been evaluated upon entrapment of 4 ophthalmic active
pharmaceutical ingredients (APIs).
Materials and Methods
Materials
Poloxamers P407 (Kolliphor P407; EO98PO69EO98; average mo-
lecular weight (Mw) 13,498 g/mol) and P188 (Lutrol micro F68;
EO80PO27EO80; average Mw 8902 g/mol) were purchased from BASF
SE (Ludwigshafen, Germany). More than 90% deacetyled ultrapure
PROTASAN™ chitosan salt (ProtasanUPCL214;Mw150,000-400,000
g/mol; viscosity 20-200 mPa  s) (CS) was obtained from NovaMa-
trix® (Sandvika, Norway). Timolol maleate (TIMO), dexamethasone
(DEX), dorzolamide hydrochloride (DORZO) were kindly donated by
TEVA Pharmaceutical Industries Ltd. Tobramycin (TOBRA) standard
waspurchased fromtheUnited States Pharmacopeia (Rockville,MD).
Simulated tear ﬂuid (STF), pH 7.4, was prepared by dissolving the
following substances indouble-distilledwater:KCl (1.4mg/mL),NaCl
(6.8mg/mL),NaHCO3 (2.2mg/mL), andCaCl22H2O(0.08mg/mL).
23
Final step in STF preparation was ﬁltration of solution (Whatman™
membrane ﬁlters, 0.2 mm, RC58; GE Healthcare Limited, Buck-
inghamshire, UK).
Cellulose acetate 0.8 mm membranes for in vitro release (IVR)
test (CA 0.8) were obtained from Sartorius Stedim Biotech
(G€ottingen, Germany).
Preparation of In Situ Forming Ophthalmic Gels
In situ forming ophthalmic gels were prepared by slightly
modiﬁed cold method.24 Brieﬂy, appropriate amounts of all mate-
rials were weighed in a glass bottle and deﬁned amount of previ-
ously refrigerated water for injection (WFI; PLIVA Croatia Ltd.) was
added. Samples were stirred (speed 400-600 rpm) in an ice bath
until clear solution was obtained. In case when CS was used in
mixed systems, after ice bath, additional means of ultrasound at
20C-25C (Bandelin Sonorex digital 10P; BANDELIN electronic
GmbH& Co. KG, Berlin, Germany) was applied to aid its dissolution.
All prepared systems had an ophthalmically acceptable osmolality,
whichwas achieved by the addition of appropriate amounts of NaCl
to the solution. Osmolality was determined by the freezing point
depression method (Advanced® 3D3 Single-Sample Osmometer;
Advanced Instruments Inc., Norwood, MA). For CS-free solutions, it
was in the range of 295.4-301.8 mOsm/kg, whereas for
CS-containing solutions, it was in the range of 310.4-332.0mOsm/kg.
pH was measured using PHM240 pH/Ion Meter (Radiometer
Analytical SAS, Villeurbanne, France) andwas in the range of 5.8 for
CS-containing solutions to 6.5 for CS-free solutions. The trans-
parency of in situ forming ophthalmic gels was determined by
measuring the refractive index (RE40 Refractometer; Mettler-
Toledo, LLC, Columbus, OH). Refractive index of all systems was in
the ophthalmically suitable range for eye drops (i.e., not greater
than 1.47625).
Out of 4 APIs, 6 API-loaded in situ forming ophthalmic gels were
prepared, namely mixed P407/P188/CS system containing: 2%
(w/w) DORZO, 0.5% (w/w) TIMO, 2% (w/w) DORZO, and 0.5% (w/w)
TIMO, 0.1% (w/w) DEX, 0.3% (w/w) TOBRA, 0.05% (w/w) DEX and
0.3% (w/w) TOBRA. In situ forming ophthalmic gels containing
TIMO, DEX, and DORZO were prepared in same way as API-free
systems. For preparation of systems containing TOBRA, API was
ﬁrst dissolved in deﬁned aliquot of WFI and then mixed with P407/
P188/CS solution. pH was adjusted to 5.8 since addition of TOBRA
increased pH of the solution. All in situ forming ophthalmic gels
were isotonized taking into account NaCl equivalent for each API.
Measurement of Temperature of Gelation and Complex Viscosity
The temperature sweep test was performed to determine the
Tgel, the temperature dependence of complex viscosity (h*) and the
temperature dependence of storage (G0) and loss modulus (G00).17,26
The rheological measurement was performed using Rheometer
Anton Paar PhysicaMCR 301 (Anton Paar GmbH, Graz, Austria) with
parallel plate (PP50) measuring system equipped with H-PTD 200
Truly Peltier temperature-controlled hood (U.S. Patent 6,571,610)
connected to circulating water bath (JULABO GmbH, Seelbach,
Germany). Samples were equilibrated at 5C for 5 min. Angular
frequency and strain applied were ﬁxed at 1 s1 and 1%, respec-
tively, whereas gap was d ¼ 0.5 mm. Data were calculated by
Rheoplus™ software (Anton Paar).
G0, G00, and h* were recorded in the temperature range of 5C-
85C with a rate of 10C/min. Tgel is deﬁned as the temperature
point at which intersection of G00 and G0 curves occurs.17,27 All
measurements were done in triplicate.
Design of Experiments
Quality by Design principles were employed to optimize
formulation parameters and evaluate their impact on Tgel, G
0, and
h*. Statistical software JMP®, version 12.0.1, (SAS Institute Inc., Cary,
NC) was used to set of experimental design, establish the mathe-
matical models, and analyze the collected data. Designs were
generated within the class of optimal designs, and D-optimality
criterion was selected based on the particularities of the experi-
mental situation.
The independent variables were the concentration of P407,
P188, and CS, whereas dependent variables were Tgel, G
0, and h*
obtained from temperature sweep test. Sequential approach to
experimentation was applied through screening, reﬁning, and
optimizing designs (Table 1). Data set was initiated with the results
of preliminary screening, consisting of 5 samples, which contained
only P407. For the subsequent design of experiment (reﬁning), a
new factorwas added in order to explore inﬂuence of concentration
levels of CS on the responses and include it into the model. Finally,
to evaluate the error of mixed system preparation and measure-
ment, 3 replicated samples were added.
Data were checked for the basic assumptions needed for the
statistical test. Normality of the data was tested with Kolmogorov
test. Log-transformed response variables G0 and h* were ﬁtted
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using a regression model. Logarithmic transformationwas found as
optimal within Box-Cox power transformation for the responses
G0 and h* so the usual regression assumptions of normality and
homogeneity of variance were more closely satisﬁed.
Multiple regression and ANOVAs were used to evaluate exper-
imental results (JMP® version 12.0.1). Factorial models were set to
determine all main effects and interactions for the factors of
interest, that is, concentrations of P407, P188, and CS. Signiﬁcance
of the regression models was assessed with ANOVA. Level of sig-
niﬁcance for all tests was a ¼ 0.05. Factor Proﬁling platform (JMP®)
was utilized to explore and visualize estimated models, for
example, to explore the shape of the response surface, ﬁnd opti-
mum settings of the factors, and simulate response data.
To validate the models, the experimental values of Tgel, G
0, and
h* of 4 optimal mixed P407/P188/CS systems were statistically
compared with their predicted responses.
Strain and Frequency Sweep Testing
The viscoelastic behavior of in situ forming ophthalmic gels was
investigated by strain sweep and frequency sweep test using the
rheometer system with cone-and-plate (CP50) geometry with 1
incline. Gap in the measuring conﬁguration was d ¼ 0.05 mm. For
strain sweep analysis, the angular frequency was set at 62.8 rad/s,
and the strain was varied from 0.001% to 1000%. The linear visco-
elastic (LVE) range at 35C was identiﬁed as the region inwhich the
moduli are independent of the strain. For frequency sweep ana-
lyses, strain was set at 1%, which was in the LVE range, whereas the
angular frequencies were in the range of 0.628-199 rad/s.
Gelation time was determined as the time point at which
intersection of the curves of measured G00 and G0 occurred.27 The
samples were placed at rheometer plate preheated at 35C. Strain
(1%) was constantly in LVE range, whereas applied frequency was 1
Hz throughout the test.
The evaluation of in situ forming ophthalmic gel under
biorelevant conditions was performed by sample dilution with STF
(40:7). The STF diluted samples were submitted to strain and
frequency sweep analysis at 35C.
In Vitro Release Study
IVR testing was performed using the Vision Microette (Hanson,
Chatsworth, CA), a commercial Franz diffusion cell apparatus
equippedwith 6 static vertical diffusion cell with 12mL volume and
15 mm oriﬁce (providing area for release of 1.767 cm2), an AutoFill
sample collector and circulating water bath. Donor part of vertical
cell consisted of open cell top with cap which is suitable for
retaining less viscous liquids. Temperature was maintained at 35C,
and stirring speed of 400 rpm assured homogenized sample in the
receptor medium (STF). Sink conditions were assured. An aliquot of
2.5 mL of sample was placed on the CA 0.8 membranes in donor
compartment. Suitability of CA 0.8 membranes (low drug adsorp-
tion and low diffusion resistance) was demonstrated in the
membrane selection study (data not shown).
IVR testing of in situ formulations was performed during 24 h
One milliliter of samples was collected automatically at pre-
determined time intervals. System's rinsing volume was set at
1.5 mL to assure no carryover of an API prior each sampling point.
Quantiﬁcation of TIMO was done by ultraperformance liquid
chromatography as detailed in the Supplementary Materials and
Methods.
In Vitro Biocompatibility Study
The biocompatibility was assayed using corneal epithelial
models based on the immortalized human corneal epithelial cell
line (HCE-T) (RIKEN Cell Bank, Tsukuba, Japan). The cultivation of
HCE-T cellebased models was performed as detailed in the
Supplementary Materials and Methods. The mixed P407/P188/CS
system was applied directly onto cell-based models. After the
30-min treatment at 37C, treated models were incubated at the
room temperature for 5 min to induce formulation gel-sol
Table 1
Sample Sequence From Design of Experiment (DoE) and Corresponding Experimental Temperature of Gelation (Tgel), Complex Viscosity (h*), Storage Modulus (G
0), and
Damping Factor
DoE Samplea P407 P188 CS Tgel h* logh* G
0 Damping
Factor (tand)
Form
(%, w/w) (%, w/w) (%, w/w) (C) (Pa  s) (Pa) logG0
Preliminary screening 1ο 11.4 33.4 0.05 1.34 3.56 0.55 0.825 Gel
2ο 13.8 24.4 19.5 1.29 119 2.08 0.259 Gel
3ο 15.2 24.3 702 2.85 4320 3.64 0.206 Gel
4ο 16.9 20.7 1520 3.18 9360 3.97 0.197 Gel
5ο 19.3 15.1 2430 3.39 15,200 4.18 0.101 Gel
Screening 6 11.32 0.87 31.6 0.44 0.36 2.45 0.39 0.494 Gel
7 19.1 0.8 15.1 2370 3.37 14,700 4.17 0.142 Gel
8 15.8 0.84 22.5 277 2.44 1660 3.22 0.315 Gel
9 14.12 4.01 29.8 2.17 0.34 13.20 1.12 0.248 Gel
10 14.61 4.24 33.4 1.21 0.08 7.01 0.85 0.413 Gel
11 18.39 4.64 22.5 131 2.12 794 2.90 0.271 Gel
12 10.59 7.4 49.4 0.02 1.68 n.d. n.d. 1Eþ30 Solution
13 15.49 7.66 35.1 0.48 0.32 4.30 0.63 0.685 Gel
Reﬁning step (addition of CS) 14▪ 16.4 0.85 0.08 23.8 169 2.23 975 2.99 0.425 Gel
15▪ 10.93 4.2 0.08 52.5 0.02 1.61 0.0156 1.81 9.46 Solution
16▪ 15.92 3.97 0.08 31.1 7.77 0.89 46.4 1.67 0.327 Gel
17▪ 13.61 2.51 0.66 33.5 0.54 0.27 9.17 0.96 0.748 Gel
18▪ 11.16 0.95 1.29 54.8 0.4 0.4 0.27 0.56 9.09 Solution
19▪ 16.2 0.92 1.22 26.3 26.2 1.42 229 2.36 0.201 Gel
20▪ 10.8 4.18 1.25 47.7 0.49 0.31 0.93 0.03 3.14 Solution
21▪ 15.7 3.96 1.18 33.5 3.32 0.52 35.6 1.55 0.46 Gel
22▪ 11.31 0.89 0.10 38.2 0.04 1.4 n.d. n.d. 2.37 Solution
Replicate step 23 (14)▫ 16.4 0.84 0.09 23.9 1245 3.1 7270 3.86 0.2745 Gel
24 (15)▫ 10.93 4.21 0.09 52.4 0.02 1.63 0.03 1.53 12.4 Solution
25 (16)▫ 15.88 3.97 0.08 31.1 2.36 0.37 21.20 1.33 0.2935 Gel
a
ο-preliminary screening, -screening, ▪-screening with addition of CS, ▫-optimization step; n.d., not determined.
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transition. The cell surface was rinsed with Hank's balanced salt
solution and exposed to air-liquid interface for the following 24 h.
The cell viability was assessed by MTT (3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide) test according to the pro-
tocol by Pauly et al.28 as detailed in the Supplementary Materials
and Methods.
Results and Discussion
In Situ Forming Ophthalmic Gel Optimization Using a Design of
Experiment
The aim of the employed Quality by Design approach was to
determine the minimal total concentrations of P407, P188, and CS
that would yield an in situ forming ophthalmic gel with the
potential to ensure the deﬁned formulation characteristics. For the
establishment of the mathematical model, it was necessary to
generate the data of Tgel, G
0, and h* of the sample based on the
independent variables (Table 1). In the screening step of the applied
sequential approach, inﬂuence of concentration levels of 2 factors
(independent variables; P407 and P188 concentration) on Tgel, G
0,
and h* (dependent variables) was tested. Based on the particular
experimental conditions, a custom D-optimal designwas applied to
provide estimates for the effect testing with smallest standard
errors, as it maximizes the information in the selected set of
experimental runs with respect to a model stated.29 Two center
points were included in the experimental runs to allow the testing
for nonlinear factor effects and estimation of the pure experimental
error and to increase the power of the experiment. A total of 8
experimental runs were generated for the evaluation of the main
effects and possible interactions. Accordingly, 8 samples, varying in
concentrations of P407 (10.59%-19.1%, w/w) and P188 (0.8%-7.66%,
w/w), were prepared, and their Tgel, G
0, and h* were determined
(Table 1). Collected data were analyzed, and signiﬁcant cause-and-
effect relationship was identiﬁed. Data set was expanded with the
results of preliminary screening, consisting of 5 samples, which
contain only P407 (11.4%-19.3%, w/w).
In the subsequent, reﬁning step, CS concentration was added
as an additional independent variable. Concentration ranges of
factors P407 and P188 were selected based on the result obtained
in screening step, and CS concentration was evaluated in the
range of 0.08%-1.29% (w/w) based on the literature data.19,30
D-optimal statistical design with 1 center point was applied.
Nine experimental runs were required for analyzing the main
effects and all second-level interactions. Additionally, to evaluate
error of mixed P407/P188/CS system preparation and measure-
ment, 3 replicated runs were added to the experimental
sequence (replicate step). Based on this approach, 3 mathemat-
ical models were established, that is, Tgel, G
0, and h* models, as
the prerequisite for the optimization of in situ forming
P407/P188/CS ophthalmic gel.
The Model of Temperature of Gelation
Within the established Tgel model, the response of interest is
represented by following regression equation:
Tgel ¼ 35:46  13:84  P407 þ 6:70  P188þ 2:74  CS
þ 7:07 P407  P188 þ 9:16 P407  P188
 CS
(1)
where factors denoted as overlined represent centered factors, that
is reduced by mean value and divided by the half of the factor
range. The obtained coefﬁcient of determination between the
experimental and predicted values of Tgel was R
2 ¼ 0.93 (Fig. S1a).
Statistical analysis of the collected data revealed signiﬁcant ef-
fects of P407, P188, and CS concentrations on the Tgel (p < 0.05). The
concentration effect impacts Tgel in following order: P407
(coefﬁcient ¼ 13.84) > P188 (coefﬁcient ¼ 6.70) > CS
(coefﬁcient ¼ 2.74). The negative value of the coefﬁcient indicates
an inverse relationship between the factor (concentration) and the
response (Tgel), showing that increase of the P407 concentration
will result in a decrease of Tgel. The positive value of the coefﬁcient
observed for P188 indicates that increasing the concentration of
P188 shifts Tgel to higher values, as already reported in the litera-
ture.11,14 Similar to P188, but to a lesser extent, the increase in CS
concentration increases Tgel. Evidently, CS affects the onset of gel-
ling, but it does not interfere with the formation of in situ gel, thus,
making it a suitable additive in this mixed poloxamer system. In the
similar concentration range, CS was already shown not to induce
marked changes in the Tgel of poloxamer systems.
19
Signiﬁcant higher order terms include the interaction between
P407 and P188 (coefﬁcient ¼ 7.07) and the interaction among
P407, P188, and CS (coefﬁcient ¼ 9.16). These interactions, shown
as response surface and contour plots (Figs. 1a-1c), indicate that
one factor may vary depending on the level of the other factor.
P407 and P188 interaction proﬁle suggests that the impact of P407
on the Tgel decrease is more pronounced at the lower level of P188
(Fig. S1b). At the other side, higher level of P407 assures more
pronounced effect of P188 on the Tgel increase. Curvatures shown
on the Figure 1a indicate that this relation is not linear. These
interactions reveal the complexity of interplay of the components
in the measured mixed systems. The complexity of interplay is
highly related to the concentration of P188 in the system as sug-
gested by Zhang et al.11 who revealed the formation of 2 distinct
populations of micelles in mixed P407/P188 systems. They sug-
gested that P188 micellization was responsible for the Tgel
increase.
Models of Rheological Properties: Complex Viscosity and Storage
Modulus
Critical attribute that determines the dosing accuracy, retention
time, and drug release from in situ forming ophthalmic gels is
formulation rheological behavior. The systems with ﬁne-tuned
rheological properties would withstand the high shear rates and
tear dilution thus preventing the drainage of an API from the site of
the absorption.4
The Model of Complex Viscosity
We investigated and mathematically described the inﬂuence of
different P407, P188, and CS concentration levels on the measured
h* at 35C and angular frequency of 1 s1. Before the statistical
analysis, h* data were checked for normality. Kolmogorov test
conﬁrmed that data follow the log-normal distribution. Thus, log
transformation was applied on the measured h* data.
In this mathematical approach, the response of interest [log(h*)]
is represented by following regression equation:
log

h
*

¼ 0:37þ 1:53  P407  1:60  P188 0:55
 P407  P188  0:76  P407  CS þ 0:70
 CS  CS þ 1:56  P407  P407  P188
(2)
Developed h* model shows good ﬁt between experimental and
predicted logarithmic values of h* with resulting coefﬁcient of
determination R2 ¼ 0.97 (Fig. S2a).
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Statistical analysis of the collected data revealed signiﬁcant
effects of P188 and P407 concentrations on log (h*) (p <0.05). The
increase of P188 concentration results in the decrease of log (h*) as
revealed by its negative coefﬁcient (coefﬁcient ¼ 1.60). On the
contrary, the increase of P407 concentration results in the increase
of log (h*) (coefﬁcient ¼ 1.53). The complexity of interactions is
noticed on the response surface and contour plots of P407 and P188
(Fig. 1d) and P407 and CS (Fig. 1e), whereas less complex relation-
ship is noticed for P188 and CS on the response (Fig. 1f; which is in
agreement with the linear lines on Fig. S2b). The model indicated 2
interactions with negative effect on the response. Namely, these
were interaction between P407 and CS (coefﬁcient¼0.76) as well
as between P407 and P188 (coefﬁcient ¼ 0.55). Concomitantly,
2 higher order terms were found with the positive effect on the
response, namely the interaction among P407, P407, and P188
(coefﬁcient ¼ 1.56), and CS (coefﬁcient ¼ 0.70). At higher level of
P188, the effect of P407 on increase of log (h*) is less pronounced
(Fig. S2b). In contrary, the omission of P188 from the system results
in faster increase of log(h*) when increasing P407 concentration. CS
and P407 interaction proﬁle suggests that the impact of P407 on the
log(h*) increase is more pronounced at the lower level of CS
(Fig. S2b). As it can be seen by comparing the response surface and
contour plot images of the Tgelmodel and log (h*) model (Figs.1a-1c
and 1d-f), higher degree of complexity, that is curvatures, was found
in the log(h*) model. This indicated the absence of linear relation-
ship between the concentrations of 3 tested polymers to a response.
Figure 1. Response surface of the effects of the concentration of P407, P188, and CS on the Tgel (a-c), log10 (h*) (d-f), and log10 (G
0) (g-i). (a) Effect of concentration of P407 and P188
on Tgel. (b) Effect of concentration of P407 and CS on Tgel. (c) Effect of concentration of P188 and CS on Tgel. (d) Effect of concentration of P407 and P188 on log10 (h*). (e) Effect of
concentration of P407 and CS on log10 (h*). (f) Effect of concentration of P188 and CS on log10 (h*). (g) Effect of concentration of P407 and P188 on log10 (G
0). (h) Effect of
concentration of P407 and CS on log10 (G
0). (i) Effect of concentration of P188 and CS on log10 (G
0).
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The Model of Storage Modulus
As for the log(h*), inﬂuence of different independent variables
(P407, P188, and CS concentration levels) on the measured
response G0 at 35C and angular frequency of 1 s1 was tested and
mathematically described. Again, Kolmogorov test conﬁrmed that
data follow the log-normal distribution; therefore, log trans-
formation was applied on the measured G0 data.
Log(G0) is described by following regression equation:
logðG0Þ ¼ 1:13þ 2:16  P407  0:77  P188 0:26
 P407  CS þ 0:56 P188  CS (3)
Developed log (G0) model exhibits suitable ﬁt between exper-
imental and predicted logarithmic values of G0 with resulting
coefﬁcient of determination R2 ¼ 0.93 (Fig. S3a).
Statistical analysis of the acquired data revealed signiﬁcant
effects of P407 and P188 concentrations on log(G0) (p <0.05),
with P407 concentration having stronger effect on the response.
As expected, similar to the model for log(h*), the increase of P188
concentration results in the decrease of log (G0) due to its
negative coefﬁcient (coefﬁcient ¼ 0.76). On the contrary, the
increase of P407 concentration results in the increase of log(G0)
(coefﬁcient ¼ 2.16). As seen on the Figures 1g and 1h, relation
between P407 and P188 and P407 and CS on the response in
model appears to be relatively simple. More complex relation of
P188 and CS on the log(G0) was found to have statistically
signiﬁcant interaction with positive effect on the dependent
variable (coefﬁcient ¼ 0.56) (Fig. 1i).
The increase of P188 at lower level of CS results in decrease of
log (G0), whereas this effect is not observed when CS is at highest
level (1.3%, w/w). The increase in CS at low level of P188 lowers the
response of interest. However, this effect is opposite at higher
level of P188 (7.66%, w/w).
Another interaction included in the model, but with no sta-
tistical signiﬁcance, was interaction between P407 and CS, having
a negative impact on the response (coefﬁcient ¼ 0.26). Same
interaction with signiﬁcant negative effect was noticed in the
model for log(h*).
Selection of Rheologically Improved In Situ Forming Ophthalmic
Gel
Tgel of innovative ophthalmic in situ forming gels is the most
critical parameter related to efﬁcacy and safety as well as patient
compliance since it inﬂuences the accuracy of dosing, (dis)comfort
associated with the instillation, and residence time at the eye
surface. Namely, if the system gels at room temperature, dosing
would be hindered. Storage at low temperature would diminish
this problem; however, the instillation of cold formulation can
possibly be irritating and painful. Therefore, the optimal Tgel in situ
forming ophthalmic gel should be between 25C, the average
ambient temperature, and 35C, the eye surface temperature.19 In
our study, the optimal range of Tgel was set to 28
C-32C.
Viscosity is one of the key attributes for innovative ophthalmic
in situ forming gels deﬁning the residence time at the eye surface
and drug release proﬁle. The optimal range of viscosity is much
more difﬁcult to select in relation to Tgel. A wide range of viscos-
ities reported for poloxamer-based in situ forming ophthalmic gels
have suitable in vivo response.6,13,19 Therefore, we characterized
the commercially available in situ forming ophthalmic gels with
rotational test with controlled shear rate (Supplementary
Materials) to enable the recognition of leading candidates. Oscil-
latory tests of selected leading candidates reveled the lower limit
for h* (at 35C and 1 s1) at 1.2 Pa  s. Ta
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G0 is a measure of the deformation energy stored by the sample
during the shear process. After the load is removed, this energy is
completely available, now acting as the driving force for the
reformation process which will compensate partially or completely
the previously obtained deformation of the structure. G0 presents
the elastic behavior of a sample, and it assures adequate gel
stability. As minimal G0 values for gel structures are around 5 Pa,27
this value was set as minimal value for this dependent variable.
Considering the optimal Tgels, G
0 and h* suggested by corre-
sponding models, 4 mixed P407/P188/CS systems were selected
(Table 2). The additional criterion of the selection was the lowest
possible total polymer content in in situ forming ophthalmic gel. To
validate the data obtained by the models, mixed P407/P188/CS
systems were prepared. Tgel, G
0, and h* were determined by tem-
perature sweep test and compared with predicted values (Table 2).
High coefﬁcient of determination (R2 ¼ 0.93) and the overall
recovery of experimental to predicted Tgel (110.23 ± 0.08%; relative
standard deviation [RSD] ¼ 7.02%) conﬁrmed the suitability of Tgel
model. Similar agreement was found for log (G0) model (R2 ¼ 0.93)
with the average recovery of experimental to predicted Tgel of 97.25
± 19.07%, having slightly higher variability (RSD ¼ 19.61%). In case
of log (h*) model, even better coefﬁcient of determination (R2 ¼
0.97) was observed, and despite the lower overall recovery of
experimental to predicted log (h*) (63.83 ± 0.16%; RSD¼ 24.3%), the
developed model enabled the development of mixed P407/P188/CS
system with targeted viscosity (>1.2 Pa  s). The higher variability
Figure 2. Rheological properties of selected mixed P407/P188/CS systems (PL1, PL2, PL3, and PL4) and respective controls under biorelevant conditions. Frequency sweeps analysis
before (circles) and after (squares) dilution with simulated tear ﬂuid (STF) 40:7 at 35C. G0 ﬁlled symbols, G00 empty symbols. Control sample for PL1, PL3, and PL4 is labeled CPL1,
CPL3, CPL4; control sample for PL2 is labeled CPL2.
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of this model could be related to the heating rate-dependent
kinetics of gel formation. Mixed P407/P188 systems exhibit very
complex rheological behavior with internal relaxations and slow
reorganizations taking place in the temperature range preceding or
following the Tgel.
11 However, the fast temperature change is the
one expected in vivo.
In Depth Rheological Characterization of In Situ Forming
Ophthalmic Gel
With the aim of in depth rheological characterization, selected
mixed P407/P188/CS systems were subjected to frequency sweep
analysis. Strain sweep analysis was carried out to determine the
limit of LVE range, that is, the range where stress is directly pro-
portional to strain.
Frequency sweep analysis gives an insight on the behavior of G0,
G00, and h* as a function of angular frequency. The frequency sweep
measurements for all 4 mixed P407/P188/CS systems indicated that
G0 was higher than G00 revealing suitable gel stability (Fig. 2).
Moreover, the presented rheological proﬁle suggests the existence
of soft gels known to be formed at moderate poloxamer concen-
tration.31 This phenomenon has been ascribed to the weak attrac-
tion of spherical micelles as the solvent becomes poorer on heating.
To determine the inﬂuence of CS on the gel mechanical strength,
frequency sweep analysis was carried out also for the respective
control systems without CS (Fig. 2). As expected, the presence of CS
in mixed systems resulted in higher G0 and G00 values indicating
increased gel mechanical strength. It was already suggested that
the elastic characteristic of the system increased owing to an effect
on microscopic diffusion within gel structure which facilitated the
accommodation of unbound water and consequently micelle
packaging.19
Mixed systems were further characterized under biorelevant
conditions, that is, diluted with STF at the ratio of 40:7 mimicking
their mixing with tear ﬂuid after instillation.10 Despite the dilution,
mixed systems retained their ability to form gel at temperature
lower than 35C (i.e., the sample PL2 formed gel at 28.7C, whereas
PL1, PL3, and PL4 formed gel at 33.5C). The observed increase in
Tgel relative to undiluted systems (Table 2) can be related to both
the decrease in the total concentration of polymers and the
modiﬁcation of the physicochemical properties of the hydrogels in
the presence of STF electrolytes.19,32
The dilution of all mixed systems with STF resulted in no change
in G0 to G00 ratio or their overall proﬁle (Fig. 2). Furthermore, there
was no signiﬁcant change in the absolute values of G0 and G00 in case
of samples prepared with the same poloxamer concentration and
different CS concentration (Fig. 2; PL1, PL3, and PL4). On the con-
trary, comparing the mixed system PL2 (P407/P188/CS 15.0/2.0/
0.5%, w/w) with PL4 (P407/P188/CS 14.2/1.7/0.5%, w/w), it may be
observed that the small increase in poloxamer concentration
inﬂuenced the resistance to dilution.
The decrease of h* values with the increase of angular frequency
arguments suitable pseudoplastic behavior of in situ forming
ophthalmic gels. The viscosity proﬁles of all mixed systems did not
change signiﬁcantly upon dilution with STF suggesting the main-
tenance of their pseudoplastic behavior (Fig. S4). Moreover, there
was no marked change in the absolute values of h* upon dilution
except, again, in the case of PL2 sample.
Comparing our mixed P407/P188/CS systems with mixed
P407/CS system developed by Gratieri et al.19 in terms of resistance
to dilution, it may be concluded that P188 signiﬁcantly contributed
to gel stability. In mixed P407/CS system the concentration of P407
was higher (16%, w/w and 14%, w/w, upon dilutionwith STF) than in
case of mixed P407/P188/CS system (14.2%, w/w and 12.09%, w/w,
upon dilution with STF). However, upon dilution mixed P407/CS
system behaved as viscoelastic solution at 35C and decreased
frequencies while mixed P407/P188/CS system behaved as soft gel.
Based on minimal polymer content (P407, P188, and CS con-
centration of 14.2%, 1.7% and 0.25%, w/w, respectively), favorable
rheological characteristics (Tgel¼ 31.1
C, h*¼ 2.1 Pa s) and in vitro
resistance to tear dilution (G0 212.4 Pa and 175.3 Pa before and after
dilution, respectively), the PL1 was selected as optimal in situ
forming gel.
Effect of Active Pharmaceutical Ingredients on Temperature of
Gelation and Complex Viscosity
The addition of APIs in the mixed P407/P188/CS system is
expected to cause a modiﬁcation of the physicochemical properties
of in situ forming gels. Four ophthalmic APIs were selected in order
to gain understanding of their effects on Tgel and h* of selected PL1
in situ forming gel. We tested APIs in the concentrations and
combinations relevant for topical ophthalmic use. API-loaded P407/
P188/CS systems were characterized for Tgel and h
* before and after
dilution with STF (Table 3). All APIs, except TOBRA, notably
decreased Tgel in comparison with Tgel of PL1. This effect was
highest for DEX showing the decrease of the Tgel for 8.5
C. DEX has
already been shown to decrease the Tgel of P407-based in situ
forming gels.33,34 Such an effect can be ascribed to the promotion of
P407 self-assembly in the presence of hydrophobic drug allowing
the formation of gel at lower temperatures.35 The Tgel of the mixed
P407/P188 systems was also reported to be affected by the addition
Table 3
Effect of Active Pharmaceutical Ingredients on Temperature of Gelation (Tgel) and
Complex Viscosity (h*)
Variable Before Dilution With STF After Dilution With STF
Tgel (
C) h* (Pa  s)a Tgel (
C) h* (Pa  s)a
PL1eDORZO 27.50 ± 1.70 7.88 ± 1.18 33.50 ± 0.01 0.67 ± 0.06
PL1eTIMO 26.30 ± 0.01 4.90 ± 0.54 29.90 ± 1.20 2.44 ± 1.50
PL1eDORZO/TIMO 28.70 ± 0.02 4.82 ± 1.07 32.90 ± 0.80 0.64 ± 0.10
PL1eTOBRA 30.30 ± 1.40 1.52 ± 0.66 31.10 ± 0.01 0.52 ± 0.10
PL1eDEX 22.60 ± 1.70 6.11 ± 0.70 28.70 ± 0.01 1.56 ± 1.16
PL1eDEX/TOBRA 23.65 ± 3.18 6.88 ± 1.59 31.15 ± 0.07 0.639 ± 0.21
PL1 31.10 ± 1.40 2.10 ± 0.74 33.50 ± 0.70 0.37 ± 0.15
Values are mean ± SD (n ¼ 3).
a h* at 35C determined by temperature sweep test (angular frequency and strain
were 1 s1 and 1%, respectively).
Table 4
Samples Tested in the IVR Study
Sample Description/Composition Tgel/
C h* (Pa  s)
PL1 14.2% P407, 1.7%P188, 0.25% CS, 0.2% TIMO (w/w) 31.1 ± 2.0 1.2 ± 0.3
C1 14.2% P407, 0.25% CS, 0.2% TIMO (w/w) 26.9 ± 2.2 4.12 ± 1.2
C2 11.4% P407, 0.2% TIMO (w/w) 31.1 ± 1.7 0.097 ± 0.07
TIMO solution TIMO solution in STF, 2.5 mg/mL n/a n.m.
h* at 35C determined by temperature sweep test (angular frequency and strain were 1 s1 and 1%, respectively).
n/a, not applicable; n.m., not measured.
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of hydrophobic APIs; the Tgel decreased with increasing the
pH-dependent hydrophobicity of API in the systems.36 Smaller Tgel
decrease was observed for the systems containing dissolved APIs,
namely Tgel decreased for 4.8
C and 2.4C in case of TIMO and
DORZA, respectively. As anticipated by many authors, the decrease
of Tgel induced by dissolved APIs could be related to the API salting-
out effect.37,38 Their presence could shift the concentration and
temperature at which micelles are formed to lower values and,
moreover, could affect the close packing of micelles, resulting in Tgel
decrease.32,36 However, despite the decrease of Tgel by the addition
of APIs, all the samples except those with DEX formed gels at
temperature higher than 25C. The addition of APIs in the mixed
P407/P188/CS system prolonged the gelation time in all cases
except for DEX/TOBRA. However, the obtained gelation time values
were still in the appropriate range (41.1-87.4 s) for ocular
administration.39,40
The h* values for API-loaded PL1 were in the range of 1.52-7.88
Pa s indicating no pronounced inﬂuence of API entrapment on gel
viscosity (Table 3).
Dilution with STF, as expected, led to the increase in Tgel and
certain decrease in h* for all the API-loaded PL1. All the samples
retained their gel structure after dilution as suggested by the
frequency sweep analysis (data not shown).
These results indicate the robustness of selected PL1 in situ
forming gel against entrapment of APIs with different physico-
chemical characteristics. The decrease in Tgel caused by API
entrapment open the possibility to further decrease the concen-
tration of poloxamers required to obtain in situ forming gels with
appropriate biopharmaceutical properties.41
Drug Release From In Situ Forming Gel
IVR study was performed to investigate the inﬂuence of vis-
cosity related to the functional excipient concentration on the drug
release rate. The optimal in situ forming gel (PL1) was characterized
in terms of its inﬂuence on drug release proﬁle. For that purpose,
TIMOwas selected as themodel drug and incorporated in PL1 in the
lowest efﬁcient dose. Control in situ forming gel C1 was charac-
terized by h* comparable to PL1, whereas control in situ forming gel
C2 was characterized by Tgel comparable to PL1 (Table 4). TIMO
solutionwas also used as the control sample. The IVR proﬁles of PL1
and respective controls are shown in Figure 3. IVR of TIMO from PL1
and C1 was signiﬁcantly slower that form C2 and TIMO solution
indicating viscosity as the critical factor inﬂuencing drug release.
Similar observations were already reported for in situ forming
ophthalmic gels.26,42
Biocompatibility Assessment of In Situ Forming Ophthalmic Gel
Biocompatibility of the optimal in situ forming gel (PL1) was
assessed by using 2 3D cell-based corneal epithelial models, namely
multilayered HCE-T epithelium cultivated on ﬁlters with 0.4 mm
pores and model consisting of an apical lipophilic HCE-T epithelial
monolayer and a basolateral lipophilic monolayer of migrated
HCE-T cell cultivated on ﬁlters with 3 mm pores.43 In the
preliminary studies, simple 2D HCE-Tmonolayer was used to assess
the formulation biocompatibility. However, exaggerated toxicity
was found in comparison to in vivo studies.44 In vitro 2Dmodels are
generally characterized by certain shortcomings, such as a more
pronounced susceptibility to cytotoxicity, as they replicate only a
limited segment of tissue structure/function.45 Consequently, the
concentration of polymers/formulation that can be safely applied to
such models may be reduced in comparison to the in vivo system.
Therefore, we employed more complex 3D corneal epithelial
models to screen the formulation biocompatibility. Contrary to
HCE-T epithelial monolayer, 3D models reveled biocompatibility of
the formulation tested. Namely, 30-min treatment resulted in
decrease in 3D model cell viability lower than 20%.
Conclusions
In this study, we developed in situ forming gel characterized by
Tgel in physiologically relevant range, pseudoplastic behavior and
resistance to dilution. D-optimal design was successfully applied to
reduce the total polymer content in in situ forming P407/P188/CS
gel while retaining its advantageous rheological properties. The
developed system was proved to be robust against entrapment of
APIs making it a suitable platform for ophthalmic delivery of active
pharmaceutical ingredients with diverse physicochemical proper-
ties. Moreover, the developed in situ forming ophthalmic gel was
proved to provide prolonged drug release in relation to the system
viscosity.
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A B S T R A C T
In this study, we suggest the development of nanoparticle loaded in situ gelling system suitable for
corticosteroid nasal delivery. We propose lipid/alginate nanoparticles (size 252.3  2.4 nm, polydisper-
sity index 0.241, zeta-potential 31.7  1.0 mV, dexamethasone (Dex) content 255  7 mg ml1) dispersed
in pectin solution (5 mg ml1) that undergoes a sol-gel phase transition triggered by Ca2+ present in nasal
mucosa. The viscoelasticity of gel obtained by mixing nanoparticle suspension in pectin continuous
phase with simulated nasal ﬂuid (1:1 V/V) is characterised by a log-linear shear thinning viscosity
behaviour. Observed viscosity corresponds to the range of viscosities of nasal mucus at physiological as
well as under disease conditions. Nanoparticle-loaded gel was biocompatible with the selected epithelial
cell model and, in comparison to dexamethasone solution, provided reduction in Dex release (t50% 2.1 h
and 0.6 h, respectively) and moderated transepithelial permeation in vitro (Papp 7.88  0.15 and
9.73  0.57  106 cm s1, respectively). In conclusion, this study showed the potential of the proposed
system to provide local therapeutic effect upon administration of a lower corticosteroid dose and
minimize the possibility for adverse effects as it can be easily sprayed as solution and delivered beyond
nasal valve, ensure prolonged contact time with nasal mucosa upon gelation, and moderate
corticosteroid release and permeation.
© 2017 Elsevier B.V. All rights reserved.
1. Introduction
Chronic rhinosinusitis is one of the most commonly diagnosed
chronic nasal illnesses worldwide (Fokkens et al., 2012). The site of
inﬂammation and potential nasal polyp growth is located beyond
the nasal valve. Nasal polyps are grape-like structures which affect
about 20% people with chronic rhinosinusitis and cause symptoms
of prominent nasal obstruction and reduction/loss of smell.
Chronic rhinosinusitis with nasal polyps can be treated with
pharmacotherapy, but in more severe cases it may be necessary to
remove nasal polyps by endoscopic sinus surgery. Unfortunately,
post-surgical recurrence is common because the underlying
inﬂammatory process fails to be addressed (Martino et al., 2015).
The mainstream treatment for patients with nasal polyps are
corticosteroids. Even though oral corticosteroids are effective, they
can cause well known side effects including suppression of
hypothalamic-pituitary-adrenal axis, osteoporosis,
hyperglycaemia, gastrointestinal bleeding, hypocalcaemia, insom-
nia, hypertension, cataracts and glaucoma. Therefore, topical nasal
corticosteroids are the natural choice for patients with nasal
polyps. However, to reduce polyp size, nasal steroid must reach the
inﬂammation site in sufﬁcient quantities. Therefore, lately high-
dose topical nasal corticosteroids have been suggested and have
shown promising results as well as less systemic effects than oral
corticosteroids. High-dose topical nasal corticosteroids are
thought to penetrate the sinus cavities at an increased dose and
therefore allow for greater control of polyp growth (Martino et al.,
2015). However, long term use of high topically applied doses could
be related to adverse effects such as changes in serum cortisol
levels and intraocular pressure.
The current interests are focused on the development of nasal
delivery device that could ensure corticosteroid delivery beyond
the nasal valve, i.e. to the site where nasal polyps occur (Hansen
et al., 2010; Vlckova et al., 2009). However, in addition to nasal
delivery device, characteristics of formulation also impact
therapeutic outcome. In this study, we suggest the development
of nanoparticle loaded in situ gelling system able to provide an* Corresponding author at: A. Kova9cica 1, 10000 Zagreb, Croatia.
E-mail address: ahafner@pharma.hr (A. Hafner).
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optimal nasal deposition, prolonged residence time and prolonged
corticosteroid release. More particularly, we propose lipid/alginate
nanoparticles dispersed in pectin solution that undergoes a sol-gel
phase transition triggered by Ca2+ present in nasal mucosa. Anionic
polysaccharides are known for their biocompatibility and biode-
gradability, and are therefore often used as constituents of
numerous drug delivery systems. Both alginate and pectin show
mucoadhesive properties. Their adhesion to mucus layers and
increased elasticity of mucus secretions is based on the interpen-
etration with mucin chains (Fuongfuchat et al., 1996). The
electrostatic repulsion between alginate/pectin and mucin due
to the same charge may cause an uncoiling of polymer chains and
facilitate chain entanglement and bond formation (Joergensen
et al., 2011; Wattanakorn et al., 2010). Pectin solutions form gels in
the presence of Ca2+ at the concentration expected at the nasal
mucosa. Ionotropic gelation of polymer chains results in a highly
ordered three-dimensional network with “egg-box” junction
zones (Watts and Smith, 2009).
Nanoparticle loaded in situ gelling system can be easily sprayed
as a solution and, with appropriate device, delivered to the site of
inﬂammation. The Ca2+ triggered gel formation in the nasal cavity
would ensure prolonged contact time with nasal mucosa. Such
biopharmaceutical properties, along with the prolonged cortico-
steroid release from lipidic matrix nanoparticles, would allow local
therapeutic effect upon administration of a lower corticosteroid
dose, minimizing the possibility for adverse effects.
2. Materials and methods
2.1. Materials
Sodium alginate PRONOVA UP LVG (low viscosity; L-guluronate
(G)/D-mannuronate (M) Ratio  1.5) was purchased from
NovaMatrix1, Norway. Lecithin S100 was obtained from Lipoid,
Germany. Di-methyldioctadecylammonum bromide (DDAB) was
purchased from Sigma-Aldrich, Germany. Dexamethasone (Dex)
was obtained from Sanoﬁ Aventis, France. Low methylester (LM)
amidated pectin CF 025 (pectin; degree of esteriﬁcation (DE) 23–
28%; degree of amidation (DA) 22–25%) was kindly donated by
Herbstreith&Fox, Germany. Sodium dodecyl sulphate (SDS) was
obtained from Merck, Germany. Acetonitrile (ACN), tetrahydrofur-
ane (THF) and methanol, gradient grade for liquid chromatography,
were purchased from Merck, KGaA, Germany. 0.2 mm SpartanTM
regenerated cellulose ﬁlters were obtained from Whatman, United
Kingdom. Simulated Nasal Fluid (SNF) was prepared as an aqueous
solution containing 150.0 mmol NaCl (Kemig, Croatia), 40.0 mmol
KCl (Kemig, Croatia) and 5.3 mmol CaCl2 2H2O (Sigma-Aldrich,
Germany) per litre (Martinac et al., 2005). Hank’s balanced salt
solution (HBSS, pH 7.4) was prepared by dissolving the following
substances in double-distilled water: MgSO4 7H2O (0.4 mM), KCl
(5.4 mM), NaHCO3 (4.2 mM), NaCl (136.9 mM), D-glucose mono-
hydrate (5.6 mM) (all purchased from Kemig, Croatia), CaCl2 2
H2O (1.3 mM) (Sigma-Aldrich, Germany), MgCl2 6H2O (0.5 mM)
(Merck KGaA, Germany), KH2PO4 (0.4 mM) (Kemika, Croatia),
Na2HPO4 2H2O (0.3 mM) (Fluka Chemie AG, Switzerland) and
HEPES (30.0 mM) (AppliChem, Germany) (Hafner et al., 2015) and
it was used for nanoparticle biocompatibility assessment. Hank’s
balanced salt solution with 5.3 mM Ca2+ (HBSS-Ca2+; pH 7.4) was
prepared by dissolving KCl (5.4 mM), NaHCO3 (4.2 mM), NaCl
(136.9 mM), D-glucose monohydrate (5.6 mM) (all purchased from
Kemig, Croatia), KH2PO4 (0.4 mM) (Kemika, Croatia), Na2HPO4 2
H2O (0.3 mM) (Fluka Chemie AG, Switzerland) and CaCl2 2H2O
(5.3 mM) (Sigma-Aldrich, Germany) in double-distilled water and
was used for in vitro permeability study. Ultrapure water for
chromatographic analyses was produced by Ultra ClearTM UV Plus
(SG Wasseraufbereitung und Regenierstation GmbH, Germany).
2.2. Preparation of lipid/alginate nanoparticles
Lipid components, lecithin and DDAB were dissolved in 96%
ethanol. Concentration of lecithin in ethanolic solution was
25 mg ml1, while lecithin to DDAB weight ratio was 50:0.7,
50:1, 50:3 or 50:5. Dex was dissolved in the ethanolic solution of
lipids at the concentration of 5 mg ml1, i.e. at lecithin to Dex
weight ratio of 5:1. Alginate was solubilised in distilled water at
concentration of 10 mg ml1 and the aliquot of alginate solution
(0.5 ml) was further diluted with distilled water to a volume of
23 ml. Dex-loaded nanoparticles were obtained by injection of 2 ml
of ethanolic lipid/Dex solution (syringe inner diameter of 0.75 mm)
into 23 ml of diluted alginate solution under magnetic stirring
(900 rpm). A ﬁnal alginate concentration of 200 mg ml1 and
lecithin to alginate weight ratio of 10:1 was obtained in the
prepared nanoparticle suspensions. Dex that precipitated during
nanoparticles production was separated by ﬁltration using
0.45 mm membrane ﬁlters (Millipore1, Switzerland).
Dex-free lipid and lipid/alginate nanoparticles were prepared
by the injection of ethanolic lipid solution into distilled water and
diluted aqueous solution of alginate, respectively, and were used as
controls when appropriate.
2.3. Determination of Dex loading
About 0.5 g of resuspended samples containing nanoparticles
was accurately weighed in 25 ml volumetric ﬂask. 2 ml of
tetrahydrofurane (THF) and 10 ml of diluent (60% methanol/40%
ultrapure water, V/V) was added into the ﬂask and sample was
placed on the ultrasonic bath. After 20 min of sonication sample
was checked for transparency visually and ﬁlled with diluent up to
the total volume of 25 ml. Prior Ultra-Performance Liquid
Chromatography (UPLC) analysis described in the Section 2.11,
all samples were ﬁltrated through 0.2 mm SpartanTM regenerated
cellulose ﬁlters.
2.4. Physical characterization of the particle size and surface charge
The size and zeta potential of nanoparticles were measured by
Photon Correlation Spectroscopy (PCS) using Zetasizer 3000 HS
(Malvern Instruments, Malvern, UK). For that purpose nanoparticle
samples were diluted with 0.45 mm ﬁltered distilled water and
10 mM NaCl solution, respectively. Zeta-potential measurements
were performed at 25 C. Samples were placed in the electropho-
retic cell, where a potential of 150 mV was established.
2.5. The preparation of in situ forming nanoparticle-loaded gel
Pectin was dissolved in distilled water at the concentration of
40 mg ml1. Pectin solution was added to the nanoparticle
suspension to the ﬁnal pectin concentration of 5 mg ml1.
Nanoparticle suspension with pectin in continuous phase was
then mixed with SNF in volume ratio of 1:1, which resulted in
instantaneous gel formation.
2.6. Rheological evaluation
The rheological behaviour of in situ forming nanoparticle-
loaded gel was determined by frequency sweep test using
Rheometer Anton Paar Physica MCR 301 (Anton Paar GmbH,
Austria) with cone plate (CP25) measuring system equipped with
H-PTD 200 Truly Peltier-temperature-controlled hood (US Patent
6,571,610). Peltier heating element was connected to circulating
water bath (F25-ME Refrigerated/Heating Circulator, JULABO
GmbH, Germany). Sample was placed carefully on the lower plate
of rheometer, measuring bob was placed in the measuring position
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and sample was equilibrated for 5 min at 37 C. Gap was set to d =
0.05 mm, and angle was 1. The strain applied was in the linear
viscoelastic range (at 0.3%) while the angular frequencies were in
the range of 0.628–199 rad/s. The elastic moduli (G0), viscous
moduli (G00) and complex viscosity (h*) were recorded. Data were
calculated by RheoplusTM software (Anton Paar).
Zero shear viscosity at 37 C of the NP suspension in pectin
continuous phase prior gelling was determined by creep test. A
shear stress (10 Pa) was applied to the sample in a dynamic shear
rheometer for a duration long enough (15 min) that the deforma-
tion reaches a constant value, which corresponds to steady state
ﬂow. Zero shear viscosity was calculated by the RheoplusTM
software by ﬁtting the shear stress versus shear rate data using the
Carreau’s model (Mezger, 2014).
Shear viscosity proﬁle of samples equilibrated for ﬁve minutes
at 37 C was determined by the means of rotational rheology using
the same measurement bob as in creep and oscillatory tests in the
shear rate range of 0.01 s1–1000 s1.
2.7. In vitro release studies
The release of Dex from nanoparticles and nanoparticle-loaded
gel was assessed by the dialysis technique under sink conditions
over 5 h.
2.7.1. Release proﬁle of Dex from lipid/alginate nanoparticles
The appropriate volume of nanoparticle suspension containing
400 mg of Dex was placed into a cellulose acetate dialysis bag
(Spectra/Por1 4 Dialysis Tubing, MWCO 12–14 kDa, Medicell
International Ltd., UK). The dialysis bag was sealed from both
sides and immersed into 30 ml of receptor medium (0.03% w/w,
aqueous SDS solution) at 25 C that was magnetically stirred at
180 rpm. At scheduled time intervals, the aliquots (2 ml) were
withdrawn and replaced with equal amounts of receptor medium.
Withdrawn samples were analysed for the Dex content by UPLC
method described in the Section 2.11. All experiments were
performed in triplicate.
2.7.2. Release proﬁle of Dex from nanoparticle-loaded pectin gel
Nanoparticle-loaded gel obtained at pectin concentration of
2.5 mg ml1 and Ca2+ concentration of 2.65 mM was placed into the
dialysis bag in a volume containing 200 mg of Dex. The dialysis bag
was immersed into 30 ml of 2.65 mM CaCl2 solution at 25
C that
was magnetically stirred at 180 rpm. Equal concentration of Ca2+ in
the formulation and the receptor medium ensured gel stability
over the experiment. Sampling and the Dex content analysis was
performed as described in the Section 2.7.1.
2.8. Cell culture conditions
Caco-2 cells (American Type Culture Collection [ATCC], USA)
were cultured in DMEM medium with 4500 mg/L glucose, L-
glutamine and sodium bicarbonate, without sodium pyruvate
(Sigma-Aldrich, Germany) supplemented with 10% foetal bovine
serum (Biosera, France), nonessential amino acids (Lonza,
Switzerland) and penicillin/streptomycin/amphotericin B (Lonza,
Switzerland). Cells were passaged at 80–90% conﬂuence. The
medium was changed every 48 h. Cultures were maintained at 95%
humidity and 37 C in an atmosphere of 5% CO2.
2.9. Cell viability study
Caco-2 cells were seeded onto 96-well plates (Corning Inc, USA)
at a density of 1.5 104 cells per well and allowed to reach
conﬂuence over 2 days.
2.9.1. Nanoparticle biocompatibility assessment
Suspensions of nanoparticles were diluted with HBSS (pH 7.4),
obtaining ﬁnal nanoparticle concentration of 50–400 mg ml1with
respect to lecithin. The cells were exposed to the nanoparticle
suspensions for 2 h at 37 C. Cells incubated in HBSS were used as a
negative control. After 2 h of treatment with nanoparticles, the
cells were washed twice with HBSS and incubated with fresh
medium (100 ml/well) for 24 h. Cell viability was determined with
the colorimetric MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl
tetrazolium bromide, Sigma-Aldrich, Germany) assay. A total of
10 ml of MTT stock solution (5 mg ml1) in Phosphate buffered
saline without Ca2+ and Mg2+ (PBS) (Lonza, Switzerland) was added
to each well, and the cells were then incubated for 1 h at 37 C.
Afterwards, the medium was removed, cells were lysed and
formazan was dissolved with isopropanol. The amount of
formazan was quantiﬁed spectrophotometrically at 570 nm
(1420 Multilabel counter VICTOR3, Perkin Elmer, USA).
2.9.2. Nanoparticle-loaded gel biocompatibility assessment
Caco-2 cells were treated with nanoparticle-loaded gel
prepared by mixing nanoparticle suspension in pectin continuous
phase with SNF at volume ratio of 1:1. The cells were exposed to gel
for 2 h at 37 C. Cells incubated in SNF were used as negative
control. Cell viability was determined as reported in the
Section 2.9.1.
2.10. In vitro permeability through epithelial model barrier
Caco-2 cells were seeded onto the polycarbonate 12-well
Transwell1 inserts (0.4 mm mean pore size, 1.12 cm2 surface area,
Corning Costar Inc., USA) at density of 2.5 104 cells per well and
grown for 21–29 days. The cells were cultured with cell culture
medium volume of 0.5 ml in the apical and 1.5 ml in the basolateral
compartment. The culture medium was changed every other day
and 12–24 h prior to the permeability experiment. The trans-
epithelial electrical resistance (TEER) of the monolayers was
measured using epithelial volt/ohm meter EVOM equipped with
STX-2 chopstick electrode (WPI Inc., USA) to determine the
formation of the monolayers and their integrity. The permeability
studies were carried out in HBSS-Ca2+. Tested samples were
nanoparticle-loaded gel (prepared as reported in the Section 2.5.
with the only difference that instead of SNF, HBSS-Ca2+ was used)
and nanoparticle suspensions diluted with HBSS-Ca2+ to Dex
concentration of 60 and 112 mg ml1. Solutions of Dex (60 mg ml1)
in HBSS-Ca2+ and ethanol/HBSS-Ca2+ (3%, w/w) were used as
controls. The ethanol content in nanoparticle suspensions was
adjusted to 3% (w/w) which was equal to the ethanol content in the
nanoparticle-loaded gel. Prior to the experiment, the monolayers
were washed with HBSS-Ca2+, after which HBSS-Ca2+ was placed
into the apical (0.5 ml) and basolateral (1.5 ml) compartments. The
cell monolayers were then incubated for 30 min at 37 C. At the
beginning of the experiment, the apical compartment was emptied
and 0.5 ml of the test sample was added. Samples (0.4 ml) were
taken from the basolateral compartment at regular time intervals
over 120 min and replaced with the same volume of fresh
thermostated HBSS-Ca2+ (37 C). During the permeability experi-
ment monolayers were incubated at 37 C and 50 rpm on a
horizontal orbital shaker. At the end of the experiment, the
samples in the apical compartments were also collected. All
experiments were done in triplicate. Samples were analysed for
Dex content using UPLC (Section 2.11). The apparent permeability
coefﬁcients (Papp) were calculated according to the following
equation:
Papp ¼
@Q
@t

1
AC0
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where @Q
@t
is the steady-state ﬂux, A is the surface area of the
permeation barrier and C0 is the initial concentration of Dex in the
apical compartment (Hubatsch et al., 2007).
2.11. Quantitative determination of Dex
The quantitative determination of Dex was performed by Ultra-
Performance Liquid Chromatography (UPLC). Two types of UPLC
instruments were used: Agilent Inﬁnity 1290 (Agilent, USA) and
Waters ACQUITY UPLC H Class (Waters, USA). Data were acquired
and processed with the Empower 2 software (Waters, USA). The
chromatographic separation of dexamethasone was done on a
Waters Acquity UPLC BEH Shield RP18 column (2.1 100 mm,
1.7 mm particle size). Photodiode Array detector (PDA) was part of
the Waters systems and Diode Array (DAD detector) was used in
the Agilent instrument.
The quantitative determination of Dex in the samples from
basolateral compartments in permeability and receiver compart-
ments in in vitro release studies was performed on Waters
ACQUITY UPLC H Class instrument using isocratic UPLC method.
The mobile phase consisted of 68% of 5 mM sodium acetate buffer
(pH 4.5) and 32% of ACN (V/V). The column temperature was set at
55 C. The ﬂow rate of the mobile phase was 0.7 ml/min and
detection was at 254 nm wavelength. The samples were analysed
undiluted.
The quantitative determination of Dex in the samples from
apical compartments in permeability studies and the samples from
dialysis bag in in vitro release studies was performed on Agilent
Inﬁnity 1290 instrument by the gradient UPLC method. The mobile
phase consisted of 50% of 5 mM sodium acetate buffer (pH 4.5) and
50% of ACN (V/V) at 0 min, 25% of 5 mM sodium acetate buffer (pH
4.5) and 75% of ACN (V/V) at 0.2 min and 100% of ACN at 1.0 min.
The column temperature was set at 55 C. The ﬂow rate of the
mobile phase was 0.7 ml/min and detection was at 254 nm
wavelength. The samples were prepared in the same manner as
for determination of Dex loading (Section 2.3).
Prior analysis all samples were ﬁltrated through 0.2 mm
SpartanTM regenerated cellulose ﬁlters. The volume of injection
was 10 ml. For each sequence standard solutions were prepared in
duplicate and injected alternately. At least ﬁve standard solution
injections were done in each injection sequence. System suitability
was evaluated according to the following criteria: relative standard
deviation (RSD) of the detector response factor for all standard
solution injections in the sequence is not more than 2.0%, and
tailing factor of dexamethasone peak is not more than 2.0. Both
UPLC methods were checked and found to be suitable for linearity,
accuracy, repeatability and speciﬁcity at relevant concentration
ranges.
2.12. Statistical analysis
Statistical data analyses were performed on all data by a 1-way
ANOVA followed by multiparametric Tukey’s post-hoc test with
P < 0.05 as the minimal level of signiﬁcance. Calculations were
performed with the GraphPad Prism program (GraphPad Software,
Inc., San Diego, USA; www.graphpad.com).
The closeness between the two in vitro release proﬁles was
evaluated based on the similarity factor (f2), as described
previously (Blazevic et al., 2016). The mean cumulative amounts
of drug released of the two formulations were compared at each
time point. The release proﬁles were evaluated as similar when
f2 > 50 (Xie et al., 2015).
3. Results and discussion
3.1. Characterisation of nanoparticles
The detailed composition of lipid/alginate nanoparticles
proposed as nasal delivery platform for dexamethasone is shown
in Table 1. Lecithin S100 was selected as the main lipid component
to ensure drug entrapment and control over Dex release.
Incorporation of DDAB (cationic lipid) provided the positive net
charge of the lipid mixture to enable electrostatic interaction with
alginate, i.e. the formation of negatively charged nanoparticles.
Such nanoparticles are suitable for the proposed route of
administration as they are unperturbed by the presence of the
mucin (Grifﬁths et al., 2015).
The main characteristics of the nanoparticles prepared are
given in Table 2. Dex-loaded lipid/alginate nanoparticles were
successfully prepared with all lecithin/DDAB weight ratios
employed. Mean diameter of Dex-loaded nanoparticles ranged
between 109.1 3.1 nm and 258.6  2.4 nm while zeta-potential
was between 14.2  0.3 mV and 31.7  1.0 mV. Negative zeta-
potential values indicated the presence of alginate at the surface of
nanoparticles. The increase in DDAB content led to the increase in
positive net charge of the lipid mixture (data not shown) and
stronger interaction with alginate, resulting in an increase of both
the nanoparticle size and the negative surface charge. Dex loading
induced a slight reduction in the nanoparticle size, suggesting the
possible inﬂuence of Dex on the nanoparticle structuring.
However, no signiﬁcant difference between Dex-loaded and
Dex-free nanoparticle surface charge has been observed. Thus it
Table 1
The composition of ethanolic and aqueous solutions used for the preparation of
Dex-loaded lipid/alginate nanoparticles.
Samples Lecithin (mg) DDAB (mg) DEX (mg) Alginate (mg)
DN1 50 0.7 10 5
DN2 50 1 10 5
DN3 50 3 10 5
DN4 50 5 10 5
Ethanolic solution (2 ml) Aqueous solution (23 ml)
Table 2
The main characteristics of Dex-loaded (DN) and Dex-free (N) lipid/alginate nanoparticles.
Sample DDAB/lecithin ratio (w/w) Dex content (mg ml1) Size (nm) PDI Zeta-potential
(mV)
DN1
(N1)
0.7/50 218  3 109.1  3.1
(129.7  1.2)
0.540
(0.531)
14.2 0.3
(16.0  0.4)
DN2
(N2)
1/50 207  1 129.1  2.5
(134.9  4.4)
0.514
(0.610)
21.9  0.5
(19.5  0.3)
DN3
(N3)
1/50 204  7 258.6  4.2
(278.9  1.4)
0.343
(0.519)
26.5  0.3
(24.9  0.6)
DN4
(N4)
5/50 255  7 252.3  2.4
(276.6  4.6)
0.241
(0.374)
31.7  1.0
(30.6  1.0)
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can be concluded that Dex was entrapped within the lipid domains
of nanoparticles, exerting no inﬂuence on nanoparticle surface
characteristics. The highest Dex entrapment efﬁciency (63.8%) was
obtained for nanoparticles prepared with the highest DDAB
content (DN4). Furthermore, the same nanoparticles were
characterised by the lowest polydispersity index and the largest
negative zeta potential value (31.7  1.0 mV) that assured
physical stability of nanoparticle suspension.
3.2. In vitro release of Dex from nanoparticles
Dex release proﬁles from nanoparticles was determined using
the dialysis technique with SDS aqueous solution (0.03%, w/w) as a
receptor medium. The proﬁle of Dex diffusion from the SDS
aqueous solution (0.03%, w/w) across the dialysis membrane was
also determined, in order to assess the inﬂuence of resistance of
the dialysis membrane to Dex diffusion on overall Dex release rate.
All lipid/alginate nanoparticles were characterised by pro-
longed Dex release and a signiﬁcantly lower release rate than that
observed for Dex solution (Fig. 1). This particularly refers to DN4
nanoparticles that showed the potential to ensure prolonged Dex
delivery in vivo.
3.3. Evaluation of lipid/alginate nanoparticle biocompatibility
The biocompatibility of topical drug delivery nanosystems with
biological cell membranes at the application site is partially
governed by the surface characteristics of the nanoparticles, as the
possible toxic effect can be the consequence of the interaction
between nanoparticles and the cell surface. In general, negatively
charged nanoparticles are compatible with cell membranes and
are not likely to produce membrane disruption and cytotoxic
effects. Nanoparticle cytotoxicity can also be the consequence of
nanoparticle internalisation by cells (Verma and Stellacci, 2010).
Alginate and lecithin are generally regarded as safe, and are
used in the development of numerous topical drug delivery
systems. Alginate is negatively charged in the physiological pH
range of nasal mucosa. Lecithin S100 is mainly composed of
phosphatidyl choline that is primary natural constituent of
biological membranes. However, the main concern is related to
the potential dose-dependent cellular toxicity of cationic lipid
present in the lipid mixture (Lv et al., 2006).
The biocompatibility of lipid/alginate nanoparticles was
investigated using Caco-2 cells. Despite its intestinal origin, the
Caco-2 cell line has already been used to screen the biopharma-
ceutical properties of drug delivery systems intended for nasal
administration (Ekelund et al., 2005; Hafner et al., 2009; Mao et al.,
2005). In the biocompatibility study, the concentration of nano-
particles was expressed as the concentration of lecithin in the
system, and ranged from 50 to 400 mg ml1. Cell viability assay
showed no toxic effects of nanoparticles at the concentration range
tested and during the 2 h exposure (Fig. 2). In addition, alginate-
free lipid nanoparticles, characterised by the positive surface
charge proportional to DDAB content, were used as controls and
were also shown not to inﬂuence the cell viability at DDAB
concentration range tested (0.7–40 mg ml1; data not shown). Such
concentration of DDAB is in the range for which there are literature
reports of cytotoxic in vitro effect (Scarioti et al., 2011). It can be
concluded that the presence of a high portion of phosphatidyl-
choline in alginate-free lipid NP hindered DDAB cytotoxicity.
Cortesi et al. have already observed signiﬁcantly lower cytotoxicity
of DDAB when it was incorporated into liposomes (phosphatidyl-
choline:cholesterol:DDAB 8:2:1 mol/mol/mol) in comparison to
micellar solution (Cortesi et al., 1996).
Physico-chemical characteristics, in vitro release proﬁle and
biocompatibility of DN4 nanoparticles provided the rationale to
denote this formulation as the lead one (termed as NP further in
the text).
3.4. The preparation of in situ forming NP-loaded gel
Aqueous solutions and suspensions present favourable nasal
formulations, since very predictive and controlled dispersion and
deposition pattern within the nasal cavity can be achieved by
appropriately designed nasal delivery device. However, the main
drawback refers to the limited residence time at the nasal mucosa
which can be overcome by the development of in situ gelling
systems (Karavasili and Fatouros, 2016). In the system proposed by
this study, in situ gelling properties were provided by the addition
of pectin known for its ability to form gels in contact with Ca2+ ions
present in the nasal mucosa. NP-loaded gel was prepared by
mixing NP suspension in pectin continuous phase with SNF at
volume ratio of 1:1. Since the nasal epithelial lining ﬂuid was
estimated to be 136  17 ml (Kaulbach et al., 1993) and nasal
formulations are administered in small volumes, ranging from 25
to 200 ml with 100 ml being most common (Romeo et al.,1998), the
selected ratio of 1:1 between SNF and NP suspension in pectin
continuous phase simulates well the conditions in vivo. The Ca2+
concentration in simulated nasal ﬂuid used in this study (5.3 mM)
corresponds to the Ca2+ concentration in nasal ﬂuid determined in
healthy volonteers (5 1 mM) (Vanthanouvong and Roomans,
2004). The ratio of 1:1 between SNF and NP suspension in pectin
Fig. 1. Release proﬁles of Dex from lipid/alginate nanoparticles in water containing
SDS (0.03%, w/w). The proﬁle of Dex diffusion from the SDS aqueous solution (0.03%,
w/w) across the dialysis membrane is also presented. Data are expressed as the
mean  SD (n = 3).
Fig. 2. Caco-2 cell viability (%) determined by MTT after 2 h of incubation with lipid/
alginate nanoparticle suspension diluted in HBSS pH 7.4 obtaining ﬁnal
nanoparticle concentration of 50–400 mg ml1 with respect to lecithin (mean
values  S.D, n = 3).
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continuous phase resulted in ﬁnal pectin concentration of 2.5 mg
ml1 and Ca2+ concentration of 2.65 mM.
Apart from pectin-Ca2+ interaction, the impact of interaction of
pectin and alginate present at the surface of nanoparticles, as well
as with alginate in the free form, on the rheological properties of in
situ forming pectin gel should be expected. Namely, microstructure
and rheological behaviour of pectin/alginate mixed gels have
already been studied (Walkenstrom et al., 2003). The properties of
polymers such as alginate a-L-guluronate (G) content and pectin
degree of esteriﬁcation and amidation affected the alginate/pectin
mixed gel network density and rheological properties.
The frequency sweep measurements of NP-loaded gel and
relevant controls are shown in Fig. 3. Among gels prepared in the
presence of ethanol (3%, w/w), the complex formulation containing
NPs in pectin gel and NP-free pectin gel showed equal rheological
behaviour. However, slightly lower elastic and viscous modulus
were recorded for NP-free pectin/alginate gel. The observed
decrease can be ascribed to the interaction of pectin and alginate
in simple mixed system. It has already been reported that mixing of
LM amidated pectin and high G alginate resulted in gels with the
impaired elastic modulus (Walkenstrom et al., 2003). The absence
of impact of alginate on the rheological behaviour of NP-loaded
pectin gel can be ascribed to alginate immobilization at the
nanoparticle surface. Compared to the gels prepared in the
presence of ethanol, signiﬁcantly lower elastic and viscous
modulus were observed for ethanol free pectin gel (Fig. 3). The
inﬂuence of ethanol on viscoelastic properties can be ascribed to
the decrease in polarity of the solvent and consequent decrease in
interactions between polymer and solvent molecules (Guo et al.,
2016).
NP-loaded gel is characterised by a log-linear decrease of
complex viscosity. For angular frequencies between 0.922 and
92.9 rad/s, the viscosity decreased from 219.00 to 2.14 Pa s.
Observed complex viscosity corresponds to the range of viscosities
of nasal mucus at physiological as well as under disease conditions
(Lai et al., 2009).
Zero shear viscosity of the system prior gelling was determined
by creep test, at the end of the stress phase, when steady state ﬂow
behaviour was reached. Zero shear viscosity (h0) was 114.17  0.38
Pas. This relatively high value of viscosity at zero shear indicates
that the NP system would have adequate suspension stability and
would not tend to settle due to the gravity. Shear viscosity proﬁle
showed pseudoplastic behaviour of the system prior gelling. The
signiﬁcant decrease in viscosity was observed with increasing
shear rate. At shear rates above 1 s1, the viscosity stabilized at
values of 3.5  103Pa s. Such a behaviour assures good
sprayability, since, for example, the approximate shear rate for
dispensing nasal spray from plastic squeeze bottle is 20,000 s1
(Block, 2012).
3.5. In vitro release of Dex from NP-loaded pectin gel
The release proﬁles of Dex from NP-loaded gel and relevant
controls (NP suspension and solution) were determined with CaCl2
solution (2.65 mM) as a receptor medium. Equal concentration of
Ca2+ in the gel formulation and the receptor medium was a
prerequisite to ensure pectin gel stability over the experiment. SDS
was omitted from the receptor medium as it precipitates in the
presence of divalent cations (Rodriguez et al., 2001).
Results obtained clearly showed that Dex entrapment in
nanoparticles signiﬁcantly retarded Dex release in comparison
to Dex solution (Fig. 4) (t50% 1.7 h and 0.6 h, respectively; f2 = 37.8),
conﬁrming the ﬁndings obtained with SDS solution as receptor
medium. However, incorporation of Dex loaded nanoparticles in
pectin gel provided only scarce reduction in Dex release in
comparison to Dex-loaded nanoparticle suspension (Fig. 4) (t50%
2.1 h and 1.7 h, respectively; f2 = 55.9). These results suggest that
Dex release from NP is the rate-limiting step that governed the
overall Dex release proﬁle from NP-loaded gel. The possible better
control over the drug release can be achieved by gel of ﬁne tuned
stiffness and mesh size or binding afﬁnity of the drug to the gel
constituents. However, such an approach requires a gel matrix
tailoring for each speciﬁc drug (Nowald et al., 2017; Watts and
Smith, 2009). In addition, extensive reduction in release rate could
be unfavorable as it could impair the therapeutic effect.
3.6. Evaluation of NP-loaded gel biocompatibility
Pectin is described as “generally regarded as safe” due to the
long history of usage in pharmaceutical and food products (Watts
and Smith, 2009). LM pectin has already been used in PecFent1, an
innovative nasal fentanyl formulation (Watts et al., 2013). As
expected, NP-loaded pectin gel prepared in this study, was shown
not to induce the decrease in cell viability under experimental
Fig. 3. Elastic (G0; open symbol) and viscous (G00; ﬁlled symbol) modulus as a
function of angular frequency of different gels obtained at pectin concentration of
2.5 mg ml1 and 2.65 mM Ca2+: NP-loaded pectin gel (circle), pectin/alginate gel in
the presence of ethanol (4%, v/v) (square), pectin gel in the presence of ethanol (3%,
w/w) (rhomb) and pectin gel (triangle).
Fig. 4. Release proﬁles of Dex from NP and NP-loaded gel in CaCl2 solution
(2.65 mM). The proﬁle of Dex diffusion from the solution across the dialysis
membrane is also presented. Data are expressed as the mean  SD (n = 3).
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conditions employed and was proven to be biocompatible with the
selected epithelial cell model (data not shown).
3.7. In vitro permeability through epithelial model barrier
NP-loaded in situ gelling system is designed in a way to control
the release of the drug over time ensuring prolonged activity and at
the same time limiting the absorption through nasal mucosa. In
order to assess the potential of proposed system to inﬂuence Dex
transmucosal permeation, we determined the apparent perme-
ability coefﬁcients (Papp) of Dex from NP-loaded gel, NP suspension
and solution across Caco-2 monolayer (Table 3). HBSS-Ca2+ and
ethanol/HBSS-Ca2+ (3% w/w) Dex solutions were used as controls.
The results obtained suggested no inﬂuence of ethanol at
concentration tested on Dex permeation. Papp values for both
Dex solutions were comparable to the value reported in the
literature (Beck et al., 2007). Dex permeation tended to decrease
with the incorporation into nanoparticles compared to the Dex
solution, but the difference observed was shown to be statistically
insigniﬁcant. At the same time NP suspension provided signiﬁcant
reduction in Dex release compared to Dex solution (t50% 1.7 h and
0.6 h, respectively; f2 = 37.8). These results lead to the conclusion
that permeation is not fully controlled by the drug release. One of
the possible mechanisms that could contribute to Dex permeation
across the model epithelial barrier is the internalisation of Dex-
loaded nanoparticles. Mechanisms of internalisation/endocytosis
of polymeric and lipidic nanoparticles have been well described in
the literature and were shown to be highly dependent on the
physicochemical properties of the nanoparticles such as size and
zeta-potential (Beloqui et al., 2016). Nanoparticles characterised by
similar mean diameter and surface charge as nanoparticles
developed in this study were readily internalised by different
epithelial cells. Namely, carboxylated chitosan grafted nano-
particles with mean diameter of 300 nm and zeta-potential of
35 mV were shown to be internalised and transported across
Caco-2 cell monolayers (He et al., 2012). PLGA nanoparticles coated
with Carbopol with mean diameter of 285.9 nm and zeta-potential
of 25.7 nm were characterised by enhanced internalisation in
comparison to uncoated PLGA nanoparticles (mean diameter about
250 nm and zeta-potential about 18 mV) (Surassmo et al., 2015).
The enhanced internalisation of Carbopol coated PLGA nano-
particles has been ascribed to the enhanced adhesion forces related
to the large amount of Carbopol carboxylic groups.
Statistically signiﬁcant Dex permeation decrease in comparison
to solution was achieved upon the entrapment of Dex-loaded
nanoparticles into gel formed in contact with Ca2+ (P = 0.004). The
observed behaviour can partially be ascribed to retarded diffusion
of Dex-loaded nanoparticles through gel matrix which could
moderate nanoparticle cell internalisation and contribute to the
decrease of Dex Papp. Nanoparticle diffusion through the polymer
matrix is hindered by the presence of the polymer network ﬁbres
or chains and their possible interactions with nanoparticle surface
(de Kort et al., 2015). Diffusion-related nanoparticle cell internal-
isation in case of biopolymer gel matrix systems was already
shown for doxorubicin-loaded PLGA/PEG nanoparticles and 3D
collagen system cell cultures (Biondi et al., 2013). The overall
attenuation factor of 0.81, obtained for NP-loaded gel in relation to
Dex solution (Table 3), is comparable to those reported for Dex-
loaded nanoparticle-coated microparticles (Beck et al., 2007).
In order to further analyse the mechanisms of Dex permeation
control, we correlated data obtained by in vitro permeation and
release studies for NP suspension and NP-loaded pectin gel with
Dex content of 112 mg ml1. Fig. 5 presents the exponential
correlation between cumulative amount of Dex permeated across
epithelial cell model and cumulative amount of Dex released for NP
suspension and NP-loaded pectin gel, indicating that Dex
permeation is related to the concentration of the Dex released
at the site of absorption. Similar results were already obtained for
Dex-loaded nanoparticle-coated microparticles (Beck et al., 2007).
However, the shift between the correlation curves obtained for NP
suspension and NP-loaded gel suggested the existence of another
factor inﬂuencing the Dex permeation across the model epithelial
barrier. More speciﬁcally, in case of NP suspension, each
cumulative amount of Dex released was correlated with higher
amount of Dex permeated than in case of NP-loaded pectin gel.
This supports the already mentioned assumption that Dex
permeation could also be related to cell internalisation of Dex-
loaded nanoparticles, and that such process might be hindered by
nanoparticle incorporation into pectin gel.
4. Conclusions
Herein we propose nanoparticle loaded in situ gelling system
for corticosteroid effective nasal delivery for the treatment of
chronic rhinosinusitis with nasal polyps. Such a sprayable system
bears the potential to: (i) allow corticosteroid delivery beyond the
nasal valve where the polyps occur and, after sol-gel transition
triggered by Ca2+, (ii) ensure prolonged local action of cortico-
steroid due to prolonged residence time at the site of application
and moderate corticosteroid release and permeation. The pro-
posed study gives an in vitro proof-of-concept for the potential of
developed system to provide efﬁcient local corticosteroid delivery/
effect. However, for the ﬁnal proof-of-concept, the study must be
extended to an appropriate in vivo model.
Table 3
Permeation of Dex across Caco-2 monolayer from solution in HBSS-Ca2+ and
ethanol/HBSS-Ca2+ (3%, w/w), NP suspension in HBSS-Ca2+, NP-loaded pectin gel
presented by apparent permeability coefﬁcients (Papp). Data are expressed as the
mean  SD (n = 3). Statistically signiﬁcant differences between NP-loaded pectin gel
and Dex solution in HBSS were observed (P < 0.05).
Sample Dex content
(mg mL1)
Papp
(106 cm s1)
Attenuation factora
Dex/HBSS-Ca2+ 60 9.73  0.57
Dex/EtOH/HBSS-
Ca2+
60 9.68  0.68 1.00
NP 60 8.89  0.50 0.91
NP 112 9.12  0.09 0.94
NP-loaded pectin
gel
112 7.88  0.15 0.81
a Attenuation factor represents the ratio of Papp of dexamethasone from the
tested sample and Papp of dexamethasone from HBSS solution.
Fig. 5. Correlation between cumulative amount of Dex permeated across epithelial
Caco-2 cell model and cumulative amount of Dex released from NP suspension and
NP-loaded pectin gel.
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